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ABSTRACT
Thus far, the most thorough evaluation of GAB-2, SHP-2 and PI3K complexes has 
been concentrated in the area of growth factor and cytokine receptor signalling. In 
this regard, such complexes have been shown to orchestrate positive signalling roles, 
including stimulation of the Ras/MAP kinase cascade, activation of PI3K signalling 
pathways and the induction of immediate-early gene expression. Using a variety of 
techniques, this study highlighted, for the first time, the broader involvement of 
GAB-2, SHP-2 and PI3K signalling complexes downstream of the TCR and CD28 
during T cell activation and in the control of SDF-1-induced T cell chemotaxis.
Preliminary investigations in Jurkat T cells revealed that stimulation of the T cell co­
stimulatory receptor, CD28, by its endogenous ligand B7.1 induced the tyrosine 
phosphorylation of GAB-2 and its co-precipitation with both SHP-2 and class 1a 
PI3K; consistent with the formation of a multimeric signaling complex, similar to 
that suggested to exist downstream of the TCR. The overexpression of WT GAB-2 in 
transient transfection assays significantly inhibited the transcription of both NFkB 
and AP-1-directed luciferase reporters, induced by co-ligation of the TCR and CD28 
(approximately 3 fold and 2 fold inhibition, respectively), implicating GAB-2 in the 
negative regulation of the IL-2 promoter. Notably, only the deletion of the GAB-2 
PH domain was able to rescue this inhibitory effect and GAB-2 mutants defective in 
SHP-2 and PI3K binding still retained their inhibitory potency. The role of SHP-2 in 
T cell function was also examined, using Jurkat T cell clones that inducibly 
expressed a dominant-negative 2SH2-SHP-2 mutant. Overexpression of 2SH2-SHP- 
2 in these cells completely abrogated the phosphorylation of ERK 1 and 2 at the later 
time points of TCR stimulation, confirming the role of SHP-2 as a facilitator of MAP 
kinase signalling.
This study similarly demonstrated the capacity of the CXC chemokine, SDF-1, to 
stimulate the tyrosine phosphorylation of GAB-2 and the concomitant recruitment of 
SHP-2 and class Ia PI3K. Moreover, examination of the 2SH2-SHP-2 expressing 
clones in Jurkat T cell chemotaxis assays provided the first evidence that SHP-2 
positively influences the migratory response towards SDF-1.
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CHAPTER 1: Introduction 1
THE BIOLOGY OF T LYMPHOCYTES
The T lymphocyte, through its ability to specifically recognise and appropriately 
respond to foreign antigen, represents a fundamental cell within the adaptive immune 
system.
1.1 - HAEMATOPOIESIS AND EARLY TLYMPHOCYTE DEVELOPMENT
Lymphocytes are one of many types of white blood cell produced in the bone 
marrow by the process of haematopoiesis. In humans, haematopoiesis begins during 
the first weeks of embryonic development from a collection of primitive cells within 
the embryonic yolk sac. These cells, termed haematopoietic stem cells, are self- 
renewing, pluripotent and can accordingly differentiate into any functionally 
specialized mature blood cell. In the third month of gestation, haematopoietic stem 
cells migrate from the yolk sac to the foetal liver and then to the spleen, where 
haematopoiesis continues until the seventh month of pregnancy. By birth, the bone 
marrow has become the major organ involved in the generation of new blood cells. 
During these early stages of development, pluripotent stem cells differentiate to 
generate progenitor cells committed to either the lymphoid or myeloid lineage. 
Common lymphoid progenitor cells give rise to B, T and NK cells, whereas, 
common myeloid precursors give rise to progenitors of erythrocytes, varied 
leukocytes and platelets. The commitment of a progenitor cell to a particular 
differentiation pathway is largely determined by the cytokine milieu bathing the cell, 
along with the concomitant expression on the cell surface of membrane receptors 
specialised for these growth factors. Accordingly, T lymphocyte progenitors arise in 
the bone marrow from where they migrate to the thymus gland in order to mature 
(reviewed by Goldsby, Kindt and Osborne in Immunology). Figure 1.1 illustrates 
how pluripotent stem cells pass through a series of differentiations and clonal 
expansions to give rise to functionally diverse and distinct populations of mature 
blood cells.
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Figure 1.1 - Haematopoiesis; The generation o f multi-lineage mature blood cells from haematopoietic stem 
cells is tightly regulated by the haematopoietic cytokines (indicated in red). These specialised growth factors 
promote the differentiation commitment and clonal expansion o f haematopoietic progenitors. In the absence 
of infection, the bone- marrow stromal cells are the major source o f the cytokines. In the presence of 
infection, activated T helper cells and macrophages may induce additional haematopoiesis.
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1.2 - MATURATION AND THYMIC SELECTION OF THE T LYMPHOCYTE 
REPERTOIRE
The thymus occupies a central role in T cell biology, since it is where T cells acquire 
their antigenic diversity and are shaped into the functionally distinct subpopulations 
that comprise the primary T-cell repertoire. The exact process of T-cell maturation 
within the thymus is a complex, multi-step sequence of events and as yet is not 
completely understood. After progenitor T cells generated during haematopoiesis 
enter the thymus, they proliferate rapidly within the cortex and begin to express the 
surface molecules characteristic of T cells, such as the T-cell receptor complex, CD4 
and CD8. The thymocytes at this stage are called double positive (DP), or CD4+8+ 
cells and are primed to undergo the two-step process of positive and negative 
selection that will ultimately generate either single-positive CD4+ thymocytes or 
single-positive CD8+ thymocytes (Shortman and Wu., 1996).
1.2.1 - Positive Selection
Positive selection takes place in the cortical region of the thymus and is entirely 
influenced by the ability of the T-cell receptor, expressed by the immature 
thymocytes, to recognise and interact with major histocompatibility complex (MHC) 
molecules. Thymic stromal cells (epithelial cells, dendritic cells, and macrophages), 
which express high levels of class I and class II MHC molecules, play a role in this 
process. Thymocytes able to interact with the cortical epithelial cells, mediated by 
MHC- restricted T-cell receptors, are widely thought to receive a protective signal 
that rescues them from programmed cell death. Multiple interactions with Class I or 
Class II MHC may also instruct the thymocytes to differentiate into either CD8+ or 
CD4+ single-positive cells. Conversely, those cells whose receptors are not MHC 
restricted ultimately fail at this critical developmental check point and consequently 
are eliminated within the thymus by apoptosis (Von Boehmer., 1994; Fowlkes and 
Schweighoffer., 1995; Owen and Moore., 1995).
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1.2.2 - Negative Selection
The population of MHC-restricted thymocytes that survive positive selection 
comprises some cells with high affinity receptors for self-antigen presented by self- 
MHC molecules. These thymocytes undergo negative selection, following an 
interaction with bone-marrow-derived APC’s (dendritic cells and macrophages) in 
the medulla, culminating in their death by apoptosis. An overview of the processes 
involved in the positive and negative selection of thymocytes is shown in Figure 1.2. 
Passing through the entire process of thymic selection only antigen specific, MHC- 
restricted and non-self reactive T cells are allowed to mature. Indeed, the selection 
process is so rigorous that an estimated 95%-99% of thymocyte progeny undergo 
programmed cell death within the thymus without ever maturing. The small 
percentage of T-cells that do eventually emerge from the thymus accumulate in the 
secondary lymphoid tissues, primarily in the paracortex of the lymph nodes, in the 
periarteriolar lymphoid sheath of the spleen and in the interfollicular areas of the 
Peyer's patches. It is from here that the now immunocompetent T cells have the 
potential to encounter antigenic peptide displayed in the groove of an MHC molecule 
and become activated.
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Figure 1.2 - Positive and Negative selection o f  Thymocytes; Thymic selection is a critical process that 
ultimately allows only antigen specific, MHC-restricted and non-self reactive T cells to mature (adapted from 
Goldby, Klint and Osbourne, Immunology).
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T LYMPHOCYTE ACTIVATION
The appropriate activation and subsequent clonal expansion of T cells is a central 
event in the body's immune defence against foreign antigen. By contrast, aberrant 
activation of T cells can have catastrophic effect in terms of human health. Common 
manifestations of T cell dysfunction include debilitating autoimmune diseases, 
malignancy, immunodeficiency and host versus graft rejection. It is unsurprising, 
therefore, that the events underpinning T cell activation are highly complicated and 
tightly controlled.
1.3 - THE TWO-SIGNAL HYPOTHESIS OF T CELL ACTIVATION
In 1970, Bretscher and Cohn were the first to describe that effective T cell activation 
required the generation of at least two distinct biochemical signals (Bretscher and 
Cohn., 1970). This two signal model is now widely accepted, with the first signal 
(signal 1) being provided by engagement of the T cell antigen receptor (TCR)/CD3 
complex with processed antigenic peptide. Despite this interaction with antigen being 
highly specific, it alone is insufficient to elicit a productive T cell response. Indeed, 
in the absence of a second co-stimulatory signal, the T cell descends into a state of 
unresponsiveness (anergy) or in the extreme, may even undergo apoptosis (Mueller 
et al., 1989). CD28 is, by far, the best characterised of the co-stimulatory molecules 
and is expressed on resting T lymphocytes. It is, however, not the only co- 
stimulatory receptor, as evidenced by investigations into the immune responses of 
CD28-deficient mice (Shahinian et al, 1993); for example LFA-l/ICAM-1 and more 
recently, 0X40, 4-IBB and ICOS can also augment the T cell response to antigen 
MHC or anti-CD3. Attention has perhaps focused on the CD28 molecule, since 
ligation by its endogenous ligands B7.1 (CD80) or B7.2 (CD86) has been shown to 
promote the classical markers of T cell activation; IL-2 production, T cell 
proliferation and cell survival (reviewed by Ward., 1996; Lenschow et al., 1996; 
Chambers and Allison, 1999).
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1.4 - THE PHENOTYPE OF A N  ACTIVATED T CELL
Once the strict requirements for T cell activation have been fulfilled, a cascade of 
biochemical events is initiated that promotes Go-to-Gi transition and thereby induces 
the resting cell to enter the cell cycle. The activated cell enlarges into a lymphoblast, 
which undergoes several rounds of proliferation and differentiation to generate 
effector cells (T hi or Th2 cells) and memory cells (an overview of these events is 
shown in Figure 1.3). These profound changes initiated by the encounter between the 
T cell and MHC-peptide complexes are principally co-ordinated by the signal- 
transduction pathways elicited by the TCR and CD28 receptors. Numerous genes are 
upregulated, which can be broadly grouped into three categories reflecting how early 
the gene product may be detected after antigen recognition, these are summarised in 
Table 1.1.
Table 1.1 -Time course of Gene Expression following Antigen Recognition
Immediate genes: expressed within half an hour of antigen recognition; encode transcription factors 
such as c-Fos, c-Jun, NFAT and NFkB, which are required to induce the second wave o f gene 
activation.
Early genes: expressed within l-2h of antigen recognition; encode IL-2, IL-2 receptor (IL-2R), IL-3, 
IL-4, 11-5, IL-6, myc, IFN-y, GM-CSF and numerous other proteins which overall promote 
proliferation and functional differentiation.
Late genes: expressed more than 2 days after antigen recognition; encode very late activating (VLA) 
molecules, belonging to the integrin family of cell adherence molecules.
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Figure 1.3 - Activation o f a T helper cell; Engagement o f the TCR (signal 1) and a co-stimulatory 
molecule (signal 2) upregulates expression o f the lymphokine IL-2 and its high affinity receptor, 
leading to proliferation and differentiation.
THE T CELL ANTIGEN RECEPTOR (TCR)
Knowledge of the signal transduction pathways triggered by the TCR will yield a 
better understanding of how the T cell is stimulated into cell cycle entry and the 
transcriptional promotion of genes such as IL-2. In addition, TCR signalling provides 
a platform from which to understand those pathways generated by the CD28 
receptor, and furthermore how this co-signal may be integrated.
CHAPTER 1: Introduction 9
1.5 - STRUCTURAL FEATURES OF THE TCR/CD3 COMPLEX
The antigen-specific nature of T cell responses is governed by the clonally restricted 
T cell receptor. Identification and isolation of the T cell receptor was first achieved 
by J.P.Allison in 1982, using an immunological approach that involved generating 
numerous monoclonal antibodies from T cell clones and screening these for their 
clonal specificity (Allison et al., 1982). Further complex biochemical and molecular 
biological manipulations finally revealed that the TCR was a disulphide-linked 
heterodimer composed of either a  and p or y and 5 chains, with a domain structure 
strikingly similar to that of the immunoglobulins (Hedrick et al, 1984; Yanagi et al., 
1984; Bentley et al.9 1995, Garcia et al.9 1996, Jardetzky., 1997). Between 1% and 
3% of T cells in the blood have TCRs that consist of y and 5 chains, the remaining T 
cells in the blood have TCRs consisting of a  and p chains. These TCR heterodimers 
are always membrane bound and always associated with additional glycoproteins 
such as CD4 and CD8. In order to participate in signal transduction the TCR also 
forms an obligatory association with the CD3 accessory molecule (Allison and 
Lanier., 1987). Indeed, CD3 is an integral part of the TCR complex, being essential 
for membrane expression of the ap heterodimer. Consistent with this, loss of the 
genes encoding either the CD3 or the TCR chains results in the loss of surface 
expression of the entire membrane complex.
The CD3 complex itself, comprises five polypeptide chains, that can associate to 
form three dimers (ye, 5s, ^  or £n). The principal subunit that regulates coupling of 
the TCR/CD3 complex to protein tyrosine kinases and hence to downstream signal 
transduction pathways, is called the immunoreceptor tyrosine-based activation motif 
(ITAM), which includes two YXXL motifs typically separated by 6-8 amino acids 
(Reth., 1989). In CD3, the cytoplasmic tails of the y,8 and s chains each contain a 
single ITAM, whereas, the % and r| chains each contain three copies. A schematic 
representation of the TCR/CD3 complex is shown in Figure 1.4.
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Figure 1.4 - Schem atic Representation o f  the TCR/CD3 Complex, Taken as a whole, the TCR/CD3 
receptor complex can be viewed simply as four dimers; the aP  or y8 TCR heterodimer determining 
antigen peptide binding specificity and the CD3 dimers being required for functional receptor 
expression and for signal transduction (W eiss., 1993).
1,6 -  SIGNAL TRANSDUCTION BY THE TCR
One of the earliest detectable events (at <5s) following cross-linking of the TCR 
complex by MHC-peptide is the activation of protein tyrosine kinases (PTK's). At 
least three families of PTK’s are associated with, and activated by the TCR, the Src 
family (p56 Lck and p59 Fyn), the Syk family (ZAP-70) and the Tec family (Itk) of 
non-receptor tyrosine kinases (reviewed by Chu et al., 1998; Latour and Veillete, 
2001; Miller and Berg., 2002). The TCR/CD3 complex does not possess intrinsic 
enzyme activity and, as previously described, the ITAM regulates coupling o f the 
TCR to PTKs.
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Many researchers currently subscribe to the theory that during the initial stages of T 
cell activation supra-molecular activation clusters (SMACs) are formed at the site of 
the immunological synapse (Monks et al., 1998; Grakoui et al., 1999). Moreover, 
mounting evidence suggests that the aggregation of lipid raft microdomains might 
facilitate immunoreceptor signalling by generating physical environments rich in 
kinases, adaptor molecules and intracellular effectors. Indeed, this dynamic 
phenomena provides an elegant mechanism for the transient activation of Lck and 
Fyn by CD45, and furthermore explains how these Src kinases are brought into close 
proximity with the cytoplasmic tails of the TCR/CD3 complex (Janes et al., 2000; 
llangumaran et al., 2000). Once activated, the primary function of the Src family 
kinases is to phosphorylate critical tyrosine residues present within the ITAMs of the 
CD3 complex. These phosphoiylated motifs, in turn, recruit other non-receptor PTKs 
to the TCR. Notably, phosphorylation of the % chain creates phopshotyrosine binding 
sites for the src-homology 2 (SH2) domains of the Syk family kinase, ZAP-70 (zeta - 
associated protein) (Chan et al., 1991; Hatada et al., 1995). The activation of PTKs is 
an absolute requirement for TCR signalling, setting in motion the biochemical 
cascades that will culminate in the transcription of genes required for both mitosis 
and lymphokine production.
1.6.1 - The Phospholipase C (PLC), Protein Kinase C (PKC) and Calcium 
(Ca2+) Signalling Pathways
Activation of TCR-associated PTKs is rapidly followed by the activation of another 
enzyme, phospholipase C y (PLCy), a member of the PLC group of enzymes. PLCy 
hydrolyses the minor membrane phospholipid, Phosphatidylinositol-4,5-P2 (Ptdlns-
4,5-P2) into IP3 and diacylglycerol (DAG) (Imboden and Stobo., 1985; Secrist et al., 
1991; Dasgupta et al., 1992). These two products represent important second 
messengers of T cell activation since they propagate signalling pathways leading to 
the activation of nuclear factors involved in the transcriptional regulation of the IL-2 
gene. In one pathway, DAG, activates the protein kinase C (PKC) family of 
serine/threonine kinases, which can co-ordinate the release of NFkB. In the other 
pathway, IP3 triggers the intracellular release of calcium from specialised storage 
vesicles. The associated rise in cytosolic calcium activates calcineurin (a calmodulin
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dependent phosphatase), which subsequently de-phosphorylates the inactive form of 
NFAT (reviewed by Weiss and Littman., 1994; Cantrell., 1996; Acuto and Cantrell., 
2000). The potency of the calcium and PKC signalling pathways are underscored 
experimentally by the use of agents that directly mimic the effects of IP3 and DAG 
within the cell. PKC can be activated by phorbol esters, for example PMA (phorbol 
myristic acetate) which resemble DAG. Calcium levels can be elevated by treating 
cells with a calcium ionophore, such as Ionomycin. Together, these pharmacological 
treatments have been shown to promote many aspects of antigen receptor triggering, 
including cell cycle entry and secretion of IL-2 in T lymphocytes.
It should be emphasised that T cells express multiple functionally distinct PKC 
isoforms; the classical PKCs (a, Pi, pn and y), novel PKCs (5, s, r\ and 0) and 
atypical PKCs (£ and A,) (reviewed by Mellor and Parker., 1998; Oancea and Meyer., 
1998). Among these PKC family enzymes, attention has more recently focused on 
PKC0, since this isoform seems to exert non-redundant functions that are essential 
for T cell activation. For example, PKC0 is required for activation of the 
transcription factors NFkB and AP-1 (Baier-Bitterlich et al., 1996; Sim et al., 2000). 
Moreover, PKC0 appears to localise selectively into the centre of the mature 
immunological synapse (Monks et a/., 1998).
1.6.2 - The Ras Regulated Mitogen Activated Protein Kinase (MAPK) Cascade
The TCR also stimulates rapid and transient activation of the Ras-regulated 
ERK/MAPK cascade, another major pathway involved in the transduction of 
mitogenic signals (Downward et al, 1990). The small (21 kDa) guanine nucleotide 
binding protein, Ras, may be activated by a number of mechanisms. In cells, Ras 
cycles between an active, signal-transducing GTP-bound form and an inactive GDP- 
bound form. Consequently, the levels of active Ras-GTP complexes reflect a balance 
between the rate of hydrolysis of bound GTP and the rate of exchange of bound GDP 
for cytosolic GTP. The PTK dependent activation of Ras is fairly well characterised 
and is principally co-ordinated through stimulation of guanine nucleotide exchange. 
Sos (mammalian homologue of the Drosophila 'Son of Sevenless' protein) is a 
guanine nucleotide exchange factor (GNEF), found constitutively associated with the 
src-homology 3 (SH3) domains of the adaptor molecule, Grb2, and such complexes
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are known to stimulate Ras in a variety of cells (Downward., 1992; McCormick., 
1993; Buday et al., 1994). The transient activation of Ras initiates a cascade of 
protein phosphorylation that serves to upregulate the MAPKs, alternately known as 
ERK1/2 (Izquierdo et a l , 1993; Marshall., 1994; Rincon., 2001). The MAPKs can 
phosphorylate members of the Fos and Jun family of transcription factors and thus 
promote the formation of AP-1 heterodimers. Downstream of the TCR, the 
Ras/MAPK cascade ultimately co-operates with the calcium/PKC signalling pathway 
to tightly coordinate the transcription factors involved in the regulation of both cell 
proliferation and IL-2 production (Rayter et al., 1992; Woodrow et al., 1993).
Until recently, the Grb-2/Sos complex was thought to be the primary connection 
between antigen receptors and Ras, since targeting of Sos to the membrane of 
lymphocytes was sufficient to induce GTP-bound Ras. However, the Grb-2/Sos 
mechanism could not explain the striking activation of Ras in lymphocytes after 
phorbol ester stimulation and the PLCy dependency of optimal TCR-induced ERK 
activation (Zhang et al., 2000). Indeed, exciting new studies have revealed additional 
complexity in Ras activation. The cloning of RasGRP, a guanine nucleotide 
exchange factor that binds to DAG and phorbol esters, has highlighted a novel 
candidate for the regulation of Ras activation in T cells (Ebinu et al., 1998). 
Moreover, analysis of mice with a null mutation for this gene has provided 
compelling evidence that RasGRP is necessary for Ras activation during T cell 
development (Dower et al., 2000). As yet, it is not known whether the binding of 
Ras-GRP to DAG alone is sufficient to activate Ras, or whether DAG and the Grb- 
2/Sos complex cooperate in its induction. However, it does seems likely that T cells 
may have multiple ways of activating Ras, enabling the tight control of this growth 
and differentiation factor. An overview of these important signal transduction 



















Figure 1.5 - Overview o f Signal Transduction Events Downstream of the T Cell Antigen Receptor; Upon aggregation of the TCR/CD3 complex multiple 3
signalling pathways are triggered that tightly co-ordinate the activation of transcription factors involved in the regulation of proliferation and IL-2 production. £
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THE CD28 COSTIMULATORY RECEPTOR
1.7 - CD28 STRUCTURE AND EXPRESSION
CD28 is a homodimeric cell surface glycoprotein, composed of two disulphide- 
linked 44 kDa chains. It is expressed constitutively on the surface of 80 % of human 
T cells; all CD4+ cells and approximately 50 % of CD8+ cells express CD28 (June et
al., 1994). Close examination of the amino acid structure of the CD28 cytoplasmic
tail (shown in Figure 1.6) provides some clues as to the proteins which may interact 
here and perhaps elicit downstream signalling events.
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Figure 1.6 -  Structure and Potential Signalling Domains o f  the Human CD28 Cytoplasm ic
7aiV,*CD28 has a YXXM  m otif that binds to the SH2 domain o f the p85 subunit o f  c lasslA PI3Ks. 
Within this m otif CD28 has an asparagine (N) for binding o f  the SH2 domain o f  Grb-2 and possibly 
Gads. Tandem Grb-SH3- domain binding potentially occurs at the carboxy-terminal proline residues 
(W ard., 1996; Rudd and Schneider 2003).
1.8 - B7.1 AND B7.2 GLYCOPROTEINS
B7.1, described in 1982 by Yokochi et al was the first ligand identified for CD28 
(Yokochi et al., 1982). The human B7.1 gene was cloned by Freeman et al, and 
shown to be a member of the immunoglobulin superfamily (Freeman et al, 1989; 
Freeman et al., 1991). Similarly, B7.2 was identified and cloned (Freeman et al., 
1993; Azuma et al., 1993). The overall structure of B7.2 was found to be very similar 
to B7.1, with an extracellular domain containing two Ig-like domains, a
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transmembrane domain, followed by a cytoplasmic tail. The functional importance of 
the B7 molecules has been demonstrated in a number of studies of T cell activation. 
Both B7.1 and B7.2 transfectants augment T cell proliferation and IL-2 production to 
anti-CD3 or PMA (Gimmi et al., 1991; Linsley et al., 1991; reviewed by Lenschow 
et al., 1996). Analysis of the ligand binding site of CD28 has identified the site of 
interaction with B7.1 and B7.2 to a conserved sequence Met-Tyr-Pro-Pro-Pro-Tyr in 
the extracellular region of CD28 (Gimmi et al, 1991).
1.9 - CD28 SIGNALLING CASCADES
1.9.1 -Theories of Co-stimulation
As discussed, neither the TCR nor CD28, individually, can induce functional T cell 
activation. A combination of receptor ligation is required for optimal IL-2 production 
and cell proliferation. Consequently, it has been proposed that the biochemical 
pathways which constitute the co-stimulatory signal should be qualitatively different 
from those orchestrated by TCR stimulation, in order to tip the balance between 
anergy and activation. It can be argued that CD28 may contribute in a number of 
ways:
1. Provide a unique biochemical signal, complementary to that of the TCR.
2. Provide similar signals to those triggered by the TCR, but at different time points 
or in different cellular compartments.
3. Enhance the amplitude or duration of the TCR-activated signals; perhaps 
reaching a threshold to elicit downstream signalling cascades.
4. Abrogate a negative, anergy-inducing TCR signal.
5. A combination of the above.
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1.9.2 -  Activation of Protein Tyrosine Kinases by CD28
CD28 signalling clearly involves protein tyrosine phosphorylation, catalysed by 
protein tyrosine kinases. This is indicated by the fact that the CD28 signal is 
herbimycin A sensitive (PTK inhibitor) and that CD28 ligation results in the tyrosine 
phosphorylation of a number of substrate proteins, including the CD28 receptor itself 
(Vandenberghe et al., 1992; Lu et al., 1992; June et al., 1994; Guinan et al., 1994). 
Like the TCR, the structure of the cytoplasmic tail of CD28 indicates that it has no 
intrinsic enzyme activity. It has been suggested therefore, that CD28 may similarly 
couple to non-receptor tyrosine kinases. As previously mentioned, the cytoplasmic 
tail of CD28 becomes tyrosine phosphorylated following ligation. In particular, four 
tyrosine residues, Tyr173, Tyr188, Tyr191and Tyr200, are thought to be involved in the 
recruitment of signalling molecules to CD28 via phosphotyrosine/SH2 domain 
interactions. The PTKs p56 Lck, p59 Fyn and Itk have all been implicated in 
regulating such tyrosine phosphorylation post CD28 stimulation (August and 
Dupont., 1994a; Hutchcroft and Bierer., 1994; August et al., 1994b; Raab et al.,
1995).
It is recognised that CD28 generates a biochemical signal that is, in part, distinct 
from the TCR-induced Ca2+ / Calcineurin pathway. For example, CD28 plus PMA 
stimulation can trigger IL-2 production that is Cyclosporin-A resistant, while TCR 
induced production is sensitive to this inhibitor (June et al., 1987; Sigal and 
Dumont., 1992). Moreover, whilst CD28 and the TCR can elicit tyrosine 
phosphorylation of identical proteins, there are still some major distinctions in those 
proteins that can be phosphorylated by CD28; unique CD28 induced tyrosine 
phosphorylation of 62 kDa, 75 kDa and 100 kDa proteins is observed (Vandenberghe 
etal., 1992; Lu etal., 1992).
1.9.3 - CD28 Associates with and is a Major Activator of Phosphatidylinositol 3- 
Kinase (PI3K)
An important clue as to the mechanism underlying these signalling differences 
became apparent with the finding that CD28 ligation induced the prolonged 
accumulation of the D3-phosphoinositide lipids, the products of activated
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Phosphatidylinositol 3-Kinase (PI3K) (Ward et al., 1993). Indeed, PI3K was later 
shown to directly associate with the cytoplasmic tail of the CD28 receptor via a 
consensus binding site, (p)Y173MNM, for the SH2 domains of the p85 adaptor 
subunit (Prasad et al., 1994; Pages et al., 1994). Whether this specific recruitment of 
PI3K to the CD28 receptor accounts for the observed increase in associated lipid 
kinase activity is not clear. However, phosphopeptide binding studies do indicate that 
occupation of the p85 SH2 domains may be involved not only in recruitment, but 
also in regulating enzyme activity (Carpenter et al, 1993a)
PHOSPHATIDYLINOSITOL 3-KINASE
1.10 - PI3K STRUCTURE AND CLASSIFICATION
PI3K was originally described some fourteen years ago as a Ptdlns Kinase activity 
found in immunoprecipitates of the viral oncoproteins, v-Src, v-Ros and 
polyomavirus middle-T, derived from transformed cells. Analysis of the enzymatic 
activity of this PTK-associated Ptdlns kinase revealed it capable of phosphorylating 
the D3 position of phosphatidylinositiol to produce phosphatidylinositol-3-phosphate 
(PtdIns-3-P), a lipid that had not previously been described (Whitman et al, 1988). 
Further studies with the purified enzyme led to the identification of a whole new set 
of lipids phosphorylated at the D3 position of the inositol ring. In the 3- 
phosphoinositide pathway, Ptdlns, PtdIns-4-P and PtdIns-4,5-P2 are phosphorylated 
resulting in the production of PtdIns-3-P Ptdlns-3,4P2 and PtdIns-3,4,5-P3, 
respectively. The mechanism of action of PI3K family enzymes is shown in Figure 
1.7.
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Figure 1 . 7 - M echanism o f  Action o f  PI3K Family Enzymes; PI3K phosphorylates Phosphatidylinositol 
lipids at the D3 position o f  the inositol ring (reproduced from Vanhaesobroeck and Alessi., 2000).
At the time, the discovery of PI3K was considered a major advance since it provided 
the promise of a novel signalling system involving lipids as second messengers. 
Consequently, the last decade has witnessed a rapid growth in our understanding of 
the signalling capabilities of PI3K and its lipid products. In fact, since its initial 
discovery, cDNA cloning efforts have led to the identification of nine PI3K family 
members. For classification purposes, the catalytic subunits of this family of 
enzymes can be divided into three main classes according to the lipids that they 
preferentially use as substrate, structure and likely mode of regulation as shown in 
table 1.2 (reviewed by Vanhaesebroeck et al, 1997a)
Table 1 .2 -  Classification o f  P13K Family Enzymes
Class Catalytic Subunit Substrate specificity Adaptor
Ia p i 10a p85a
p i 10(3 Ptdlns P85P
p i 108 Ptdlns(4)P
PtdIns(4,5)P2
p55y
I b pllO y plO l
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1.10.1 - Class Ia PI3-Kinases
The class Ia/PTK associated PI3K is the prototypical and best characterised family 
member and comprises a heterodimer of two peptides with apparent molecular 
masses of 110 kDa and 85 kDa (Carpenter et al., 1990). Cloning of the cDNAs of 
these protein subunits, revealed that the catalytic domain resides in the 110 kDa 
subunit, whereas the 85 kDa subunit was proposed to have a regulatory role 
(Escobedo et al, 1991; Otsu et al., 1991; Skolnik et al., 1991; Hiles et al., 1992).
The Adaptor Subunit
Three isoforms of the 85 kDa subunit have been identified (a, p,y isoforms), each 
containing an N-terminal src-homology 3 domain (SH3), two src-homology 2 
domains (SH2) and two proline rich sequences which flank a Bcr (Break-cluster 
region gene product) homology domain. The p85 SH2 domains bind to specific 
phosphotyrosine-containing motifs (pTyr-x-x-Met), thereby linking class Ia catalytic 
subunits to tyrosine kinase signalling pathways. The SH3 domain binds to short 
amino acid sequences rich in proline residues. Together, these domains of p85 
mediate the specificity of association of PI3K with other proteins.
The p i  10 subunit
The region that separates the two SH2 domains (inter-SH2 region) in the p85 subunit 
is both necessary and sufficient for binding to the N-terminal region of the 110 kDa 
catalytic subunit of PI3K. The class Ia PI3K catalytic subunits include the 
mammalian isoforms pi 10a, p and 8. Each contains several conserved regions 
including the adaptor- and Ras-binding sites, the PI-Kinase (PIK) region and the C- 
terminal kinase domain, as shown in Figure 1.8. The kinase domain of all PI3Ks is 
related to the catalytic domain of protein kinases (Hunter., 1995; Fruman et al.,
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1998). As well as the lipid kinase activities described above, the pi 10 subunit has 
also been reported to possess an intrinsic protein kinase activity (Hunter., 1995). 
This serine kinase activity may be directed towards either the catalytic subunit itself, 
or the class Ia adaptor proteins and is thought to regulate lipid kinase activity 
(Carpenter et al., 1993b; Dhand et al., 1994). A clearly documented example of this 
phenomenon is the autophosphorylation of the pi 108 isoform which completely 
down-regulates its lipid kinase activity both in vitro and in vivo (Vanhaesebroek et 
al., 1999).
The class I PI3Ks can interact with and be regulated by the small GTP-binding 
protein Ras via an N-terminal region of the catalytic subunit. At present, the 
physiological role of this interaction is still somewhat ill defined. It has been 
proposed that Ras binding may allosterically enhance the activation of PI3Ks, or 
perhaps contribute to their recruitment to membrane-bound lipid substrates 
(Rodriguez-Viciana et al., 1996; Rubio et al., 1997). Alternatively, some research 
suggests that PI3K activity could, itself, be necessary for Ras activation (Satoh et al.,
1993). In an elegant scenario Ras may help stabilise PI3K at the membrane, whilst 
PI3K could potentiate Ras activity by protecting it from the action of GTPase 
activating proteins (GAPs).
1.10.2 - Class Ib PI3-Kinases
The product of PI3K, PtdIns(3,4,5)P3 was first described in neutrophils stimulated 
with the GPCR agonist N-formyl-methionyl-leucyl-phenylalanine(fMLP) (Traynor- 
Kaplan et al., 1988; Traynor-Kaplan et al., 1989). However, whilst the prototypical 
p85/pll0 heterodimers could establish a link to receptor activated tyrosine kinase 
cascades, they could not explain the production of the 3-phosphoinositides 
downstream of heterotrimeric G-protein-coupled receptors. For a while the 
mechanism of GPCR signaling to PI3K remained obscure. The puzzle was finally 
resolved with the discovery of a fourth isoform, named PI3Ky or pllOy, since this 
enzyme was demonstrated to be sensitive to the py subunits of trimeric G proteins 
(Gpy) (Stephens et al., 1994; Stoyanov et al., 1995). Uniquely, it was found not to 
associate with p85, but instead with a novel 101 kDa adapter protein (Stephens et al.,
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1997; Krugmann et al., 1999). The structural characteristics of the class Ib PI3K 
isoform are shown in Figure 1.8.
To date, the PI3K enzymes have been identified in most cell types, and their 
activities implicated in a plethora of cell regulatory pathways. Whereas the p i 10a 
and P isoforms appear to be ubiquitously expressed, pi 108 is mainly restricted to 
haematopoietic cells (Vanhaesebroeck et al., 1997b). The G protein-regulated, 
pllOy, has so far been described mainly in haematopoietic cells (Stephens et al, 
1994).
Class IA
Ras-B C2 PIK Kinase pi 10a,(3,8
SH3 Pi Bcr Pi SH2 Inter-SH2 SH2
Pi SH2 Inter-SH2 SH2
Pi SH2 Inter-SH2 SH2
SH3 Bcr Pi SH2 Inter-SH2 SH2
1pJ SH2 Inter-SH2 SH2





Derived from a 




Ras-B C2 PIK Kinase pllO y
plO l
Figure 1 .8 -  Structural Characteristics o f  the Class l A and Class IB PI3K Family Enzymes; The PIK 
domain is a helical domain that is found in lipid kinases but not protein kinases. C2 domains bind to 
phospholipid in a calcium-independent fashion. The inter-SH2 domain o f p85a, p55a, p50a, p85|3 
and p55y constitutively interacts with the N-terminal domain o f  p i 10a,P ,8. Dual SH2 domains bind to 
tyrosine phosphorylated proteins, p i 01 specifically interacts with the N-terminal o f  p i 10y. Functions 
o f  the Ras-binding domain (Ras-B), SH3 and Bcr domains and the proline-rich region (Pr) are not 
fully understood (adapted from Koyashu., 2003).
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1.11- PROBES FOR DISSECTING PI3K SIGNALLING EVENTS 
1.11.1- Pharmacological
Early advances in understanding the role of PI3K as an important component of lipid 
signalling cascades were precipitated by the availability of pharmacological 
inhibitors of this enzyme. In particular, the discovery of the fungal metabolite 
wortmannin as a selective and potent inhibitor of PI3K (Arcaro and Wymann, 1993) 
led to an explosion in the number of publications describing the functions of PI3K in 
many systems. At concentrations up to lOOnM (Ki 1-lOnM), wortmannin irreversibly 
inhibits both the lipid kinase and serine kinase activity of PI3K, through covalently 
modifying the pi 10 catalytic domain. However, at concentrations higher than lpM, 
wortmannin has been shown to inhibit other enzymes and signalling pathways. Later, 
a structurally unrelated inhibitor of PI3K, LY-294002, was identified in a screen of 
compounds related to quercetin, a weak PI3K inhibitor (Vlahos et al, 1994). Despite 
the limitations of pharmacological inhibitors of PI3K, the careful use of both LY- 
294002 and wortmannin can still be used to accurately predict whether certain 
cellular events may be attributed to PI3K.
1.11.2 - Molecular
More recently, there have been several approaches developed which enable the 
manipulation of cDNAs corresponding to PI3K, so as to render the enzyme either 
constitutively active or inactive. Importantly, these methodologies have allowed 
more specific analysis of PI3K-dependent events. Altered forms of p85, that lack the 
pi 10-binding site, have been shown to behave as dominant-negative proteins that 
block the activation of the class Ia PI3Ks (Hara et al., 1994). Conversely, a 
membrane targeted version of pi 10a, engineered by fusing it to the extracellular and 
transmembrane domains of rat CD2 cell surface antigen, was shown to be active 
independently of p85-mediated regulation (Reif et al., 1997). A dominant negative
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mutant of the class Ib PI3K, pi lOy (K799R), that lacks lipid kinase activity has also 
been described (Lopez-Ilasaca et al., 1997; Takeda et ah, 1999)
1.11.3 - Genetic
Studies of PI3K signalling using immortalised cell lines can be problematic, and 
efforts in recent years have been channelled into studying the function of this 
signalling system in the intact organism. So far, mice deficient in either the catalytic 
or regulatory subunits for the class Ia and class Ib PI3Ks have been generated for 
analysis. Of these, pi 10a and pllOp knockout mice die in utero after 10 days 
gestation (Bi et ah, 1999; Bi et ah, 2002). In contrast, pi 108 and pllOy-deficient 
mice grow normally and p85a knockout mice expressing p55a and p50a are also 
viable (Sasaki et ah, 2000; Okkenhaug et ah, 2002; Suzuki et ah, 1999). Not 
surprisingly, mice lacking p85a, p55a and p50a have a much more severe 
phenotype than the p85a single knockout and die shortly after birth (Fruman et ah, 
1999a).
The analysis of these gene-targeted mice has already shed considerable new light on 
the importance of PI3K for T lymphocyte function. Notably, mice with a mutation in 
the pi 108 locus that allowed the continued expression of a catalytically inactive 
subunit, pi lOS091^ ,  exhibited a number of defects in T cell responses (Okkenhaug et 
ah, 2002). These included an approximate 50% reduction in CD3-stimulated 
proliferation of pi lOS09107^ 091^  CD4+ T cells and impaired PKB phosphorylation in 
response to TCR stimulation. Interestingly, pi 108D910A/D910A T cells also showed a 
reduced capacity to form lipid rafts in response to stimulation with CD3 and CD28. 
A deficiency in the class Ib PI3K, pllOy, reportedly affects T cell development and 
function. Indeed, pi 10y'7' thymocytes showed defective cell survival in one of three 
independent pllOy knockout mouse lines (Sasaki et ah, 2000). In addition, pllOy"7' 
lymph node T cells exhibited impaired responses to antigen-receptor triggering both 
in vitro and in vivo. As mentioned, genetic approaches have also targeted deletion of 
the p85 gene. However, the strategies adopted have so far only singly deleted either 
the a  or p isoforms of the p85 subunit. The possibility that one isoform may be able 
to compensate functionally for the loss of the other could explain the apparent lack of
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a T cell phenotype in the p85a'/_ and p85pv' mice (Suzuki et al., 1999; Ueki et al., 
2002).
1.12 - PI3K TARGET PATHWAYS DOWNSTREAM OF CD28
The T cell responses that are induced by CD28 co-stimulation, such as proliferation, 
cell survival, adhesion and actin rearrangement seem to closely mirror the reported 
functions of PI3K in lymphocyte activation. It is conceivable, therefore, that the 
activation of PI3K may be a critical event in determining T cell co-stimulation. 
Accordingly, the analysis of transgenic mice that express a CD28 mutant lacking the 
ability to bind PI3K, along with the use of wortmannin and LY294002 has 
demonstrated that CD28 activated PI3K is absolutely necessary for proliferation and 
IL-2 production both in vivo and in vitro (Ward et al, 1995; Harada et al., 2001). The 
PtdIns-3,4-P2 and PtdIns-3,4,5-P3 are believed to be the important products of 
activated PI3K, in linking it to downstream signalling cascades. These lipids possess 
the capacity to recruit a variety of proteins containing specialised lipid binding 
motifs, termed pleckstrin homology (PH) domains (Bottomley et al., 1998; Leevers 
et al., 1999). The phosphoinositide binding selectivity of a number of PH domain 
containing proteins has already been established, as shown in Table 1.3.
Table 1.3 -  Selectivity o f  PH Domain Containing Proteins; (Dowler et a l 2000; reviewed by 
Maffuci and Falasca., 2001)
Selectivity PH domain Protein function
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1.12.1 -  Protein Kinase B (PKB) / Akt
Interestingly, the 57 kDa serine, threonine kinase PKB was among the first proteins 
known to contain a PH domain, even before the function of this domain was 
elucidated. The PH domain (amino acids 1-106) spans a large proportion of the 
amino-terminal regulatory domain of this kinase and has been demonstrated to 
preferentially interact with PI(3,4)P2 and PI(3,4,5)P3 over other Pi’s (Isakoff et al., 
1998; Fruman et al., 1999b). A firm link between PI3K lipid products and PKB 
signalling has long been established, with extensive evidence coming from several 
cellular systems (reviewed by Coffer et al., 1998). Not surprisingly, PKB is activated 
following CD28 ligation (Parry etal., 1996).
Activation Hydrophobic 
loop m otif
PK B a, PKBp, PKBy
v-Akt = 
v-PKJBa
Viral Gag protien PH Glycine - Catalytic domain Regulatory
domain rich domain
Figure 1.9 - Schem atic representation o f  PKB structure; PKB was identified simultaneously in 
1991 by three groups, leading to some confusion over it’s nomenclature. Two groups identified the 
kinase was as a result o f  its high homology with the protein kinases A and C: this gave rise to the 
names PKB and RAC-PK (related to the A and C kinases). At the same time it was identified as the 
cellular homologue o f  the viral oncoprotein v-AKT, and is therefore also referred to as c-Akt or Akt 
(reviewed by Coffer et al., 1998; Vanhaesebroeck and Alessi., 2000).
The exact mechanism of PKB activation is complex, hence the model that has been 
proposed is still incomplete. Early experimental data demonstrated that the activation 
of PKB was accompanied by its dual phosphorylation; at Thr308 in the kinase domain 
and Ser473 in the C-terminal regulatory domain of the protein (mutagenesis of each of
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these residues to alanine confirmed that both are required for complete enzyme 
activation). Moreover, the sensitivity of this phosphorylation to PI3K inhibitors 
provided the first evidence for the involvement of PI3K and perhaps its lipid 
products in the sequence of events leading to activation (Alessi et al., 1996). PDK-1 
(3’-phosphoinositide dependent kinase) was initially identified by its ability to 
phosphorylate the Thr residue in PKB (Alessi et al., 1997a). Further investigations 
with this enzyme helped to reinforce the hypothesis that PKB activity was indeed 
induced in a PI3K-dependent manner. Critically, these studies revealed that the in 
vitro activity of PDK-1 to phosphorylate Thr308 on PKB could be dramatically 
enhanced (over 1000-fold) in the presence of lipid vesicles containing low amounts 
of PtdIns-3,4,5-P3 and PtdIns-3,4-P2 (Alessi et al., 1997a). In addition to verifying a 
role for the 3-phosphoinositides, similar experiments also highlighted the 
requirement of the PH domains of both PKB and PDK-1 in the reaction mechanism 
(Stokoe et al., 1997; Alessi et al., 1997b). Compatible with this evidence, the 
following model for the activation of PKB has been described (Figure 1.10).
CD28






I V 1 PIF
PDK2?
PH D O M A I N ^
[308
KINASE DOMA I N - J
Figure 1.10 -  M odel o f  the Activation M echanism o f  PKB by PI3K and PDK-1; Firstly, stimulation 
o f  PI3K initiates the synthesis o f  the 3-phosphoinositides, which accumulate at the plasma membrane 
and in turn orchestrate the translocation o f  PKB from the cytosol. Interaction o f  the PH domain o f
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PKB with PI(3,4)P2 and PI(3,4,5)P3 relieves the conformational inhibition that this motif exerts over 
the catalytic kinase domain and subsequently exposes the two specific phosphorylation sites at Thr308 
and Ser473. As mentioned, PDK-1 is responsible for phosphorylating die Thr308 residue and, by virtue 
of its own PH domain interaction with PI(3,4)P2 and PI(3,4,5)P3> lies conveniently at the membrane in 
juxtaposition with PKB. PDK-1 is believed to bind to basal levels o f the D3-polyphosphoinositides 
and hence be constitutively active (PH domain binds with a significantly higher affinity than that of 
PKB). Whilst, Thr308 is a substrate for PDK-1, the identity of the kinase that phosphorylates PKB at 
the Ser473 position is still in question. It has been suggested that a ‘modified’ PDK-1 (PDK1 can 
interact with a fragment of the C-terminus of PRK2, termed PIF) may also be able to phosphorylate 
PKB at this position, so leading to complete enzyme activation. However, no concrete evidence exists 
to support this notion and the identity o f the enzyme responsible remains elusive (reviewed by 
Vanhaesebroeck and Alessi., 2000).
1.12.2 - Downstream Targets of PKB that may be Relevant to T Cell Survival, 
Transcriptional Regulation and Cell Cycle Progression
Cell Survival
Over expression of PKB has an anti-apoptotic effect in many cell types, although 
how PKB actually contributes to cell survival is not fully resolved. One putative
12Amechanism involves the phosphorylation, by PKB, of a critical serine residue (Ser ) 
on the pro-apoptotic target protein BAD. BAD exists in cells as a heterodimer with 
the cell survival protein BC L xl, and accordingly functions to stifle the protective 
effect of this factor. The phosphorylation of BAD is accompanied by its interaction 
with 14-3-3 proteins, which recognise specific phosphoserine motifs. As a result of 
this newly formed association, BC L xl is liberated from the inhibitory complex and 
subsequently may exert its anti-apoptotic effect. Several groups have shown that 
PKB may specifically phosphorylate Ser136 both in vitro and in transfected cells 
(Datta et al., 1997; Del Peso et ah, 1997; Blume-Jensen et al,, 1998). However, PKB 
activation and BAD phosphorylation does not always correlate and there are many 
instances where cell survival is regulated independently of both these events, not 
suprising given the fact that expression of BAD is somewhat restricted (Scheid and 
Duronio., 1998).
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Crucially, the capacity of CD28 to promote cell survival via the regulation of BCL xl 
expression is abrogated in T cells with a targeted mutation of (p)YMNM (the motif 
that directs PI3K binding to the cytoplasmic tail of CD28). This clearly reflects an 
important role for PI3K/PKB in promoting the upregulation of BC L xl downstream 
of CD28 (Okkenhaug et al., 2001; Burr et al., 2001). While the ability of CD28 to 
engage this particular signalling pathway helps to promote T cell survival, additional 
signals are obviously required to encourage T cell proliferation and prevent the 
induction of anergy. Likewise, these too may be dependent upon PI3K and PKB. 
Indeed, activated PKB could prevent apoptosis by directly targeting the cell-death 
machinery. The caspases are a group of intracellular proteases that function as 
initiators and effectors of programmed cell death and human caspase 9 can be 
inhibited by PKB mediated phosphorylation (Cardone et al., 1998).
More recently, a transcription-based mechanism has been proposed that could 
explain how PKB interferes with apopotosis via members of the family of 
Forkhead/Foxo transcription factors (FKHR, FKHRL1 and AFX). The currently held 
view is that phosphorylation of these forkhead transcription factors by PKB promotes 
their export from the nucleus to the cytoplasm, where they are effectively retained, 
via an interaction with 14-3-3 proteins, away from their target genes. Targets of the 
forkhead transcription factors include the cyclin inhibitor, p27kipl, and the pro- 
apoptotic protein Fas ligand. Thus, inhibition of the expression of these proteins 
would aid cell survival and cell cycle progression (Brunet et al., 1999; Kops et al., 
1999; Rena et al., 1999; Biggs et al., 1999., Medema et al., 2000).
Transcriptional Regulation
In addition to promoting cell survival, the PI3K/PKB cascade is also capable of 
influencing transcription of IL-2 (Kane et al., 2001). An important mediator of any 
transcriptional effects is likely to be the enzyme p70-S6 kinase. Activation of p70- 
S6K has been implicated in the control of NFkB by CD28, a transcription factor that 
is involved along with NFAT and AP-1 in regulating the IL-2 gene enhancer 
(Downward., 1994). Downstream of CD28, p70-S6K is activated in a wortmannin 
sensitive manner (Chung et al., 1994). Although p70-S6K was initially thought to be 
a sequential effector of PI3K/PKB, emerging evidence suggests that p70-S6K may,
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in fact, lie parallel to PKB in the PI3K dependent signalling cascade, perhaps being 
activated directly by PDK-1.
It is important to note that PDK-1 may, in its own right, couple to effectors other 
than PKB. Amino acid sequences similar to those surrounding Thr308 and Ser473 in 
PKB are conserved in all members of the AGC family of Serine/Threonine kinases. 
Accordingly, PDK-1 has been demonstrated to phosphorylate the equivalent residues 
on PKC isoforms, p70-S6K and PKA (reviewed by Vanhaesebroeck and Alessi, 
2000). With respect to CD28 co-stimulation, PDK-1 may be involved in the 
activation of the novel 0 form of PKC. PKC 0 is believed to be involved both in the 
induction of IkB  Kinase-P (IkK -P) and in the activation of Cot-like kinase, which in 
turn regulates IkB  Kinase-a (IkK -gc). In addition, PKC0 has also been implicated in 
the control of JNK activation during co-stimulation of T cells. Hence, PKC0 could 
contribute to N F kB  and AP-1 regulation of the IL-2 enhancer (Sun et al., 2000; 
Moller et al., 2001).
Cell Cycle Progression
Relatively little is actually known regarding the role of PKB in the regulation of cell- 
cycle progression, although it has been suggested that the cell-cycle regulator E2F is 
a critical component of the proliferative pathway. Induction of E2F transcriptional 
activity by PKB and p70-S6K is thought to up regulate cyclin expression and thus 
help promote Gl-phase/S-phase transition (Brennan et al., 1999).
An overview of these potential downstream targets of PKB relevant to cell survival, 
transcriptional regulation and cell cycle progression is shown in Figurel.il.
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Figure 1.11 -  Overview o f  Downstream Targets o f  PKB Relevant to Cell Survival; PKB has been 
implicated in the regulation o f  multiple pathways leading to the upregulation o f  anti-apoptotic genes 
and the down-regulation o f  pro-apoptotic genes. Red lines show pathways inhibited by PKB 
phosphorylation events. Black arrows show pathways activated downstream o f  PKB (adapted from 
Vanhaesebroeck and Alessi., 2000).
1.13 - REGULA TORS OF CD28 STIMULA TED PI3K SIGNALLING EVENTS
1.13.1 - SHIP and PTEN
The PI3K signalling cascade is subject to modulation by inositol phosphatases which 
degrade the major lipid product of PI3K, PtdIns(3,4,5)P3, namely the 3’ phosphatase 
PTEN (phosphatase and tensin homologue deleted on chromosome 10) and the 5’ 
SH2-containing inositol(poly)phosphate 5’-phosphatase (SHIP).
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PTEN acts as tumour suppressor and is one of the most commonly mutated genes in 
human cancer. The role of this phosphatase seems to be particularly important with 
regard to T cell biology, since mice lacking PTEN develop T cell lymphomas and 
leukaemias (Suzuki et al., 1998; Di Cristofan et al., 1998; Podyspania et al., 1999). 
SHIP is a 145kDa protein that becomes tyrosine phosphorylated in response to 
stimulation of T and B cell antigen receptors, as well as the co-stimulatory receptor 
CD28 (Chacko et al., 1996; Edmunds et al., 1999). The role of SHIP is best 
characterised in B cells, where its negative regulatory activity is controlled by 
inhibitory receptors such as the FcyRIIB (Ono et al., 1997). Accordingly, SHIP- 
deficient mice exhibit a predominantly B cell phenotype, with hyperresponsive B 
cells, elevated levels of circulating antibodies, as well as symptoms of autoimmune 
disease (Liu et al., 1998; Helgason et a l, 1998). Despite SHIP having been linked 
biochemically to CD28 activation, the functional importance of this phosphatase in T 
cells is not fully understood. Significantly, SHIP'7' mice have been reported as having 
normal TCR/CD28- driven T cell proliferation and IL-2 production. Whilst PTEN 
may well be the key enzyme involved in the general clearance of the 3’- 
phosphoinositide lipids, recent studies have suggested that SHIP may act more subtly 
as a gatekeeper of spatio-temporal signalling in T cells (Freebum et al., 2002). 
Indeed, controlled dephosphorylation of the 5’ phosphate could shunt signal 
transduction pathways away from PI(3,4,5)P3 dependent effectors towards targets 
that are exclusively driven by PI(3,4)P2.
It is important to mention that leukaemic T cell lines, widely used in the study of T 
cell signalling, demonstrate aberrant expression of PTEN and SHIP compared with 
normal peripheral blood lymphocytes. Jurkat T cells lack the expression of both 
SHIP and PTEN at the protein level, whereas two other well-characterised T cell 
lines, CEM and MOLT-4 cells, express SHIP but not PTEN. As a consequence of the 
loss of one or other of these key lipid phosphatases, leukaemic T cells exhibit high 
basal levels of PI(3,4,5)P3 and constitutive activation of some PI3K signalling 
pathways (Freebum et al., 2002).
1.13.2 -C b l
The phenotype of mouse strains deficient in either Cbl-b or c-Cbl, two members of 
the Cbl family, are consistent with a role for these adaptor proteins as major negative
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regulators of immune cell signalling. Mutation of c-Cbl results in a thymic 
phenotype, with elevated expression levels of the TCR and altered positive selection 
(Murphy et al., 1998; Naramura et al., 1998). Whereas, mice bearing a gene-targeted 
mutation of Cbl-b display normal thymic development, but hyperproliferation of 
mature T and B cells (Bachmaier et al., 2000; Chiang et ah, 2000). Notably, Cbl-b-/- 
mice also develop spontaneous autoimmunity, and the loss of Cbl-b seems to 
uncouple T cell proliferation and IL-2 production from the requirement for CD28 co­
stimulation.
An important clue as to the mechanism by which Cbl might perform its negative 
regulatory function was brought to light with the finding that the RING-finger 
domain of Cbl acts as an E3-ubiquitin ligase (Joazeiro et al., 1999). The 
ubiqutination of proteins is an important cellular process, controlled by a cascade of 
enzymatic reactions involving El, E2 and E3 enzymes. The latter of these enzymes 
the E3s, are the components responsible for specific substrate recognition and for 
transferring ubiquitin to the target protein, thereby marking it for degradation by the 
26S proteasome. Hence, the ubiquitination of proteins by Cbl could be instrumental 
in down-regulating the response to receptor stimulation by altering the levels of 
active signal transducing components available. Perhaps most significant in terms of 
T cell co-stimulation, is the recent observation that the p85 adaptor subunit of the 
class Ia PI3Ks may be one such protein targeted for ubiquitination and degradation 
by Cbl (Fang et al., 2001).
THE IL-2 GENE ENHANCER
T cells that receive the correct combination of TCR-mediated and co-stimulatoiy 
signals enter the cell cycle and begin the synthesis of several cytokines, most 
importantly of the autocrine growth factor interleukin-2 (IL-2). IL-2 is the critical 
factor required for the progression of the newly activated T cell from G1 to S phase 
of the cell cycle and consequently is an essential determinant of whether a productive 
T cell effector response can be mounted. Occupancy of the TCR without a co­
stimulatory signal can lead to the development of a state of functional 
unresponsiveness within the T cell, termed clonal anergy. Anergic T cells 
characteristically fail to produce and respond to IL-2 (Schwartz., 1997). Therefore,
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analysis of the biochemical events that fine tune IL-2 transcription may be hugely 
important in identifying those factors that will ultimately determine functional 
outcome i.e., T cell anergy or activation.
Transcription of IL-2 is at the earliest detectable 40 mins after activation, with peak 
levels of mRNA around 6h and a return to near basal levels by 18h. Regulation of 
transcriptional activity is controlled by the IL-2 gene enhancer extending -52 to -319 
relative to the transcription initiation site. Within these base pairs, several specific 
regulatory sequences that bind nuclear factors have been identified. The sites include 
proximal and distal sequences for the nuclear factor of activated T cells (NFAT) and 
proximal and distal sequences for AP-1, for NFkB, for CD28-activated factors 
(CD28 RE), and for octamer factors, as shown in Figure 1.12 (Jain et al., 1995a; 
Hughes and Pober., 1996).
REL
NFAT AP-1 OCT NFkB DIMERS AP-1 NFAT NFAT AP-1 OCT NFAT
-280 -250 -205 -160 -150 -135 -90 -85 -75 -45
CD28RE
Figure 1.12 - Schem atic Representation o f  the IL-2 gen e enhancer; The IL-2 promoter is fine-tuned 
by several transcriptional elements (Jain et al., 1995a; Hughes and Pober., 1996).
1.14 - N F kB/REL t r a n s c r i p t i o n  f a c t o r  c o m p l e x e s
The term Nuclear factor kB (NFkB) describes a family of transcription factor 
complexes that act as mediators of inducible transcription in response to a variety of 
stimuli. In particular, NFkB is known to exert its pleitropic effects on many genes 
that participate in inflammatory responses and in the immediate early phase of 
lymphocyte activation. As mentioned, NFkB corresponds to a number of 
heterodimeric complexes composed of members of the structurally related and 
evolutinarily conserved Rel/ NFkB family of polypeptides. In eukaryotic cells, this 
family is comprised of p50 (NFkBI), p65 (RelA), p52 (NFkB2), RelB and the proto-
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oncoprotein c-Rel. In most cells, p50/p65 heterodimers represent the vast proportion 
of rapidly induced NFkB complexes and serve as relatively potent inducers of gene 
expression (reviewed by Bacuerle and Henkel., 1994). Following CD28 co­
stimulation a biphasic induction of NFkB heterodimers has been reported, with 
early-phase induction of both p50/p65 and c-Rel/p65, followed by late-phase 
induction of p50/c-Rel (Harhaj et al., 1996). Notably, c-Rel knockout mice exhibit 
profound defects in T cell functions including IL-2 secretion and T cell proliferative 
responses to CD28-mediated upregulation (Kontgen et al., 1995).
All NFKB/Rel proteins share a 300-amino acid conserved domain (Rel homology 
domain) at their N terminus and it is here that the sequences essential for 
dimerisation, DNA binding and nuclear translocation are localised (Siebenlist et al.,
1994). In resting cells, the N F kB  complexes lie dormant in the cytosol, sequestered 
there by physical association with inhibitory ankyrin-containing members of the IkB  
family of proteins, including IkB  a  and IkB P (Beg and Baldwin., 1993). The function 
of the IkB  proteins appears to be to specifically bind to and shield the nuclear 
localisation sequences contained within the N F kB  complexes, thereby preventing 
their nuclear translocation. Indeed, the ubiquitin dependent degradation of IkB  
proteins has been identified as a major step in the process of N F kB  activation. This 
degradation is preceded by the phosphorylation of IkB  and it has been proposed that 
a phosphorylation-dependent alteration in the conformation of the protein targets it 
for the activity of chymotrypsin-like proteases (Baldi et al., 1996; Sun et al., 1996). 
The cellular degradation of IkB cc only results in the transient activation of N F kB , 
since amongst the genes activated by this nuclear transcription factor is that of the 
IkB(x protein. As a consequence, the depleted pool of IkB oc is rapidly replenished 
through de novo protein synthesis (Arenzana-Seisdedos et ah, 1995). In contrast to 
that of IkB cx, the degradation of IkBP is associated with persistent nuclear expression 
of NFKB/Rel (as the expression of this gene appears not to be under the control of 
N F kB ) (Thompson et al., 1995). Recently, two serine kinases, IKKa and IKKp have 
been cloned and demonstrated to phosphorylate both IkB oc and IkB P in response to 
CD28 (Harhaj and Sun., 1998). Moreover, it looks increasingly probable that these 
IkB  kinases represent an important point of convergence for TCR and CD28 
signalling pathways, resulting in the sustained down-regulation of the inhibitory IkB
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proteins and thus prolonged activation of NFkB (Lai et al., 1994; Harhaj et al.,
1996).
1.15- THE CD28 RESPONSE ELEMENT (CD28RE)
Following CD28 co-stimulation a dramatic enhancement in the induction of IL-2 
mRNA is observed. In addition to promoting the transcriptional up-regulation of the 
IL-2 gene, the stimulatory effect of the CD28 signal is at least partially due to post- 
transcriptional modification of the IL-2 mRNA. In fact, CD28 not only confers 
stability for IL-2 mRNA, it has also been shown to prolong the half-life of other 
lymphokine transcripts including interferon-y, tumour necrosis factor-a and 
granulocyte-macrophage colony-stimulating factor (Thompson et al., 1989; Fraser et 
a l , 1991).
Verweij et al first identified a sequence within the IL-2 enhancer between -162 and 
-153 (5’-AGAATTCCA-3’) that served as a CD28 responsive element. The 
sequence of the CD28 motif is strongly conserved between the human and murine 
IL-2 gene and shows significant similarity to the consensus NFkB binding site. 
Consistent with this, cross-competition studies demonstrated that the HIV-1 NFkB 
binding motif could efficiently compete for CD28RE binding activity (Verweij et al., 
1991). To date, the NFkB family members p50, p65 and c-Rel have all been 
implicated in activation through the CD28RE and elevated nuclear expression of 
each of these polypeptides occurs upon CD28 stimulation (Ghos et al., 1993; Bryan 
et al., 1994). Naturally, the initial identification of the CD28RE led to the simple 
presumption that the co-stimulatory dependence of IL-2 expression was entirely 
mediated by this slightly modified NFkB binding site. However, it is now thought 
that CD28 responsiveness may be conferred by a composite element containing both 
the CD28RE and an adjacent AP-1 site and that cooperative binding occurs between 
Rel, c-Fos and c-Jun proteins at this multimerized location (Shapiro et al., 1997; 
McGuire and Lacobelli., 1997; Parra et al., 1998; Kempiak et al., 1999). It is clear 
that the CD28RE is an important site for signal integration within the IL-2 promoter, 
since its activation is augmented by at least two separate signalling pathways, 
through CD28, the TCR and/or mitogens such as PMA. As discussed previously, 
CD28 may stimulate the degradation of both hcBa and IkBP, two major cytoplasmic
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inhibitors of NFicB/Rel complexes. This induction of NFKB/Rel is likely to be an 
essential step in the signal-mediated activation of the CD28RE enhancer.
1.16 -AP-1
The AP-1 transcription factors are composed of members of the Jun family (c-Jun, 
Jun D and Jun B) and Fos family (c-Fos, Fos B, Fra-1 and Fra-2) proteins. These 
proteins, which belong to the class of basic-leucine zipper (bZIP) DNA binding 
proteins, form a variety of heterodimeric complexes that bind to the consensus AP-1 
binding site following cell activation. The c-Jun proteins can also form homodimers. 
However, Jun/Fos heterodimers have increased stability and display considerably 
stronger DNA-binding capacity and transactivating properties (Angel and Karin., 
1991). As previously discussed, the AP-1 and NFicB/Rel pathways act synergistically 
at the level of the CD28RE. In addition, AP-1 proteins may also complex with 
NFAT and Oct-1 proteins suggesting that AP-1 could potentially act in concert with 
a variety of transcription factors in order to delicately control IL-2 promoter activity 
(Jain et al., 1993; De Grazia et al., 1994).
The induction of genes that encode AP-1 components is an “immediate-early” event 
in T cell activation. The induction of c-Fos is rapidly mediated by the TCR- 
dependent stimulation of ERK, whereas the expression of c-Jun is potentiated by the 
activation of the JNK (c-Jun NH2-terminal kinases) group of MAPKs (reviewed by 
Karin., 1995). In T cells, JNK kinase activity (and therefore activation of AP-1 
through c-Jun) cannot be stimulated through the TCR alone, but requires a co­
stimulatory signal provided by CD28 (Su et al., 1994; Moller et al., 2001). There are 
several non-consensus sites for AP-1 binding within the IL-2 promoter, in addition to 
that flanking the CD28RE. It is possible therefore that CD28 may further contribute 
to the transcriptional regulation of the EL-2 gene through these sites.
1.17- NUCLEAR FACTOR OF ACTIVATED T CELLS (NFAT)
The inducible, lymphoid-specific transcription factor, NFAT, is essential for the 
regulation of IL-2 gene transcription upon T cell activation. The molecular makeup 
of NFAT was established by reconstitution studies that identified a T cell-specific
CHAPTER 1: Introduction 38
cytoplasmic component, pre-exisiting before activation, and a ubiquitous nuclear 
component that required protein synthesis for its induction (Flanagan et al., 1991; 
Jain et al, 1993; Northrop et al., 1993; Rao., 1994).
The constitutive component of NFAT was originally designated as NFATp (for pre- 
exisiting) and was shown to translocate to the nucleus in response to calcium 
signalling. Significantly, this calcium-dependent appearance of NFATp in the 
nucleus could be blocked by prior treatment of T cells with the immunosuppresive 
drugs cyclosporin A and FK506 (McCaffrey et al., 1993). To date, four distinct gene 
products have now been identified that can function as the cytoplasmic component of 
NFAT: NFATp, NFATc, NFAT3, and NFAT4/x/c3 (Northrop et a l , 1994). Together 
they constitute quite a divergent family of transcription factors that share weak 
identity with the NFKB/Rel family over a 300 amino-acid region appropriately 
termed the Rel homology domain (RHD). The NFAT family has at least 65% 
homology throughout the RHD, since sequences in this region govern DNA binding 
and dimerisation with AP-1 family proteins (Jain et a l, 1995). Upstream of the RHD, 
NFAT proteins are less closely related, however they do share blocks of N-terminal 
serine-rich and serine-proline repeat segments of potential regulatory function.
As mentioned, the hallmark of NFAT activity is its inducibility by stimuli that 
increase intracellular calcium (eg.TCR ligation or calcium ionophores). This calcium 
flux activates the calmodulin-dependent phosphatase calcineurin, which interacts 
with NFAT via the RHD and de-phosphorylates specific serine residues contained 
therein (Luo et a l, 1996). The targeting of NFAT by calcineurin is vital for its 
nuclear translocation and explains the sensitivity of this process to CsA and FK506 
(these drugs are potent inhibitors of calcineurin when complexed with cyclophilin 
and FK506-binding protein, respectively) (McCaffrey et a l, 1993). Several studies 
have examined the distribution and activation of cytoplasmic NFAT proteins in T 
lymphocytes. In mature cells, NFATc, NFATp and NFAT4/x/c3 have overlapping 
expression patterns and appear to be co-regulated. Perhaps functional redundancy 
between members of this protein family may in some way explain the relatively mild 
phenotype observed in NFATp null mice (lymphocytes proliferate normally and 
produce normal amounts of IL-2) ( Lykah et a l, 1997; Timmerman et a l, 1997).
The transcriptionally induced nuclear partner of the constitutive NFAT proteins 
consists of Fos and Jun family members, which seem to assist the stable assembly
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and attachment of NFAT complexes with DNA (Jain et al., 1993). The AP-1 
component of NFAT is induced within 30 min after T cell activation and is 
insensitive to CsA or FK506. Activation of protein kinase C promotes the 
transcriptional regulation of Fos and Jun genes and thus treatment with PMA can 
substitute for the TCR in their induction. In addition the TCR-dependent activation 
of ERK and the CD28-dependent stimulation of JNK may be important signals 
aiding NFAT activity.
FACTORS THAT MAY CONTRIBUTE TO TCR AND 
CD28-MEDIATED CO-STIMULATION
1.18-ADAPTER PROTEINS
As molecular scaffolds for the appropriate recruitment, localisation and regulation of 
effector enzymes, adapter (or linker) proteins are the indispensable co-ordinators of 
cellular activation. Adapters themselves do not possess any enzymatic or other direct 
effector function, but instead are defined by their expression of a variety of modular 
domains (eg. SH2, SH3, PTB or PH domains) or tyrosine based signalling motifs. 
These facilitate constitutive or inducible protein-protein or protein-lipid interactions 
with other signal transducing components. In T lymphocytes a number of adapter 
proteins have already been identified, some of which play central roles in mediating 
antigen receptor driven activation. They can be broadly grouped into two categories: 
adapter proteins that represent integral membrane proteins (transmembrane adapter 
proteins) and adapter proteins that are preferentially located in the cytoplasm 
(cytosolic adapter proteins).
1.18.1 - The LAT, Gads, SLP-76 Orchestra
The best-characterised membrane-associated scaffolding complex in T cells 
comprises LAT (transmembrane adapter), Gads and SLP-76 (both cytosolic adapters) 
and is involved in the initiation of Ca2+ flux and the stimulation of the Ras 
downstream of the TCR. LAT (linker for activated T cells) resides constitutively at
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the membrane, localised in the lipid rafts, and becomes tyrosine phosphorylated by 
ZAP-70 upon TCR stimulation (Zhang et al., 1998). Once phosphorylated, LAT 
recruits several SH2 domain containing proteins including PLCyl, the adapters Grb- 
2 (complexed with Sos) and its family member Gads. The SH3 domain of Gads 
constitutively associates with the proline-rich region of SLP-76, which upon 
phosphorylation provides the binding site for SH2 domain of the Tec family tyrosine 
kinase, Itk. Thus, recruitment of Itk into this complex occurs in parallel with the 
binding of another key effector molecule, PLCyl. It has been proposed that PLCyl 
then becomes activated by its dual phosphorylation mediated by ZAP-70 and Itk 
(reviewed by Leo et al., 2002).
1.18.2 - PAG
The Src family kinases play a central role in lymphocyte activation hence tight 
regulation of their activity is absolutely necessary for the maintenance of 
immunological homeostasis. In this respect, the transmembrane adapter protein 
phosphoprotein associated with glycosphingolipid micro domains (PAG) has 
emerged as a potential negative regulator of Src kinase activity through its 
association with C-terminal Src kinase (Csk). Crucially, overexpression of PAG in T 
cells has been shown to potently suppress Src kinase activity and T-cell activation 
(Brdicka et al., 2000)
1.18.3 - TRIM
The transmembrane adapter protein TRIM (T-cell receptor interacting molecule) was 
initially identified as a 30 kDa protein that co-precipitated with the CD3^ chain and 
thus far seems to be specifically expressed in T lymphocytes (Bruyns et al., 1998). 
One recent study assessing the functional relationship between TRIM and the TCR in 
Jurkat T cells led to the suggestion that TRIM upregulates the expression of the TCR 
complex at the cell surface by inhibiting its spontaneous internalisation. Indeed, 
Jurkat T cells overexpressing TRIM not only display elevated levels of TCR 
expression but also an approximate two-fold enhancement of Ca2+-flux after TCR 
triggering, suggesting that TRIM might additionally modulate signal strength
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(Kirchgessner et al., 2001). In relation to its signalling capabilities, TRIM becomes 
phosphorylated by members of the Src family kinases and recruits the p85 subunit of 
PI3K via a Y79XXM motif in its cytoplasmic domain (Bruyns et al., 1998). It is 
possible therefore, that TRIM could regulate the function of PI3K, a key player 
during several cellular responses such as adhesion, actin rearrangement, cell growth 
and survival (reviewed by Lindquist et ah, 2003).
1.18.4 -  MAGUK Family Proteins
Recently, members of the MAGUK (membrane-associated guanylate kinase) family 
of adapter proteins have been implicated in TCR/CD28-mediated regulation of 
NFkB and IL-2 production. MAGUKs have a distinctive structure that includes a 
PDZ domain, an SH3 domain and a prototypical GuK (guanylate kinase) domain. 
They anchor to receptors through their PDZ domains and act as molecular scaffolds 
that tether these membrane receptors to the intracellular signalling machinery 
(Dimitratos et al., 1999). The Caspase-recruitment domain (CARD) family member 
CARD 11 (CARMA-1) is of particular interest due to its preferential expression by 
lymphocytes. Upon TCR crosslinking, CARD 11 dimerizes with another CARD- 
containing protein, Bel 10, which in turn induces the oligomerization of MALT-1 and 
the subsequent activation of NFkB. Accordingly, CARD 11-deficient and Bel 10- 
deficient T cells exhibit selective defects in TCR/CD28-induced activation of IkB 
kinase (IKK) and in the induction of NFkB (Wang et al., 2002; Pomerantz et a l, 
2002; Hara et al., 2003).
Interestingly, PKC-family members are now thought to function along side 
CARD 11, since the co-expression of a constitutively active PKC0 mutant together 
with CARD 11 (or Bel 10) synergistically activated NFkB in T cells (Wang et ah, 
2002). Furthermore, CARD11, like PKC0 translocates to lipid rafts in stimulated T 
cells and is associated with Bel 10 (Gaide et al., 2002). Indeed, it is tempting to 
speculate that the CARD 11/Bel 10 complex may couple PKC0 to the IKK 
signalosome. However, it remains to be determined whether such a scaffold is in fact 
formed in T cells.
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As briefly discussed here, a number of adapter proteins have been identified as being 
essential for lymphocyte function. However, many other transmembrane and 
cytosolic adapter proteins are expressed within lymphocytes for which functional 
data is scarce. Elucidation of the signalling function of these scaffolding proteins, 
along with the continued identification of new adapters, promises to shed 
considerable new light on how TCR and CD28- mediated signals may be integrated 
at the intracellular level into an appropriate cellular response.
1.19 - THE SH2-CONTAINING PROTEIN TYROSINE PHOSPHATASES
The activation of tyrosine kinases and the initiation of protein tyrosine 
phosphorylation is an essential step in the propagation of those signals controlling 
cell proliferation and differentiation by the TCR and CD28. The overall balance of 
tyrosine phosphorylation within the cell is strictly choreographed by the action of 
PTKs working in concert with various protein tyrosine phosphatases (PTPs). Whilst 
the actions of such phosphatases are likely to be important in attenuating positive 
signals emanating from tyrosine kinases, in some instances they may also stimulate 
signalling by reversing inhibitory phosphorylation events. For example, 
dephosphorylation of the C-terminus of Src family kinases leads to the activation of 
these PTKs, which in turn transduce positive signals in T cell activation.
Tyrosine phosphatases comprise a large family of both transmembrane and 
cytoplasmic enzymes. However, a small group of SH2-containing tyrosine 
phosphatases have been strongly implicated in the control of signalling downstream 
of activated growth factor, cytokine and antigen receptors. This family of 
phosphatases contains SHP-1 and SHP-2 in vertebrates and csw, a likely homolog of 
SHP-2 in Drosophila species.
1.19.1 - Structural and Biochemical Aspects of SHP-2
SHP-2 was originally identified by cDNA cloning (Freeman et al, 1992) as the 
putative mammalian homologue of the Drosophila gene corkscrew (csw). SHP-2 is a 
ubiquitously expressed cytosolic protein tyrosine phosphatase that shares many 
structural and regulatory features with SHP-1 (approximately 60% overall identity). 
These include the two tandem N-terminal SH2 domains, followed bv a C-terminal
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phosphatase domain that contains two conserved tyrosine phosphorylation sites, Y542 
and Y580. Unlike SHP-1, SHP-2 contains an additional C-terminal proline-rich 
domain that may interact with SH3 domain containing proteins. The schematic 
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Figure 1.13 - Schem atic Representation o f  the Structure o f  SHP-2; SHP-2 comprises two tandem 
SH2 domains, followed by a catalytic domain and two conserved tyrosine phosphorylation sites, Y542 
and Y580. R, C and D are three conserved residues in the catalytic site required for phosphatase 
activity.
Studies using phospho-tyrosine containing peptides revealed that the SH2 domains of 
these tyrosine phosphatases bind to phosphotyrosyl residues within the ITIM motif 
(I/V/L/S)XYXX(L/V) (Dechert et al., 1994; Vivier and Daeron., 1997). In addition 
to characterising targets for the SH2 domains of SHP-1 and SHP-2, these early 
experiments also highlighted an auto-regulatory role for the amino-terminal SH2 
domains. A tethered biphosphotyrosyl peptide that bound with high-affinity to both 
SH2 domains of SHP-2 was shown to potently activate phosphatase activity (Pluskey 
et al., 1995). Likewise, a truncated SHP-2 protein lacking the SH2 domains exhibited 
enhanced phosphatase activity when compared to the full-length protein in vitro 
(Dechert et al., 1994). More recently, resolution of the crystal structure of SHP-2 has 
confirmed that repression by its amino-terminal domain conformationally inhibits 
substrate binding and catalytic activity (Hof et al., 1998). A model for the activation 
of SHP-2 through simultaneous occupation of its SH2 domains is shown in Figure 
1.14.
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Figure 1.14 - M odel fo r  the Activation o f  SHP-2; 1. The “closed” conformation: Under basal 
conditions the unoccupied SH2 domains and the C-terminal tail region interact with one another and 
the PTPase domain to inhibit catalytic activity. 2. Activation by phosphotyrosyl peptides: Peptide 
binding to the SH2 domains stimulates catalysis by stabilizing an “open”, active conformation. 3. A 
tethered ligand that binds the two SH2 domains simultaneously is extremely potent at stimulating 
PTPase activity. M onophosphopeptide occupancy o f the SH2 domains also stimulates catalytic rates 
(albeit much less efficiently), presumably by inducing a related open state (Pluskey et al., 1995).
Activation of receptors for a myriad of growth factors and cytokines has been shown 
to recruit SHP-2 (reviewed by Huyer and Alexander., 1999; Feng; 1999). This can 
occur either directly through an SH2 domain interaction with the receptor or 
indirectly through docking proteins. The two carboxy-terminal tyrosine residues of 
SHP-2 may also become phosphorylated upon receptor ligation, in turn providing 
potential SH2-binding sites for other proteins. In fact, these tyrosine residues 
represent consensus-binding sites for the Grb-2 adaptor and it has been proposed that 
SHP-2 may be a positive effector of signal transduction by functioning as an adaptor 
protein that links to the Ras/MAP kinase cascade (Li et al., 1994; Welham et al.,
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1994). However, overexpression of an SHP-2 protein in which these C-terminal 
tyrosines were mutated to phenylalanine was shown to have no effect on MAP kinase 
activation (Bennet et al., 1996).
Much of the evidence supporting a positive role for SHP-2 in mammalian cell 
signalling comes from studies in mice with a deletion mutation in the SH2-N domain 
of SHP-2. Disruption of the murine SHP-2 gene causes the death of mouse embryos 
at midgestation, establishing an unequivocable role for this phosphatase in normal 
development. Further studies with cells isolated (ex vivo) from the SHP-2 mutant 
embryos demonstrated pertubations in MAP kinase activation, haematopoiesis and 
cell migration (Qu et al., 1997; Saxton et al., 1997; O’Reilly and Neel., 1998; Shi 
and Feng., 1998; Yu et al., 1998; Qu et al., 2001). In fact, multiple lines of evidence 
point to the fact that SHP-2 is a critical component linking cytokine and growth 
factor receptor signalling to MAP kinase activation. Catalytically inactive mutants of 
SHP-2 inhibit the activation of the ERK MAP kinases in response to insulin, EGF 
and FGF (Noguchi et al., 1994; Tang et al., 1995; Bennet et al., 1996). In addition, 
SHP-2 is required for IL-5-induced MAPK activation in eosinophils and for IL-2- 
induced MAPK activation in T cells (Pazdrak et al., 1997; Gadina et al., 1998). 
Collectively, these experiments indicate that substrates specific for the SHP-2 
catalytic domain may be essential for its positive role in signal transduction. In some 
systems, SHP-2 function has also been linked to the activation of immediate early 
genes, such as c-fos and STAT (Bennet et al., 1996; Gadina et al., 1998). Taken 
together, this data could suggest that SHP-2 acts upstream of the MAP kinases, 
which, in turn lie upstream of the immediate-early genes. It is important to note that 
not all the data derived from the SHP-2 mutant embryos pointed to a positive role for 
SHP-2 in MAP kinase activation. In reality, the effects of SHP-2 may depend upon 
cellular context and the receptor pathway stimulated. Interestingly, SHP-2 has been 
implicated as a negative effector of JNK activation by cellular stress (Shi et al., 
1998).
1.19.2 - Evidence for the Role of SHP-2 in T Cells
Much of the work concerning the role of SHP-2 has been concentrated in the area of 
growth factor receptor and cytokine receptor signalling. However, SHP-2 recruitment 
has also been described following T-cell and B-cell antigen receptor ligation
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(Frearson and Alexander., 1998; reviewed by Tamir et al., 2000). Frearson and 
Alexander first proposed that SHP-2 participated in a signalling pathway linking the 
TCR to the Ras-regulated MAP kinase cascade in Jurkat T cells. Illustrated by 
experiments using a catalyically inactive (C-»S) mutant of SHP-2, Frearson’s model 
suggested that the initial event following TCR induced activation of PTKs was the 
tyrosine phosphorylation of a cytosolic pi 10 protein and the membrane-localized 
adaptor protein, p36/LAT. This was proposed to result in the formation of a 
multimeric complex containing tyrosine phosphorylated pi 10 as the central scaffold 
for SHP-2, PI3K and Grb-2 binding. The observed translocation of this complex to 
the plasma membrane was explained via Grb-2’s association with p36/LAT. It was 
further hypothesised that arrival at the membrane would cause full activation of 
SHP-2 and the subsequent dephosphorylation of pi 10. The promotion of the 
Ras/MAPK pathway was ascribed to the release and presumed activation, thereof, of 
PI3K (Frearson and Alexander., 1998).
At the time of this research, the SHP-2 associated pi 10 tyrosine phosphorylated 
protein in Jurkat cells had not been formally identified. However, it was thought to 
correspond to the SHP-2 associating proteins p97 and p i00 that had been observed in 
other haematopoietic cell lines (Welham et al., 1994; Adachi et al., 1997; Bone et 
al., 1997; Carlberg and Rohrschneider., 1997; Gu et al., 1997; Craddock and 
Welham., 1997). The broad electrophoretic nature of the protein could be attributed 
to multiple states of tyrosine phosphorylation, suggesting that pi 10 was a docking 
protein similar to IRS-1/2, GAB-1 or Dos. It seemed most likely that pi 10 was the 
mammalian equivalent of Dos, since Dos was the known substrate for the Drosophila 
homologue of SHP-2, csw. By analogy, it could be predicted that the p97-pll0 
protein would contain an amino-terminal PH domain, proline-rich sequences and 
multiple tyrosine phosphorylation sites.
1.20 - THE GRB-2 ASSOCIATED BINDER PROTEIN-2 (GAB-2); A  
CYTOSOLIC ADAPTER PROTEIN
Purification and cloning of the 97-110 kDa docking protein was achieved by Gu and 
co-workers in 1998 (Gu et al., 1998). As had been predicted, the newly described 
protein shared some resemblance with Dos, although this was found to be restricted
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largely to the PH domain. Significantly greater similarity was displayed with the 
mammalian adaptor GAB-1 and for this reason, the novel protein was christened 
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Figure 1.15 -  Schematic Domain Structures o f  the GAB Family Proteins; All GAB family proteins 
consist o f  an N-terminal PH domain, a central proline rich region and multiple tyrosine based 
signalling motifs (adapted from Liu and Rohrschneider., 2002).
The GAB family proteins share a common architecture defined by an N-teminal PH 
domain, a central proline-rich region and multiple tyrosine phosphorylation sites. 
Indeed, this structural make-up is consistent with the proposed role of the GAB 
proteins as the assembly points for multimeric protein complexes. Mutational 
analysis has identified the binding sites for a number of key signal relay molecules 
within GAB-2. Moreover, investigations have uncovered that these interactions may 
be functionally important in a variety of cellular contexts (reviewed by Liu and 
Rohrschneider., 2002).
The PH domain is the most conserved structural element among the GAB proteins 
and is thought to contribute to membrane targeting, through recognition of the 
phosphoinositide lipids. The PH domain of GAB-1 has been shown to specifically 
bind PtdIns-3 ,4 ,5 -P3, one of the products of activated PI3K (Maroun et al., 1999). It 
seems probable, that the PH domain of GAB-2 demonstrates similar target 
specificity, although this has not yet been verified. The central region of GAB-2 
contains numerous PXXP motifs, some of which mediate the binding of the SH3 
domains of Grb-2 (a canonical Grb-2 binding site with PXXPXR motif and an 
atypical Grb-2-binding site with PX3RX2KP motif). In fact, a signature of all GAB
CHAPTER 1: Introduction 48
proteins is their constitutive association with Grb-2 and both sites are conserved 
among family members (Schaeper et al., 2000; Lock et at., 2000; Lewitzky et al., 
2001).
As discussed, the GAB-2 protein was simultaneously identified by a number of 
groups due to its association with the protein tyrosine phosphatase SHP-2 and the 
p85 subunit of PI3K. The cloning of GAB-2 (and subsequent identification of the 
consensus binding sites for SHP-2 and p85) paved the way for the generation of 
various mutant proteins targeted to interfere with such interactions. Naturally, these 
mutants greatly facilitated research into the functional significance of GAB-2 
binding within cells.
1.20.1 - GAB-2/SHP-2 Interaction
Upon phosphorylation, two tyrosines located in the C-terminal end of GAB-2 fall 
within consensus binding motifs for SHP-2 (Y604LAL/Y633VQV). A deletion mutant 
lacking these residues (aa 604-666) was unable to bind SHP-2 upon stimulation with 
the cytokine IL-3 and furthermore failed to transduce signals for the full activation c- 
fos (Gu et al., 1998). Assembled evidence indicates that a key role of GAB-2 is to 
both recruit SHP-2 and activate its phosphatase activity. Indeed, occupation of both 
the SH2 domains of SHP-2 is known to relieve the inhibitory ‘closed’ conformation 
of this enzyme and lead to activation (Hof et al., 1998). The recent discovery that 
Y627 and Y659 of the human GAB-1 protein constitutes a biphosphotyrosyl activation 
motif for SHP-2 goes some way in supporting this notion (Cunnick et a\., 2001).
The identification of GAB-2 as a hyperphosphorylated protein in cells expressing 
catalytically inactive (substrate-trapping) mutants of SHP-2 also led to the prediction 
that GAB-2 itself may be a target for de-phosphorylation (Herbst et al., 1996; Gu et 
al., 1997; Frearson and Alexander., 1998). This argument is corroborated by in vitro 
phosphatase assays that further implicate the GAB proteins as substrates for SHP-2 
(Nishida et al., 1999; Gu et al., 1997; Cunnick et al., 2001). As yet, however, the 
collective evidence is not conclusive enough to substantiate this hypothesis. 
Moreover, the physical association between GAB-2 and SHP-2 may simply allow 
activated SHP-2 access to its true substrates, these perhaps having been recruited 
within the same complex by GAB-2. The identification of the bona fide effectors of
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SHP-2 is a formidable task, but nonetheless essential for understanding the 
mechanisms by which SHP-2 activates downstream signalling events, such as the 
MAP kinase cascade and the transcriptional activation of immediate early genes.
1.20.2 - GAB-2/p85 Interaction
Another principal binding partner of tyrosine phosphorylated GAB-2 is the p85- 
subunit of the class U PI3Ks. In total, three pYXXM motifs are present in GAB-2 
which represent consensus binding sites for the SH2 domains of p85 (Y441, Y461 and 
Y574) (Gu et al., 1998). The physical association between GAB-2 and p85 is likely to 
be crucial in mediating PI3K signalling downstream of receptors that lack the ability 
to bind p85 directly (eg. the IL-3R). Accordingly, ablation of p85 binding by the 
appropriate tyrosine to phenyalanine mutation of GAB-2 impairs the ability of IL-3 
to activate PKB and to induce cell growth. Interestingly, GAB-2 also becomes 
tyrosine phosphorylated upon stimulation of receptors that may bind p85 directly or 
which have other means for p85 recruitment. In such instances, GAB-2 could 
potentially amplify PI3K signalling or maybe even co-ordinate recruitment of select 
Class Ia PI3K isoforms (Gu et al., 1998).
It is feasible that GAB-2 transmits signals to the MAP kinase cascade via PI3K. In 
several systems, PI3K has been shown to function upstream of the MAP kinases in 
both Ras-dependent and Ras-independent pathways (Duckworth and Cantley., 1997; 
Grammer and Blenis., 1997). Such a capability would explain the observations by Gu 
et al who demonstrated, somewhat suprisingly, that GAB-2 could enhance MAP 
kinase activation, independently of its association with SHP-2 (overexpression of 
GAB-2 led to a potentiation of MAPK signalling that was not opposed by expression 
of mutants lacking SHP-2 binding) (Gu et al., 1998).







Figure 1.16 -  Overview o f  Signalling involving GAB-2, SH P-2 and P13K Downstream o f  the IL-3 
Receptor; Much o f  the early work defining the role o f  signalling complexes involving GAB-2, SHP-2 
and PI3K was carried out downstream o f  the cytokine receptor IL-3. Here, such complexes have been 
implicated in the stimulation o f  the Ras/MAP kinase cascade, activation o f  PI3K signalling pathways 
and induction o f  immediate-early gene expression (Gu et al., 1998).
1.20.3 - Evidence for the Role of GAB-2 in T Cells
Thus far, the most thorough evaluation of GAB-2 function has been in the domain of 
cytokine receptor signalling (reviewed by Liu and Roschneider., 2002). In this 
respect, GAB-2/SHP-2 and GAB-2/PI3K associations have been shown to 
orchestrate positive signalling roles. As in cytokine signalling, GAB-2 becomes 
heavily tyrosine phosphorylated upon stimulation of the T cell antigen receptor 
(Nishida et al., 1999). However, in contrast to its positive role in cytokine signalling, 
GAB-2 has been reported to negatively regulate TCR signalling by the recruitment of 
inhibitory molecules (Pratt et al., 2000; Yamasaki et al., 2001). In studies by Pratt et 
al, overexpression of wild-type (WT) GAB-2 was shown to inhibit TCR/PMA- 
evoked activation of the IL-2 promoter, by interfering with NFAT and NFkB 
transactivation. In these Jurkat cell transfection assays, the expression of a GAB-2-
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3YF mutant and a Gab-2 PH domain truncation mutant (that respectively lacked the 
capability to interact with p85 and membrane phospholipids) was not inhibitory, 
suggesting a requirement for PI3K and phospholipid binding in the GAB-2 mediated 
effect. The inhibitory action of GAB-2 in T cells appeared not to require a GAB- 
2/SHP-2 interaction since overexpression of a GAB-2 mutant unable to bind SHP-2 
retained its inhibitory potency. In conclusion, it was postulated that an inhibitory 
pool of PI3K was associated with GAB-2 and that this was key in terminating TCR 
activation events (Pratt et al., 2000).
More recently, Yamasaki and co-workers further examined the role of GAB-2 in T 
cells and similarly concluded that it was a negative regulator of TCR signalling 
(Yamasaki et al., 2001). In agreement with the findings by Pratt et al, these studies 
also demonstrated that overexpression of GAB-2 resulted in a down-regulation of 
TCR-mediated NFAT activation and IL-2 production. However, one major 
discrepancy was evident when comparing the finer details of the two groups findings. 
In Yamasaki’s experiments the inhibitory function of GAB-2 was largely dependent 
on SHP-2 and not PI3K. In this system, the GAB-2 mutants defective in SHP-2 
binding abrogated the inhibitory activity of GAB-2. Furthermore, the loss of 
inhibitory function could be restored by a chimeric protein in which active SHP-2 
was fused to the carboxyl terminus of GAB-2. At present, the reason for this 
apparent inconsistency over the involvement of SHP-2 is unclear. However, it is 
possible that the disparity could be due to experimental differences in the cell 
treatments used. In this regard, Yamasaki et al utilized anti-TCR stimulation in the 
absence of PMA and the more physiologically relevant stimulus super antigen plus 
APC. Interestingly, the observations described herein also appear to contradict those 
of Frearson who reported a positive role for SHP-2 in linking MAP kinase activation 
to the TCR. One explanation is that SHP-2 has multiple functions, both positive and 
negative, mediated via multiple binding targets in T cells. Drawing on the current 
evidence it seems possible that the negative function of SHP-2 could be dependent 
on GAB-2.
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STROMAL CELL-DERIVED FACTOR-1
1.21 - CLASSIFICATION OF CHEMOKINES AND THEIR RECEPTORS
Chemokines (chemotactic cytokines) comprise a burgeoning family of proteins, 
characterised by their effects as potent attractors and activators of various leukocyte 
subsets. They are produced by a variety of cell types in response to injury and 
infection, and have an established role in the selective recruitment and extravasation 
of leukocyte populations into inflammatory sites. Recent interest in chemokines and 
their receptors has paralleled their emerging importance in a wide range of biological 
functions, which extend beyond the mere regulation of leukocyte migration. In 
addition to their role in immune and inflammatory responses, chemokines have also 
been implicated in haematopoiesis, neuronal cell migration and in the regulation of 
angiogenesis. The involvement of chemokine receptors as co-receptors for the fusion 
and entry of human immunodeficiency virus-1 (HIV-1), perhaps represents the most 
exciting discovery in this field to date (Moore., 1997; reviewed by Rollins., 1997; 
Ward and Westwick., 1998).
Since the prototypical chemokine, IL-8, was described in 1987, over 40 chemokines 
have been identified. For classification, they can be divided into four subgroups 
depending upon the relative arrangement of the conserved amino-terminal cysteine 
residues in the mature protein, as shown in Figure 1.17 (Ward and Westwick., 1998; 
Zlotnik and Yoshie., 2000). In the CXC, or a-chemokine family, the first two 
cysteines are separated by a non-conserved amino acid, whereas members of the CC, 
or p-chemokine family, contain these two cysteine residues adjacent to each other. 
The majority of chemokines fall into these two catergories. However, two 
chemokines that do not have recently been cloned: Lymphotactin, which contains 
only two cysteines, is the only member of the C subfamily and fracktaline, a 
membrane bound glycoprotein, is a CX3C chemokine.
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Figure 1 .17 - Schem atic diagram o f  the structure o f  the chem okine fam ily members; The four 
chemokine families are distinguished by their relative arrangement o f  cysteine residues at the NH2- 
terminus (W ard and Westwick., 1998)
Chemokines mediate their effects through binding to specific receptors on their target 
cells. These receptors belong to the family of G-protein coupled, seven- 
transmembrane spanning domain receptors, and are subdivided into two main 
families, CXCR and CCR, defined by their chemokine specificity (as shown in Table 
1.4) (Ward and Westwick., 1998). Chemokine receptors are expressed on different 
types o f leukocytes, with some receptors being more widely expressed than others. 
The pattern of chemokine receptor expression on T lymphocytes is further regulated 
depending upon the activation or differentiation state of the cell (Sallusto et al., 
1998). Until recently, it was thought that chemokine receptors were purely restricted
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to leukocytes. However, they are now known to be present on other cell types as 
diverse as endothelial, epithelial, neuronal and smooth muscle cells. This in some 
way reflects a growing appreciation for the multiple biological roles mediated by 
chemokines and their receptors.
Table 1.4 -  Human Chemokine Receptors and Ligand Specificity.
Receptor Ligand
CC chemokines
CCR1 MIP-la, RANTES, MCP-2, MCP-3, MIP-5 (leukotactin-1)
CCR2A/B MCP-1, MCP-2, MCP-3, MCP-4
CCR3 Eotaxin-1, eotaxin-2, MIP-5, RANTES, MCP-2, MCP-3, MCP-4
CCR4 TARC
CCR5 RANTES, MIP-la, MIP-lp
CCR6 LARC
CCR7 ELC, SLC
CCR8 1-309, TARC, MIP-ip
CXC chemokines
CXCR1 IL-8








1.22 - STROMAL CELL DERIVED FACTOR-1 AND THE CHEMOKINE 
RECEPTOR CXCR4
The chemokine, stromal cell derived factor-1 (SDF-1) was first cloned from mouse 
bone marrow and classified with the CXC chemokine family, based on the presence 
of an intervening amino acid between the two NH2-terminal cysteines (Nagasawa et 
al., 1994). However, it is now thought to represent a distinct subgroup of the CXC 
family, due to the presence of several unusual features. Firstly, all the other known 
CXC chemokine genes cluster on chromosome 4, whereas the SDF-1 gene maps to 
chromosome 10. Sequence homology also shows that SDF-1 is evolutionarily related
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almost equally to both the CC and CXC chemokines, and the fact that it is 
extraordinarily conserved between species is consistent with the belief that it could 
be a primordial chemokine. Indeed, only a single amino acid substitution exsists 
between the mouse and human proteins. Two isoforms of SDF-1 have been 
identified, SDF-1 a  and SDF-1 p, which arise by differential splicing from a single 
encoding gene. These two proteins differ in four functionally unimportant carboxy- 
terminal amino acids that are present in SDF-1 a  but absent in SDF-1 p (Shirozu et 
al., 1995).
SDF-1 was initially characterised through its ability to stimulate pre-B cell 
proliferation and to regulate B cell maturation. In addition to its effects on B cells, 
SDF-1 is also a highly efficient chemoattractant of CD34+ haematopoietic progenitor 
cells, T lymphocytes and monocytes (Nagasawa et al., 1994; Bleul et al., 1996; Aiuti 
et al., 1997). To date, the most important information as to the multiple biological 
roles of SDF-1, has been gleaned from studies in knockout mice with a targeted 
disruption of the SDF-1 gene (Nagasawa et al., 1996). In the mutant embryos, a 
reduction in the number of B-cell progenitors and bone marrow myeloid precursors 
is reported, which is compatible with a role for SDF-1 in B-cell lymphopoiesis and 
bone marrow myelopoiesis. Based on this evidence, it has been suggested that SDF-1 
may act to direct haematopoietic progenitor cells into the correct environment to 
receive those signals essential for proliferation and differentiation. It is suspected that 
SDF-1 could also have a role in delivering these signals itself, since its first known 
biological activity was as a pre-B cell stimulatory factor.
SDF-1 is the biological ligand for the chemokine receptor CXCR4, a G-protein 
coupled transmembrane receptor. Unlike the induced expression of other chemokines 
and their receptors, SDF-1 and CXCR4 can be found constitutively expressed in a 
variety of cell types. For instance, CXCR4 is not only expressed on cells of the 
immune system but is also found distributed within the central nervous system, on 
neurones, astrocytes and microglia. With regard to biological function, mice lacking 
CXCR4 exhibit haematopoietic defects identical to those in SDF-1 deficient mice. 
This similarity of phenotype suggests a monogamous relationship between SDF-1 
and CXCR4, unusual amongst the background promiscuity of the other chemokines 
and their receptors. Extended studies in SDF-1/CXCR4 deficient mice have further 
identified activities for this chemokine/receptor pair in the vascular development of
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the gastrointestinal tract and in neuronal cell migration and patterning (Ma et al., 
1998; Tachibana et al., 1998; Zou et al., 1998). However, these functions were 
somewhat eclipsed by the discovery that CXCR4 also acts as a co-receptor for the 
cellular entry of T-cell tropic HTV strains. Consistent with this, SDF-1 has been 
demonstrated, in vitro, to specifically block the viral entry and infection of CD4+ T 
cells through CXCR4 (Feng et al; 1996; Oberlin et al., 1996).
Despite the importance of SDF-1 and its receptor CXCR4 in the pathophysiology of 
HTV infection and in various other functional settings, relatively little is yet known 
about the biochemical signals underlying these events. SDF-1 has been shown to 
elicit calcium elevation and has also been reported to stimulate phosphorylation of 
ERK1/2 in several cell models. The tyrosine phosphorylation and association of focal 
adhesion complex components (such as Pyk-2, paxillin, Crk and RAFTK) are 
enhanced upon SDF-1 stimulation. In addition, activation of the transcription factor 
NFkB and the activation of PI3K has been reported (Davis et al., 1997; Ganju et al., 
1998; Sotsios et al., 1999). Thus, the association of SDF-1 with CXCR4 activates 
multiple signalling pathways that may mediate cell growth, migration and 
transcriptional regulation.
1.23 - ACTIVATION OF PI3K ISOFORMS B Y  SDF-1
A combination of molecular and pharmacological evidence suggests that the 
activation of PI3K is an essential component of those signalling pathways that induce 
the phenomenon of leukocyte chemotaxis (reviewed by Cumock et al., 2002). 
Consistent with this, SDF-1 has been shown to activate PI3K and stimulate the 
chemotaxis of T lymphocytes in a wortmannin-sensitive manner. The accumulation 
of 3-phosphoinositide lipids is commonly exploited as a measure of PI3K activation 
following receptor ligation. In this regard, SDF-1 provokes an elevation of 
PtdIns(3,4,5)P3) in T cells, that is both rapid and transient; increased levels are 
detectable within 15 s and a return towards basal levels occurs within 5 min post 
chemokine treatment (Sotsios et al., 1999).
Given that chemokine receptors are G protein-coupled, it seems reasonable to 
assume that the observed lipid accumulation following SDF-1 stimulation is as a 
result of the class Ib PI3K, PI3Ky. Accordingly, the accumulation of PtdIns(3,4,5)P3
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stimulated by SDF-1 can be completely inhibited by pretreatment with pertussis 
toxin. Moreover, SDF-1 provokes an increase in the in vitro lipid kinase activity 
associated with anti-PI3Ky immunoprecipitates, with kinetics that closely mirror 
those observed for the accumulation of the 3-phosphoinositide lipids in intact cells 
(Sotsios et al., 1999). Whilst this biochemical evidence strongly supports the 
activation of PI3Ky by SDF-1 and its ostensible role in PtdIns(3,4,5)P3 accumulation, 
there is also a body of evidence to suggest that other classes of PI3K may be 
activated. The most convincing data argues for the activation of class Ia PI3K 
isoforms. In vitro assays using an anti-p85 antibody to immunoprecipitate the 
p85/pl 10 complex indicate that SDF-1 shares the capacity to activate these 
heterodimers in T cells. This supposition is further sustained by the observation that 
SDF-1 stimulates the co-precipitation of p85 with anti-CXCR4 in human peripheral 
blood T lymphocytes. In addition, SDF-1 is understood to stimulate tyrosine 
phosphorylation within cells, and the p85/pl 10 heterodimer is known to co-associate 
with phosphotyrosine-containing proteins in many systems. Accordingly, several 
studies have reported that lipid kinase activity may be detected in SDF-1 stimulated 
anti-phosphotyrosine immunoprecipitates (Ganju et al., 1998; Sotsios et al., 1999; 
Vicente-Manzanares et al., 1999).
Despite evidence for the activation of class Ia isoforms by SDF-1, there are still 
concerns as to whether or not they contribute markedly to the accumulation of the 3- 
phosphoinositide lipids or indeed to SDF-1 mediated chemotaxis. For instance, SDF- 
1 stimulated PtdIns(3,4,5)P3 production is completely abrogated by pre-treatment 
with pertussis toxin, whilst SDF-1 activation of p85/pll0 is insensitive to this 
inhibitor. Moreover, the increased in vitro lipid kinase activity present in anti- 
phosphotyrosine immunoprecipitates following SDF-1 stimulation exhibits slower 
time-course kinetics (maximum activation around 15 mins) compared to the rapid 
accumulation of 3-phosphoinositide lipids that is observed in intact cells (maximum 
around 1-2 min) (Sotsios and Ward unpublished observations). Thus, it appears that 
p85/pll0 makes no significant offering to the initial wave of PtdIns(3,4,5)P3 
production.
Until recently, pharmacological analysis pertaining to the contribution of specific 
PI3K isoforms to SDF-1 chemotaxis has been severly limited by the lack of 
selectivity of the available inhibitors. Fortunately, advances in molecular
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pharmacology have allowed the functional consequences of PI3K activation to be 
more accurately evaluated. A now common molecular approach is to establish stable 
transfectants that overexpress dominant negative forms of the enzyme. In one such 
study, dominant-negative constructs of the class Ia and class 1b were inducibly 
expressed in the leukaemic T cell line, Jurkat. In this system, SDF-1 mediated 
chemotaxis of Jurkat cells was significantly, but not completely, abrogated in clones 
expressing the dominant-negative PI3Ky construct. Interestingly, Jurkat cells 
expressing a dominant-negative mutant of the class Ia PI3Ks also exhibited a marked 
reduction of chemotactic responses to SDF-1, albeit to a lesser extent than observed 
with the class Ib mutant. This was the first convincing data that both class Ia and 
class Ib PI3K isoforms support optimal migratory responses to SDF-1 (Cumock and 
Ward., 2003a; Cumock et al., 2003b). Whilst previous studies were unable to detect 
any contribution of class Ia PI3K to the accumulation of the 3-phosphoinositide 
lipids, it is evident that the p85/pl 10 heterodimer does influence cell migration. One 
possible explanation is that the class Ia PI3K makes a small, but nevertheless 
important contribution to the overall pool of these lipids formed in response to SDF- 
1 stimulation. Alternatively, the biological role for p85/pl 10 may reside in the 
protein serine kinase activity of the catalytic subunit rather than its lipid kinase 
activity.
1.24 - FACTORS THAT M AY CONTRIBUTE TO SDF-1 MEDIATED 
CHEMOTAXIS
1.24.1 - SHP-2
A role for SHP-2 in cell migration was first suggested by Yu et al who reported 
impaired cell spreading and motility in fibroblasts from homozygous SHP-2'7' mouse 
embryos (Yu et al., 1998). In these studies, the authors hypothesised that the defect 
in integrin-mediated chemotaxis was due to an alteration in cytoskeletal organization 
in the SHP-2 mutant cells. Notably, the SHP-2-/- cells displayed an increased 
number of focal adhesions and condensed F-actin staining at the cell periphery when 
compared with wild-type fibroblasts. Since these abnomalities were reminiscent of 
the phenotype of focal adhesion kinase (FAK)-deficient cells, it was suggested that
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SHP-2 might work in concert with FAK in controlling the dynamic turnover of focal 
adhesions required during cell migration. The exact mechanism of how both SHP-2 
and FAK play a positive role in promoting cell movement is not fully elucidated. 
One explanation is that FAK undergoes recycling between inactive
(unphosphorylated) and active (phosphorylated) forms during cell migration and that 
SHP-2 mediates FAK dephosphorylation. Consistent with this premise, is the 
observation that FAK dephosphorylation is significantly reduced in SHP-2 mutant 
fibroblasts. Furthermore, the regulated association of FAK (and Paxillin) with Src 
SH2 domain is disrupted in SHP-2 -/- cells during attachment to and detachment 
from ECM (Yu et al., 1998). More recently, studies in MCF-7 breast 
adenocarcinoma cells expressing a dominant negative form of SHP-2 (SHP-2 C—>S) 
have strengthened the argument that the concerted activity of SHP-2 and FAK 
regulates cell motility (Manes et al., 1999). In these investigations, SHP-2 catalytic 
activity was a general requirement for cell motility mediated through different 
integrins and induced by diverse chemotactic factors, such as IGF-1 and RANTES. 
The SFIP-2 effect on migration strongly correlated with the control of FAK 
phosphorylation, which in turn governed the assembly and disassembly of focal 
adhesions.
1.29.2 - GAB-2
The close interaction between SHP-2 and the cytosolic scaffolding protein, GAB-2, 
has been well documented. This prompted Yu et al to speculate that GAB-2 might 
also play a role in the regulation of integrin mediated cell adhesion and migration. To 
test this hypothesis, the involvement and signalling function of GAB-2 in pi- integrin 
signal transduction was examined through expressing various dominant-negative 
GAB-2 molecules in the haematopoietic cell line, Ba/F3 (Yu et al., 2002). In these 
studies, GAB-2 was rapidly tyrosine phosphorylated upon pi- integrin cross-linking, 
providing docking sites for SHP-2 and Class Ia PI3K. Inhibition of the function of 
endogenous GAB-2 by transducing the PH domain of GAB-2 or a deletion mutant of 
GAB-2 without SHP-2 binding sites (Tyr604 and Tyr633) significantly reduced 
hematopoietic cell adhesion and migration (approx. 40-50%); thereby suggesting the 
importance of the PH domain (and perhaps cellular localization of the GAB-2
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complex through phospholipid binding), as well as a requirement for the GAB- 
2/SHP-2 association. As discussed, SHP-2 potentially promotes integrin-mediated 
cell motility via a FAK dependent pathway. More recently, however, another distinct 
integrin signalling pathway independent of FAK has emerged, which is mediated by 
the non-receptor tyrosine kinase, Syk. It seems that GAB-2 may be involved in the 
Syk-mediated pi- integrin signalling cascade, since GAB-2 was found to be closely 
associated with activated Syk kinase in these experiments.
PI3K plays a critical role in haematopoietic cell adhesion and migration. 
Interestingly, biochemical analyses revealed that PI3K activation in response to 
integrin ligation was compromised in the haematopoietic cells transfected with the 
mutant GAB-2 molecules (Yu et al., 2002). Indeed, GAB-2 may contribute to the 
activation of PI3K in a number of ways. Firstly, GAB-2 could provide a mechanism 
for the translocation of class Ia PI3K to the membrane, which would allow this 
enzyme access to its phospholipid substrates. Secondly, the interaction of GAB-2 
with the p85 regulatory subunit may lead to a conformational activation of the pi 10 
catalytic subunit of PI3K. Finally, GAB-2 may function as an intermediary, allowing 
SHP-2 to perhaps regulate PI3K activation. Compellingly, Yu and co-workers 
demonstrated that the dissociation of SHP-2 from the GAB-2 complex significantly 
reduced PI3K activation (Yu et al., 2002).
In reviewing the present evidence it is tempting to speculate that signalling 
complexes involving GAB-2, SHP-2 and PI3K may play a role in SDF-1 induced 
chemotaxis. Afterall, the recruitment of such complexes could provide a mechanism 
for the activation of class Ia PI3K downstream of G-protein coupled receptors. 
Many groups have shown that SDF-1 induces the tyrosine phosphorylation of 
components of focal adhesion proteins, and SHP-2 could be important in the 
regulation of this process. Recently, SDF-1 stimulation of T cells was reported to 
induce the tyrosine phosphorylation of SHP-2. In addition, enhanced SDF-1 
chemotaxis was observed in Jurkat T cells with the transient overexpression of wild 
type SHP-2 (Chemock et al., 2001).
CHAPTER 1: Introduction 61
AIMS
Elucidation of the signalling mechanisms underlying T cell activation is essential for 
the identification of suitable targets for immunotherapy. Of particular importance in 
this regard, is to gain a better understanding of how co-signals from the CD28 
receptor may be integrated with those emanating from the TCR, so as to tip the 
balance between T cell anergy and activation.
Signalling complexes comprising GAB-2, SHP-2 and PI3K have been implicated 
downstream of the TCR in the control of both MAP kinase activation and in the 
transcriptional regulation of the IL-2 gene. It was the aim of this study to define 
whether signalling downstream of the CD28 co-stimulatory receptor involved the 
coordination of similar protein complexes and to establish how these impacted 
overall on the T cell functional response. Specific objectives of the project included:
• Verify the contribution of CD28 co-stimulation to T cell activation.
• Confirm that CD28 is a major regulator of PI3K.
• Characterise the potential protein-protein interactions between GAB-2, SHP-2 and 
PI3K following CD28 stimulation.
• Identify substrates for the protein tyrosine phosphatase activity of SHP-2.
• Clarify the role of GAB-2 signalling complexes in the transcriptional regulation of 
the IL-2 gene; an important functional marker of T cell activation.
• Define the role of SHP-2 in modulating the MAP kinase signalling pathway during 
T cell activation.
Growing evidence suggests that multiple PI3K isoforms may be involved in the 
mediation of chemokine-stimulated cell migration. Indeed, both class Ia and class Ib 
PI3Ks have been implicated in SDF-1 induced chemotaxis of T lymphocytes. As yet, 
however, the mechanism by which the G-protein coupled receptor CXCR4 regulates 
the activation of the p85/pll0 heterodimers has not been resolved. Given the 
demonstrated importance of GAB-2 in recruiting PI3K to receptors that lack the 
ability to bind this enzyme directly, the present study aimed to discover whether
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GAB-2 may similarly act downstream of CXCR4 to couple SDF-1 stimulation to 
activation of the class Ia PI3Ks. Moreover, since another principal binding partner 
of GAB-2, the protein tyrosine phosphatase SHP-2 has been implicated in cell 
migration in response to various chemotactic factors, the contribution of this enzyme 
to SDF-1 chemotaxis was also investigated. The primary objectives of this study 
were:
• Verify that SDF-1 stimulates activation of the class Ia PI3Ks.
• Define whether complexes involving GAB-2, SHP-2 and PI3K are formed in 
response to SDF-1 stimulation.
• Examine the role of SHP-2 in SDF-1 mediated chemotaxis.
2MATERIALS AND METHODS
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CELLS AND CONDITIONS OF CULTURE
All cells were cultured at 37°C in a humidified atmosphere of 5% (v/v) CO2.
2 7 -  JURKAT T CELLS
The human leukaemic T cell line, Jurkat, was obtained from Dr. Andres Alcover (Paris). 
Cells were maintained in RPMI 1640 medium supplemented with 10% (v/v) fetal calf 
serum, 50 IU/ml penicillin/streptomycin and 2mM glutamine.
2.2-CHO-B7.1 CELLS
Chinese hamster ovary cells (CHO) stably transfected with B7.1 ligand were cultured in 
HAMS media supplemented with 10% (v/v) fetal calf serum and 50 IU/ml 
penicillin/streptomycin. When confluent, cells were passaged by trypsination performed 
by removal of the media, a single wash with phosphate buffered saline (PBS) and gentle 
detachment by incubation for 2-5 min at 37°C in 0.25% (w/v) trypsin.
2.3 - ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCs) 
FROM HUMAN BLOOD
50mls of venous blood was taken from a healthy human volunteer into a heparinised 
syringe. The blood was subsequently diluted 1:1 (v/v) with RPMI in a 175ml tissue 
culture flask. 35mls of the blood/RPMI mix was gently layered on to 15mls of 
Lymphoprep in clear 50ml plastic falcon tubes. The layered tubes were centrifuged at 
1500rpm for 30 minutes in a Jouan CR412 centrifuge (without the brake on). Following 
centrifugation, the milky mononuclear interface was swiftly removed and transferred 
into fresh 50ml falcon tubes. The isolated cells were washed 3 times in RPMI by 
centrifugation at 1500rpm for 5 min. The resulting PBMC preparation was subsequently 
used to generate T lymphoblasts , or were subjected to further purification procedures so 
as to separate primary T cells.
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2.4 - GENERATION AND MAINTENANCE OF T-LYMPHOBLASTS
T-lymphoblasts were enriched from the mixed population of PBMC’s by stimulation 
with lpg/ml Staphylococcus enterotoxin B for 72hrs at 37°C, 5% (v/v) CO2. Cells were 
then washed 3 times by centrifugation at 1500rpm for 5 min in a Jouan CR412 
centrifuge. The T-lymphoblasts were cultured in RPMI medium supplemented with 10% 
(v/v) fetal calf serum, 50 IU/ml penicillin/streptomycin and 2mM glutamine. The 
addition of 20ng/ml human recombinant IL-2 every 2 days was critical for sustaining 
these cells in culture. T-lymphoblasts were used in experiments following three rounds 
of IL-2 treatment.
2.5 - PURIFICATION OF PRIMARY T CELLS
Primary T cells were purified from PBMCs through a MACS separation column 
(Miltenyi Biotech, Germany). PBMCs were washed twice in PBS without calcium and 
magnesium (PBS-A). Cells were resuspended at a 1X107 cells per 80pl of buffer A 
(PBS-A, 1% (w/v) BSA, 2mM EDTA). Negative selection was carried out for 15 min at 
4°C using a primary hapten antibody cocktail against the cell surface markers of 
unwanted cells; anti-CD 19 (B cells), anti-CD36 (APCs), anti-CD 16 (mast cells), anti- 
CD 1 lb (neutrophils) and anti-CD56 (NK cells). Cells were then washed twice in PBS-A 
and resuspended in buffer A, as previously. Anti-hapten microbeads were added and the 
cells incubated at 4°C for a further 15 min. Folowing this period, cells were washed 
once more in buffer A and resuspended at a concentration 2X108 cells/ml, ready for 
addition to the magnetic column. The PBMCs were flushed through the column with 
buffer A and the eluate containing purified T lymphocytes was collected. The T 
lymphocytes were centrifuged at 1500rpm for 5 min in a Jouan CR412 centrifuge and 
then resuspended in RPMI 1640 medium.
2.6-ISOLATION OF MOUSE SPLENOCYTES AND THYMOCYTES 
Mouse thymuses and spleens were dissected out and placed in a sterile container. Cell 
suspensions were prepared by gently pressing the thymuses and spleens through a wire 
mesh into 10ml RPMI 1640 medium using the sterile barrel of a 2ml syringe. The 
resultant cell suspensions were transferred to 50ml centrifuge tubs and left for 5 min to
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allow for gravity sedimentation and removal of large debris and aggregates. The 
remaining cells were then pipetted into clean tubes and washed three times with RPMI 
1640. After the final wash, the thymocytes and splenocytes were resuspended at the 
appropriate density ready for stimulation.
Table 2.1- Tissue Culture Materials and Reagents
PRODUCT SUPPLIER
GROWTH MEDIA
HAMS Life Technologies (Paisley, Scotland)
RPMI 1640 Life Technologies
SUPPLEMENTS
Fetal calf serum Life Technologies




Lymphoprep Axis Shield (Oslo, Norway)
Staphyloccus enterotoxin B Sigma (Poole, UK)
Primary hapten antibody cocktail Miltenyi Biotec (Germany)
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BIOCHEMICAL TECHNIQUES
2.7 - BACTERIAL EXPRESSION AND PURIFICATION OF GLUTATHIONES- 
TRANSFERASE (GST) FUSION PROTEINS
PGEX-2T plasmid constructs encoding for the N and C-terminal SH2 domains of the 
p85a subunit of PI3K were generously donated by Dr. M.J. Welham (the University of 
Bath, UK). These were transformed into the Escherichia coli strain DH5a (Life 
Technologies) and grown overnight in lOmls of 2 X YT broth containing ampicillin 
(lOOpg/ml) at 37°C. The overnight culture was then subcultured 1: 50 in 500ml 2 X YT 
broth with ampicillin and grown at 37°C until a mid log OD600 between 0.6-0.8. 
Production of the GST-fusion protein was then induced with 0.1M isopropyl-P-D- 
thiogalactoside (IPTG) at 27°C overnight. Post-induction the bacteria were pelleted at 
6000 x g for 10 min at 4°C in a Beckman J2-21 centrifuge and resuspended in 15ml of 
buffer TBN150 (25mM Tris-HCl pH 7.5, 150mM NaCl, lOmM 2-mercaptoethanol, 
lOpg/ml leupeptin, 1.4pg/ml pepstatin, 10pg/ml soybean trypsin inhibitor, 40pg/ml 
PMSF, 5pg/m 1 aprotinin) on ice. Lysozyme was added to a final concentration of 
0.1 mg/ml to lyse the cells. After 10 min at 25°C, the lysate was freeze-thawed three 
times in a dry-ice/ethanol bath and a 37°C water bath. The lysate had MgCh added to 
lOmM and DNase added to 50pg/ml before being incubated at 25°C for 15 minutes. 
EDTA (pH 8.0) and NP40 were then added to final concentrations of 20mM and 2.5% 
(v/v) respectively and the lysates incubated for another 15 min at 25°C. The cell lysates 
were then centrifuged at 30,000 x g for 30 minutes at 4°C in a Beckman J2-21 
centrifuge. The crude extract supernatant was decanted and divided into 1ml aliquots for 
storage at -80°C.
The GST-fusion protein was affinity-purified from the crude extracts by incubating 1ml 
of extract with 500jil of packed glutathione sepharose beads at 4°C for 2 hours. The 
beads were washed 1 x 10ml PBS, 2 x 10ml PBS + 0.5% (v/v) NP40 and 1 x 10ml PBS 
and the GST-fusion protein then eluted by competition with reduced glutathione (for 
5ml 20mM glutathione elution buffer: 0.0307g glutathione, 1.5ml 1M Tris-HCl pH 7.5, 
3.5(4,! 2-mercaptoethanol and 2.5pl of each protease inhibitor) through a 10ml poly-prep
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column (Biorad). The 0.5ml eluted fractions were pooled and the glutathione removed 
removed by dialysis against PBS. The concentration and purity of the protein was then 
determined by Bradford assay and by SDS-PAGE respectively (see section 2.9 and 2.12)
2.8 - STIMULATION OF CELLS AND PREPARATION OF CELL EXTRACTS
T cells were harvested by centrifugation and washed three times in serum-free RPMI 
1640 medium. The viable cell count was determined by trypan blue staining and using a 
standard haemocytometer. Cell were resuspended at the required cell density in the same 
medium, supplemented with 20mM HEPES buffer and equilibrated for 30 min in a 37°C 
water bath. Cells were stimulated by gentle co-sedimentation with CHO-B7.1 (approx. 
ratio of 1 CHO-B7.1 cells: 3 T cells), followed by incubation for the required 
stimulatory period at 37°C. Stimulations were also performed using monoclonal 
antibodies against the CD28 receptor (9.3) and against the CD3 complex of the TCR 
receptor (UCHT1). In each case cells were stimulated for the required time by 
incubation with 5pg/ml of the antibody. Following stimulation cells were pelleted in a 
Jouan A14 microcentrifuge for 20-30 seconds, the supernatant was aspirated off and the 
cell pellet solubilised in an appropriate volume of ice cold solubilisation buffer (50mM 
Tris-HCl pH5, 10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 150mM NaCl, 5mM EDTA, 
ImM sodium fluoride, 40pg/ml phenylmethylsulphonyl fluoride (PMSF), lOpg/ml 
aprotinin, lOpg/ml soybean trypsin inhibitor, lOpg/ml leupeptin and 0.7pg/ml 
pepstatin). Lysates were clarified by centrifugation at 4°C, 14, OOOrpm for 5 min in a 
Beckman GS-15R centrifuge (F3602 rotor) and the supernatant transferred to a clean 
tube.
2.9 - PROTEIN QUANTIFICATION B Y BRADFORD ASSAY
The protein concentration of cell extracts was determined using the Bradford assay 
(Bradford, 1976). To generate a standard curve, a series of known concentrations of 
bovine serum albumin (BSA) were prepared. 1-5pi of each sample with unknown 
protein concentration were added to tubes containing 0.5ml water + 0.5ml Bradford 
reagent and vortexed. The optical density of the samples was determined by measuring 
absorbance at 595nm in a 96-well microplate reader (Dynatech MR5000).
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Measurements were performed in duplicate and the mean values calculated. The protein 
concentrations of the cell extracts were calculated from the standard curve prepared 
using the known dilutions of BSA.
2.10 - IMMUNOPRECIPITA TIONS
The immunoprecipition technique was used to look at the co-associations between 
proteins in this study, also in the in vitro lipid kinase assays and the in vitro phosphatase 
assays. Information about the antibodies used is given in Table 2.3. Cell extracts were 
incubated with the appropriate antibody for 2 hours on a rotator at 4°C. 30pl of a 50% 
(v/v) slurry of protein G sepharose (murine antibodies) or protein A sepharose (rabbit 
antibodies) beads were then added as necessary and the samples rotated at 4°C for a 
further 1-2 hours. The sepharose beads were washed three times in 500pl solubilisation 
buffer and the precipitated protein eluted by boiling in IX SDS-PAGE sample buffer 
(5X stock; 10% (w/v) SDS, 50% (v/v) glycerol, 0.2M Tris-HCl pH 6.8, bromophenol 
blue to colour and 2-mercaptoethanol).
2.11 - PULL DOWN EXPERIMENTS USING GST-FUSION PROTEINS
In vitro binding analyses were performed using GST fusion proteins in a similar manner 
to immunoprecipitation but 10-20pg of the GST-fusion protein were used in place of 
antibody and bound proteins were recovered using 40pl of a 50% (v/v) slurry of 
glutathione sepharose beads.
2.12 - IMMUNOBLOTTING
Immunoblot anlaysis requires the separation of isolated cellular proteins according to 
size by SDS polyacrylamide gel electrophoresis. The apparatus used was the Bio-Rad 
mini-protean-II gel equipment, which was assembled according to the manufacturer’s 
guidelines. The resolving gel was prepared at the desired percentage, poured between 
the two glass plates and overlaid with water (for details of gel composition see Table 
2 .2).
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7.5 3.75 5.6 5.6 0.25
10 5.0 4.35 5.6 0.25
12 6.0 3.35 5.6 0.25
* To each gel mixture were added 50|il 10& (v/v) ammonium persulphate and 20pl TEMED.
Once polymerisation had occurred the water was aspirated off and the stacking gel 
(1.67ml acrylamide, 6ml milli-Q H2O, 1.25ml 1M tris-HCl pH 6.8, 0.15ml 10% (w/v) 
SDS, 50pl 10% (w/v) ammonium persulphate and 20pl TEMED) was poured. A 15-well 
comb was inserted to create the wells for the loading of the protein samples. Once set the 
comb was removed and the wells filled with IX SDS-PAGE running buffer (25mM 
Tris-base, 192mM glycine, 0.1% (w/v) SDS) before the samples and molecular mass 
markers were loaded. The gels were placed into a gel tank with IX SDS-PAGE running 
buffer and the protein samples run through the stacking gel at 80V and the resolving gel 
at 170-190V until the bromophenol blue dye front had reached the bottom of the gel. 
Once the samples had run through the gel, it was removed from the apparatus and 
soaked in semi-dry transfer buffer (39mM glycine, 48mM Tris-base, 0.0375% (w/v) 
SDS and 20% (v/v) methanol). The separated proteins were transferred from the gel and 
immobilized onto nitrocellulose by semi-dry transfer using Pharmacia-Biotech 
Multiphor II electroblotting equipment. Upon the bottom (positive) of the two graphite 
electrodes a stack was made consisting of 4 pieces of gel-sized 3MM Whatman paper, a 
piece of nitrocellulose membrane, the gel and another 4 pieces of 3MM Whatman paper 
(all soaked in the transfer buffer). Any air bubbles were expelled before the upper 
(negative) electrode, dampened with semi-diy transfer buffer, was gently lowered into 
place. The gel was transferred for 60 min at a constant 0.8mA/cm2 of membrane. 
Following transfer, the nitrocellulose was stained with water-soluble Ponceau S to check 
for the successful and even transfer of proteins. The stain was removed by washing the 
blotted membrane in Tris-buffered saline (TBS) (20mM Tris-HCl pH 7.5, 150mM 
NaCl).
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The non-specific binding of antibody was blocked by incubation of the membranes with 
a blocking agent (either 5% (w/v) BSA, 1% (w/v) ovalbumin, 0.05% (w/v) azide in 
TBS, or 5% (w/v) powdered milk (marvel), 0.05%(w/v) azide in TBS, depending upon 
the specific antibody to be used) for 2 hours to overnight. After a 10 min wash with 
TBS, the blot was immersed in primary antibody (0.1-0.5pg/ml) for 3 hours (for details 
of antibodies used see Table 2.3). Following this incubation period, the membrane was 
washed 3 X 1 0  min in TBSN (TBS with 0.05% (v/v) NP-40) before application of the 
hoseradish peroxidase-conjugated secondary antibody (either goat anti-rabbit or goat 
anti-mouse IgG) for 1 hour. The membrane was washed as previously and after one 
further 10 min wash in TBS the enhanced chemiluminescent reagent (ECL) was added 
for 1 min. Reactive protein bands were visualized by exposure of the membrane to 
Kodak X-AR5 film, followed by developing with the RGII Fuji X-ray film developer.
2.13 - STRIPPING AND REPROBING IMMUNBLOTS
Antibody conjugates were stripped from blots by incubation with stripping buffer 
(62.5mM Tris-HCl pH 6.7, 2% (w/v) SDS and lOOmM 2-mercaptoethanol) in a 50°C 
water bath for 1 hour. The membranes were stringently washed with TBSN, before 
being blocked and reprobed with antibody.
Table 2.3-Antibodies Used in This Study
ANTIBODY SOURCE SUPPLIER
PRIMARY ANTIBODIES
4G10 Mouse UBI (Lake Placid, USA)
9E10 Mouse Cells from ATCC
9.3 (a-CD28) Mouse Carl June (University of 
Pennsylvania, PA, USA)
UCHT1 (a-CD3) Mouse Doreen Cantrell (University 
of Dundee, UK)
a-ERK 1 and 2 Rabbit Cell Signalling 
(Massacheucets, USA)
a- phospho-ERK 1 and 2 Rabbit Cell Signalling
a-GAB-2 Rabbit UBI
a-HA Mouse Glaxo Smithkline
^Cfairanona T Ttr\
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(Stevenage, UK)
a-p85 Mouse Doreen Cantrell
a-pl 105 Mouse Bart Vanhaesebroeck 
(Ludwig Institute, London)
a-SHP-2 Rabbit Santa-Cruz 
(California,US A)
SECONDARY ANTIBODIES
Mouse Goat DAKO (Cambridgeshire, 
UK)
Rabbit Goat DAKO
2.14 - IN  VITRO PHOSPHATASE ASSAYS
SHP-2 immunoprecipitates were prepared (as described in section 2.10) from cell 
extracts which had been lysed in solubilisation buffer containing or lacking the 
phosphatase inhibitors (ImM sodium ortho vanadate, ImM sodium molybdate and 
lOmM sodium fluoride). Samples were washed three times in the appropriate lysis 
buffer and once in phosphatase buffer (25mM PIPES pH6.25, 50mM NaCl, lOmM 2- 
mercaptoethanol, lOpg/ml soybean trypsin inhibitor, 40pg/ml PMSF), containing or 
lacking phosphatase inhibitors, before resuspension in the appropriate phosphatase 
buffer and incubation at 20°C for 50min. Reactions were terminated by pelleting and 
boiling in SDS-PAGE sample buffer.
2.15 - IN  VITRO LIPID KINASE ASSAYS
Immunoprecipitates were washed three times with solubilisation buffer, once with PBS, 
twice with 500mM lithium chloride (LiCl), PH7.4, once with distilled water and once 
with lipid kinase buffer (5mM MgCb, 0.25mM EDTA, 20mM HEPES). After the final 
wash, excess buffer was removed by aspirating with a hamilton syringe. Samples were 
resuspended in 40pl of lipid kinase buffer and the lipid kinase reaction initiated by the 
subsequent addition of 50pl substrate mix (5pCi of y-32P-ATP, IOOjuM cold ATP and 
1 mg/ml each of phosphatidylinositol and phosphatidylserine dispersed by sonication in 
25mM HEPES, ImM EDTA pH 7.4). Following a 20 min incubation at 25°C, reactions 
were quenched with lOOpl 1M HC1 and 200jal 1:1 (v/v) chloroform:methanol. Organic
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extraction was carried out by centrifuging samples for 30s at 14,000rpm, followed by the 
removal and drying down of the lower chloroform layer in-vacuo. Once dried, samples 
were reconstituted in 50pl chloroform and vortexed. Samples were applied in lOpl 
volumes onto a linear-K pre-adsorbent TLC plate (sprayed with 1% (w/v) potasssium 
oxalate). The loaded plate was placed in a TLC tank which had been pre-equilibrated 
with propan-l-ol: glacial acetic acid: water (130:4:66 (v/v)) and with a filter paper 
‘wick’. The tank was run overnight, until the solvent front had migrated to the top of the 
plate. Once removed from the solvent system, the TLC plate was air-dried and exposed 
to iodine vapour, enabling the rough detection of the radioactive lipid bands. The plate 
was then exposed to Kodak X-AR5 film and finally developed through a RGII Fuji X- 
ray film processor. The PI3K product PI(3)P was confirmed by comparison with 
previously standardised experiments performed by Dr. S. Ward. Below is a diagram of a 
typical TLC resolution with non-labelled standards (Dr. S. Ward personal 
communication).
4 — Solvent front 






Figure 2.1 -  Diagram o f a Typical TLC Resolution with Standards
2.16 - LABELLING OF CELLS WITH
EXTRACTION OF LIPIDS FOR ANALYSIS
Jurkat T cells were depleted of phosphate prior to labelling with 32P-Pi by washing 
three times in 50ml phosphate-free Dublecco’s Modified Eagles Medium (DMEM).
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Between washes cells were incubated at 37°C for 10 min. After phosphate depletion, 
cells were resuspended in phosphate-free DMEM, supplemented with 5% (v/v) dialysed 
fetal calf serum and 20mM HEPES. Following the addition of lmCi/ml 32P-Pi, the cells 
were incubated in a 37°C water bath for 4 hours. After the incubation period the cells 
were washed three times in the phosphate-free media in order to remove any 
unincorporated label. Cells were then resuspended in DMEM at a cell concentration of 
approximately 2X107 cells/ml. Appropriate cell stimulations were carried out as 
described previously, in 120pl volumes for the required times at 37°C. Reactions were 
terminated by the addition of 500 pi chloroform: methanol: H2O (32.6: 65.3: 2.1 (v/v)) 
to produce a homogeneous primary extraction phase. Phases were separated by the 
addition of 200pl chloroform containing lOpg/ml Folsch lipids and 200pl 2.4M HC1, 
5mM tetrabutylammonium sulphate. Samples were vortexed and centrifuged at 1000 x g 
for 5 min. After centrifugation, the lower phase was removed into clean tubes and dried 
in-vacuo. Once dried, the extracted lipids were deacylated by the addition of 1ml 25% 
(w/v) methylamine: methanol: N-butanol (4: 4: 1 (v/v)) followed by incubation in a 
53°C water bath for 40 min. Samples were then cooled rapidly on ice for 5 min and 
again dried in-vacuo. 0.5ml H2O followed by 0.6ml N-butanol: petroleum ether: ethyl 
formate (20: 4: 1 (v/v)) were added to the dried deacylated lipids and the samples 
vortexed and centrifuged 1000 x g for 5 minutes. The upper organic phase was then 
carefully removed and discarded. The lower phase was dried in-vacuo. The dried down 
pellet was redissolved in 60pl H2O and the deacylated 32P-labelled lipids analysed by 
HPLC using a 12.5cm Whatmen Partisphere SAX column. Samples were eluted from 
the column using a gradient based on buffer A (H2O) and buffer B (1.25M (NFL^HPC^, 
adjusted to pH 3.8 with H3PO4 at 25°C) at a flow rate of lml/min. Eluates were analysed 
with an on-line radiochemdetector and the eluted peaks compared to retention times for 
standards prepared from the commercial 3H-phosphoinositides and 32P-labelled 
phosphoinositides.
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Figure 2.2 -  Sample HPLC elution profile o f  deacylated 32IPI~labelled phosphoinositides derived from  
CD28-activated Jurkat I  Cells.
Table 2 .4 -  Reagents
REAGENT SUPPLIER







Sodium molybdate BDH (Poole, Dorset, UK)
PMSF Sigma
Aprotinin Roche Biochemical (Crawley, East Sussex, 
UK)
Soybean trypsin inhibitor Sigma
Leupeptin Sigma
Pep statin Sigma
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Bradford assay reagent BioRad (California, USA)
LMMUNOPRECIPITATIONS
Protein A sepharose Amersham (Amersham, Oxfordshire, UK)
Protein G sepharose Amersham
IMMUNOBLOTTING



















IN-VITRO LIPID KINASE AS AYS
Lithium Chloride Sigma








Glacial acetic acid BDH
LIPID LABELLING
DMEM Life Technologies










2.17 - PROPAGATION OF PLASMID DNA IN  BACTERIA
2.17.1 - Preparation of Competent E.Coli Strain DH5a
A single colony of the E.Coli strain DH5a (Life Technologies) was picked from a fresh 
agar plate and inoculated into 5ml of 2X YT broth (16g Bactotryptone, lOg yeast 
extract, 5g NaCl, made up to 1L and autoclaved) and incubated overnight at 37°C on a 
shaking platform. The following day, the culture was diluted 1:100 into 2X YT broth 
and grown until an OD550 of approximately 0.48 was reached. The culture was then 
chilled on ice for 5 min before centrifugation at 4°C, 5000rpm for 5 min in a Beckman 
M5 centrifuge with a JA-14 rotor. The bacterial pellet was resuspended in 40ml of 
solution Tfbl (30mM KC1, lOOmM RbCl, lOmM CaCL, 50mM MnCh, 15% (v/v)
CHAPTER 2: Materials and Methods 77
glycerol, adjusted to pH 5.8 with 0.2M acetic acid and filter sterilised), incubated on ice 
for 5 min and then centrifuged at 5000rpm for 5min at 4°C. The sedimented bacteria 
were then resuspended in 5ml of ice cold Tfbll buffer (lOmM MOPS, 75mM CaCk, 
lOmM RbCl, 15% (v/v) glycerol, adjusted to pH 6.5 with KOH and filter sterilised) and 
incubated on ice for a further 15 min. 200pl aliquots of cells were snap frozen and stored 
at -80°C until required.
2.17.2 - Transformation of Competent E.Coli
Competent cells were thawed at room temperature before being placed on ice for 10 
min. Plasmid DNA was added to a concentration of <0.1pg/200pl cells and placed on 
ice for 30-45 min. The cells were heat shocked at 42°C for 2 min, returned to ice for 2 
min and then diluted with 4 volumes of 2X YT broth. The bacterial cell suspension was 
then incubated in a water bath at 37°C for 1 hour. After this time the required volume of 
cells were plated out onto agar plates containing the appropriate antibiotic at a suitable 
concentration. Plates were inverted and incubated overnight at 37°C.
2.18 - PURIFICATION OF PLASMID DNA
2.18.1 - Small-Scale Plasmid Preparation
Small-scale plasmid preparations were performed using the QIAprep Spin Miniprep Kit 
(QIAGEN, Crawley, West Sussex, UK), according to the manufacturer’s protocol. In 
outline, 5ml overnight cultures of E.Coli transformed with the plasmid of interest were 
harvested by centrifugation. The bacterial pellet was resuspended in 250pl of buffer PI, 
followed by the addition of 250pl of buffer P2 and 350pl of buffer N3. Precipitated 
material was removed by centrifugation at maximum speed for 10 min in a Jouan A14 
microcentrifuge. The supernatant was then transferred to a QIAprep spin column and 
centrifuged for 1 min, as previously. The column was washed once with 0.75ml of 
buffer PE and the DNA then eluted in 50pl of water
2.18.2 - Large-Scale Plasmid Preparation
Large-scale preparations were performed using the QIAGEN Plasmid Maxi Preparation 
Kit (QIAGEN) based on alkaline lysis, according to the manufacturer’s guidelines. In 
summary, a single colony of DH5a E.Coli transformed with the plasmid of interest was
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used to inoculate starter cultures of 10ml 2X YT broth containing the appropriate 
selective agent. Cultures were grown for 8h at 37°C in a shaking incubator, following 
which 1ml of the starter culture was diluted into 500ml of selective 2X YT broth. The 
diluted culture was grown overnight at 37°C with shaking. The bacterial cells were 
harvested by centrifugation at 6000 x g in a Beckman J2-21 centrifuge for 15 min at 
4°C. The supernatant was discarded and the bacterial pellet resuspended in 10ml buffer 
PI. 10ml of buffer P2 were then added, the solution gently mixed and incubated at room 
temperature for 5 min. 10ml of chilled buffer P3 was added to the bacterial lysate, which 
was then poured into the barrel of a QIAfilter cartridge and incubated at room 
temperature for 10 min. During this incubation period, a precipitate formed containing 
genomic DNA, proteins and cell debris, which was subsequently removed from the cell 
lysate during the filter process. The cleared lysate was then added to a QIAGEN-tip 100 
that had been pre-equilibrated with 10ml buffer QBT. The tip was washed twice with 
30ml buffer QC and the DNA eluted with 15ml of buffer QF. The DNA was precipited 
from this eluate by the addition of 10.5ml room-temperature isopropanol and 
centrifugation at 15,000 x g for 30 min at 4°C. The supernatant was carefully decanted, 
taking care not to disturb the DNA pellet. The pellet was then washed in 5ml of 70% 
(v/v) ethanol to remove precipitated salt. The DNA pellet was air-dried and redissolved 
in a suitable volume of TE buffer.
2.19 - QUANTIFICATION OF PLASMID DNA
The plasmid DNA preparations were diluted 1: 250 into water and the absorbance 
measured at 260nm and 280nm using a Kontron (Uvikon 720LC) spectrophotometer. 
The concentration of the DNA was calculated as follows:
Concentration of DNA (pg/ml) = dilution factor x 50* x A260 
* The standard assumption is that a solution of 50pg/ml double-stranded DNA has an 
absorbance of 1 at 260nm.
The purity of the DNA preparation was calculated as a ratio of DNA (A260) to protein 
(A28o)- A ratio of between 1.6 and 2 was considered acceptable.
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2.20 - MANIPULATION OF PLASMID DNA
2.20.1 - Restriction Enzyme Digest
Restriction enzymes used were supplied by New England Biolabs (Massachusetts, USA) 
and came provided with the appropriate 10X buffer and 10X BSA stock (if required). 
Digests were typically performed in a 20pl reaction volume containing 2pl of restriction 
enzyme buffer, l-5pl plasmid DNA, 0.5-1 pi enzyme and distilled water to make up the 
remaining volume. 2pl of 1 mg/ml BSA were added if this were required for the activity 
of a given enzyme. Digests were incubated at 37°C for 1 hour to overnight.
2.20.2 - Ligations
Ligations of vector plasmid and DNA inserts were carried out in lOpl volumes 
containing lpl 10X T4 DNA ligase buffer (NEB), 2-10pl DNA insert, 2pl DNA vector, 
lpl T4 DNA ligase (NEB) and distilled water to volume. Ligations were incubated at 
14°C for 4 hours to overnight.
2.21 -ANALYSIS OF DNA B Y AGAROSE GEL ELECTROPHORESIS
A simple and widely used method to investigate the presence of specific sized DNA 
fragments is gel electrophoresis, whereby fragments of DNA migrate within an agarose 
gel according to their charge and mass towards a cathode. Agarose gels were prepared 
by dissolving the required quantity of agarose (1-2% (w/v)) by boiling in TAE buffer 
(50X stock; 242g Tris, 57.1 glacial acetic acid, 100ml 0.5M EDTA pH8.0). Samples 
were prepared by adding 1/6* volume of 6X DNA loading buffer (30% (v/v) glycerol, 
0.05% (w/v) Xylene/Cyanol, 0.05% (w/v) bromophenol blue), followed by a brief 
centrifugation. Electrophoresis was performed at 80V. The agarose gel was post-stained 
in a solution of 0.5pg/ml ethidium bromide in IX TAE for 15 min and the DNA then 
visualized and photographed under UV light.
DNA fragments were purified from agarose gels using the QLAquick gel extraction kit 
(QIAGEN) according to the manufacturer’s protocol. In summary, the appropriate DNA 
band was excised from the agarose gel and dissolved in approximately 800pl buffer
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QX1 at 50°C. This DNA-containing solution was then added to a QIAquick spin column 
and centrifuged for 1 min at full spead in a microcentrifuge. The column was washed 
once with 0.75ml of buffer PE and centrifuged as previously. The DNA was then eluted 
with 30-50pl of water.
2.22 - POLYMERASE CHAIN REACTION
PCR was used to affect a single point mutation that would convert the WT-SHP-2 
template to C459S-SHP-2. Reactions were also designed to incorporate XBA-1 sticky 
ends into the 2-SH2-SHP-2 and C-»S-SHP-2 inserts, so as to facilitate their more 
efficient ligation into the pUHD-10-3hygro vector. Reactions were carried out in a lOOpl 
volume in thin-walled PCR tubes (Abgene, UK) as follows:
DNA template 
2 x Primers (25pm/pl) 
dNTPs (lOmM) 








to make volume up to lOOpl



















CHAPTER 2: Materials and Methods 81
4°C End
Details of the primers used in this study are shown in Table 2.5.
The PCR products were ligated into the TOPO vector (Invitrogen life technologies) and 
the ligations transformed into competent DH5a E.Coli. Colonies were selected and 
small-scale plasmid DNA preps were made. These were sent for automated sequencing 
to identify those containing the SHP-2 inserts with the required mutations. The 
sequences were also checked for any additional errors that may have been incorporated 
during PCR.
2.23 - SEQUENCING
DNA constructs to be sequenced were provided for automated sequencing (at the 
sequencing facility, GlaxoSmithkline, Stevenage, UK) in a 20pl volume containing 
25pM of a single sequencing primer and 1.2pg of the template DNA. The primers used 
for sequencing are shown in Table 2.5.





5 ’-CGGTCGTGGTGCACTCCAGTGCTGGAATTGG-3 ’ 73.5 SENSE To generate C459S 
mutation in WT 
SHP-25 ’-CCAATTCCAGCACTGG AGTGCACCACGACCG-3 ’ 73.5 ANTI-SENSE
5 ’-GGGTCTAG ACCACCATGGAGC AGAAGC-3 ’ 69.5 SENSE To generate C-»S- 
SHP-2 and 2SH2- 
SHP-2 with Xba-1 
restriction sites as 
shown
5 ’-GGGTCTAG ATCATCTGAAACTTTTCTGCTGTTG-3 ’ 67.0 SENSE
5 ’-GGGTCTAG ATCAGGGCTGCTTGAGTTGTAG-3 ’ 69.5 SENSE
SEQUENCING PRIMERS
5 ’-GGAGGGGAGAAATTTGCCACTT-3 ’ 60.3 SENSE To sequence along 
the entire length of 
SHP-2 in order 
check for the
5 ’-AAGTGGCAAATTTCTCCCCTCC-3 ’ 60.3 ANTI-SENSE
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5 ’ - ATG AC A A AGGGG AG AGC AATG ACG-3 ’ 62.7 SENSE incorporation o f  the 
C459S mutation 
and the Xba-1 
restriction sites
5 ’-CT AC AGCCG A A A AG AGGGTC A A-3 ’ 60.3 SENSE
5 ’-TGGCGTC ATGCGTGTT AGG-3 ’ 58.8 SENSE
5 AGCCCTCTCCCGCCTTGTA-3 ’ 61.0 SENSE
5 ’-CTCCATAG AAG AC ACCGG-3 ’ 60 SENSE Primers flanking 
the insertion site on 
pUHD 10-3-hygro 
to confirm 
orientation o f the 
SHP-2 inserts.
5 ’-GC ATTCTACTTCTCCTTTCT-3 ’ 60 ANTI-SENSE
Table 2 .6 -  Plasmids Used in This Study
PLASMID DERIVATION USE
pGEX-2T-N-SH2-SHP-2
N-SH2 domain o f p85a ligated 
into the GST-fiision protein 
expresison vector pGEX-2T. 
Generously donated by Dr. M.J. 
Welham
For the expression o f  N-SH2-p85 
GST-fusion protein
pGEX-2T-C-SH2-SHP-2
C-SH2 domain o f p85a ligated 
into the GST-fiision protein 
expresison vector pGEX-2T. 
Generously donated by Dr. M.J. 
Welham
For the expression o f  C-SH2-p85 
GST-fusion protein
pUHD15-l-neo
Tetracycline transactivator (tTA) 
expression vector with addition o f 
the neomycin resistance gene.
Co-transfected with pUHD10-3 
tTA response plasmid as part o f 
the tetracycline regulated 
expression system.
pUHDl 0-3-hygro
Response plasmid pUHD10-3 
with addition o f the hygromycin 
resistance gene
For expression o f  gene o f  interest 
under influence o f  tTA.
pUHDl 0-3hygro-2SH2-SHP-2
Myc-tagged 2SH2-SHP-2 sticky 
end ligated into Xbal site o f 
pUHDl 0-3hygro.
Construct linearised and 
transfected into Jurkat cells 
already transfected with pU H dl5- 
Ineo to give tetracycline 
controlled expression o f  myc- 
tegged 2SH2-SHP-2
pUHDl 0-3hygro-C—>S-SHP-2
Generated from WT-SHP-2 
construct by PCR-based site- 
directed mutagenesis. Sticky end 
ligated into Xbal site o f 
pUHD10-3hygro.
Construct linearised and 
transfected into Jurkat cells 
already transfected with 
pUHD15-lneo to give 
tetracycline controlled expression 
o f  myc-tegged C-»S-SHP-2
pEBB-WT-GAB-2
HA-tagged WT-GAB-2 cloned 
into pEBB. Kindly donated by 
Dr. B.N. Neel (Dept. Medicine, 
Beth Israel-Deaconess Medical 
Centre, Boston, MA, USA).
Constructs transiently transfected 
into Jurkat cells for use in 
luciferase reporter assays.
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pEBB-3YF-GAB-2
HA-tagged GAB-2 with tyrosines 
441 /461 /574 mutated to 
phenylalanine, cloned into pEBB. 
Kindly donated by Dr. B.N. Neel.
pEBB-APH-GAB-2
HA-tagged N-terminal PH 
domain truncated GAB-2 cloned 
into pEBB. Kindly donated by 
Dr. B.N. Neel
pEBB-YFDH-GAB-2
HA-tagged GAB-2 with 
tyrosines 604/633 mutated to 
phenylalanine, cloned into pEBB. 
Kindly donated by Dr. B.N. Neel
pGL2-NFKB
4 tandem repeats o f the NFkB 
binding site o f  the CD28RE 
cloned into pGL2 (Promega), 
generated by Dr. C. Edmead (The 
University o f Bath)
pGL2-AP-l
4 tandem repeats o f  the AP-1 
binding site o f  the CD28RE 
cloned into pGL2 (Promega), 
generated by Dr. C. Edmead.
Co-transfected with GAB-2 
expression constructs for use in 
luciferase reporter assays.
pSV-p-galactosidase Supplied by Promega
Positive control vector for 
monitoring transfection 







Agar DIFCO-Labs (Detroit, MI, USA)
Ampicillin Sigma
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GENERATION AND CHARACTERISATION OF JURKAT STABLE 
TRANSFECTANTS
2.24 - ELECTROPORATION
Jurkat T cells expressing the tetracycline transactivator (tTA) from the plasmid 
pUHD10-l were cultured as Jurkat cells, but with the addition of 2jog/ml tetracycline. 1 
x 107 cells were electroporated in 0.8ml of electroporation buffer (25mM HEPES pH 
7.2, 140mM KC1, lOmM NaCl, 2mM MgCl2, 0.5% (v/v) Ficoll 400, filter sterilised) 
containing lOpg of linearised DNA at 950pF, 300V. Cells were grown for 48 hours in 
the presence of 2pg/ml tetracycline and then plated into 96 well trays at a concentration 
of 1 x 104 cells/well in selective medium containing 300pg/ml hygromycin, 500pg/ml 
G418 and 2pg/ml tetracycline. After 14 days live cells/clones were expanded in 
selective medium and then screened for the inducible expression of the gene of interest.
2.25 - SCREENING CLONES FOR TETRACYCLINE-REGULATED EXPRESSION
Antibiotic resistant clones were expanded in 6 well dishes and then washed three times 
in serum-free RPMI. Cells were plated out at 5 x 105 cells/ml in the presence or absence 
of tetracycline. The expression of the protein of interest was determined 24 hours later 
by lysing the cells in solubilisation buffer as described previously and immunoblotting 
with the anti-myc antibody 9E10 (detection of 2SH2-SHP-2) or the anti-SHP-2 antibody 
(detection of C-»S-SHP-2). The transfectants showing the most robust and inducible 
expression of the protein of interest were selected and further expanded in order to be 
frozen in liquid nitrogen for storage.
Table 2 .8 - Reagents
REAGENT SUPPLIER
ANTIBIOTICS
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Tetracycline Sigma
G418 Life Technologies







2.26 -  PROLIFERA TIONASSA YS
Purified primary T cells (isolated as described in section 2.5) were used to assay cellular 
proliferation. Cells were seeded into a 96-well plate at a density of 1 x 105 
cells/lOOpl/well. Cells were stimulated with 10pg/ml UCHT1 (anti-CD3) and 9.3 (anti- 
CD28). The final volume of the assay well was adjusted to 200pl with RPMI 1640 
medium (containing supplements as previously) and the 96-well plates incubated in a 
humidified cell incubator for 3 days, to allow for cell proliferation. After the 
proliferative period, cells were pulsed overnight with lpCi 3H-thymidine. 3H-thymidine 
incorporating cells (ie, cells actively replicating DNA) were harvested using a Titertek 
semi-automatic cell harvester onto filter paper discs. The radioactive content of these 
filter paper discs was then quantified by scintillation counting in a 1209 RACKBETA 
liquid scintillation counter.
2.27- LUCIFERASEASSAYS
Jurkat cells were transiently transfected with plasmid DNA using the DMRIE-C 
lipofection reagent (Invitrogen life technologies). 36pl of DMRIE-C reagent were added 
to 3mls of OPTI-MEM I reduced serum medium in a 25cm3 flask and mixed gently. 
3mls of the same medium containing lOpg GAB-2 expression plasmid DNA, 3pg
CHAPTER 2: Materials and Methods 86
luciferase reporter and 2.5pg P-galactosidase normalization plasmid were added and the 
flask incubated at room temperature for 15-45 min to allow formation of the lipid-DNA 
complexes. 1 x 107 cells were added in 1.2mls OPTI-MEM I medium and the 
transfections incubated for 5 hours at 37°C in a CO2 incubator. After the incubation 
period 12mls of RPMI 1640 medium (with supplements as previously) were added and 
the cells incubated for a further 48 hours at 37°C in a CO2 incubator prior to stimulation 
and assay for luciferase activity.
Transfected cells were stimulated for 6 hours in black, clear-bottomed 96-well plates 
(Packard). 2 x 105 cells/well were stimulated in a volume of 60pl with 10pg/ml UCHT1 
(anti-CD3) and 9.3 (anti-CD28). Following the stimulatory period, the cells were lysed 
for 2 min with the addition of 60pl of the Bright-Glo luciferase assay reagent (Promega). 
Plates were immediately read in the Packard top count 96-well luminometer. Some of 
the transfected cells were retained and lysed in solubilisation buffer for the assay of p- 
galactosidase activity to monitor transfection efficiencies and immunoblot analysis to 
verify expression of the transfected GAB-2 proteins.
2.27.1 - p-galactosidase Assay
p-galactosidase activity was determined by incubating 50pl cell extract with 150pl of 
reagent containing CPRG as substrate and 1.25mM MgCh. The colour change as a result 
of p-galactosidase enzyme activity was quantified by measuring the absorbance at 
550nM in a 96-well microplate reader (Dynatech MR5000).
2.28 - CHEMOTAXIS ASSA YS
Cells were washed twice in serum-free RPMI 1640 and resuspended at a density of 1 x 
106 cells/ml in RPMI with 0.1% (w/v) BSA. Cells were serum-starved for 1 hour at 
37°C. During the starvation period, a 96-well plate was carefully positioned into the 
chemotaxis chamber (Neuroprobe, Receptor Technologies) and loaded with the 
chemokine SDF-la (0-1 OnM final conc.) so as to form a positive meniscus within the 
well (370pl volume was required). A 5pm filter (Neuroprobe, Receptor Technologies) 
was lowered on top of the 96-well plate, taking great care not to form air bubbles at this 
stage. The gasket was positioned onto pins on the underside of the chamber lid and the
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lid gently closed, applying even pressure to the top of the chamber. The chamber was 
equilibrated in a 37°C humidified incubator for 15 min. Cells were then added to the 
wells of the chemotaxis chamber at 2 x 105 cells per well and the chamber incubated at 
37°C in a humidified cell incubator for 3 hours. Some cells were retained and serially 
diluted to give a standard curve ranging from 2 x 105 -  1 x 103 cells/lOOpl/well in a 96- 
well plate, which was also incubated at 37°C. At the end of the incubation period, any 
remaining cells were aspirated from the upper wells of the chamber, 200pl of versene 
was added per well and the chamber incubated at 4°C for 20 min. After aspirating off the 
versene, the chamber was carefully opened and the 96-well plate removed, without 
detaching the filter on top. The plate together with the filter was spun at 1500rpm for 10 
min in a Beckman GS-15R centrifuge (S2096 rotor) to pellet migrated cells. The 
filter was then removed and the remaining medium aspirated off the pelleted cells. Cells 
were resuspended in lOOpl RPMI and 20pl/well cell titre reagent added to both the 
chemotaxis and standard curve plates. Plates were incubated at 37°C for a further 1-2 
hours, after which the absorbance was measured at 490nm in a 96-well microplate 
reader (Dynatech MR5000). The number of migrated cells was calculated from the 
standard curve prepared using the known cell densities.




Optiphase ‘safe’scintillation fluid Fisher Chemicals
LUCIFERASE ASSAYS
DMRIE-C Invitrogen Life Technologies
OPTI-MEM I Life Technologies
Bright-Glo luciferase assay system Promega
CHEMOTAXIS ASSAYS
Versene Life Technologies
Cell titre reagent Promega
THE IN VITRO CO-ASSOCIATIONS OF GAB-2, 
SHP-2 AND PI3K STIMULATED BY LIGATION 
OF THE CD28 RECEPTOR
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RESULTS
3.1 -  THE REQUIREMENT OF CD28 A S  A CO-STIMULATORY MOLECULE; 
Co-Ligation o f the TCR and CD28 Receptors Elicits a Productive T Cell 
Proliferative Response
Over thirty years ago, Bretscher and Cohn first introduced the two signal hypothesis 
of T cell activation (Bretscher and Cohn., 1970). Subsequently, investigators 
established that co-ligation of the TCR and CD28 receptors was both necessary and 
sufficient for optimal lymphokine production and cellular proliferation (reviewed by 
Ward., 1996). Accordingly, the first objective of this study was to verify the 
requirement of CD28 as a co-stimulatory molecule.
Once activated, T cells are stimulated into cell cycle entry, since clonal expansion is 
necessary for a productive effector response. Therefore, the proliferation of T cells 
can be used as a convenient measure of their activation. In Figure 3.1, the 
proliferative response of primary purified T lymphocytes was assayed by H- 
thymidine incorporation. Treatment with the anti-CD3 monoclonal antibody 
(UCHT1) together with an anti-CD28 monoclonal antibody (9.3) resulted in a 
proliferative response that was markedly increased above that generated individually 
by these stimuli. In this experiment, the phorbol ester, PMA, in combination with 
anti-CD28 was used as a positive control to elicit optimal T cell proliferation. The 
response to anti-CD3/ CD28 co-stimulation was comparable with this control.
3.2 -  CD28 IS  A  MAJOR REGULATOR OF PI3K ACTIVATION: CD28 Co­
precipitates Class I  a PI3K and Stimulates PI(3,4,5,)P3 Accumulation in Jurkat T 
cells
CD28 is known to physically associate with and activate class 1a PI3K isoforms 
(Prasad et al.9 1994). Indeed, CD28 is a major regulator of PI3K in T cells and the 
co-ordination of PI3K signalling cascades helps to promote many aspects of 
activation (Ward et al., 1993; Ward et al., 1995). Thus, it was necessary to initially



























CD3/CD28 Stimulates the Proliferation of Human Blood-derived T Lymphocytes
T-lymphocytes were purified from fresh human blood and appropriately stimulated with 
anti CD3 antibody (UCHT1) and anti-CD28 antibody (9.3) for 72 hours. 3[H]-thymidine 
incorporating cells were assayed by scintillation counting. The data was subjected to 1- 
way ANOVA, following square root transformation to normalise the distribution. The 
result suggested a significant difference between the treatment groups [★ ★ ★ =  
pO .001].



















CD28 Co-precipitates Class 1A PI3K and Stim ulates PI(3,4,5)P3 Accumulation in 
Jurkat T cells
A, Jurkat T cells were stimulated with anti-CD3 antibody (UCHT1) or anti-CD28 
antibody (9.3) for 5 min. 200pg of cell extract was immunoprecipitated with the anti- 
CD28 antibody (9.3). Proteins were resolved by SDS-PAGE and immunoblotted with 
the anti-p85 antibody (a-p85). B, Jurkat T cells were labelled with 32P-orthophosphoric 
acid for 4 hours. Labelled cells were appropriately stimulated with anti-CD28 antibody 
(9.3) and B7.1 ligand, for the times indicated. Lipids were extracted, deacylated and 
subjected to HPLC analysis. Results are representative o f 2 experiments in A and one 
experim ent in B.
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confirm the CD28-dependent activation of PI3K in our system. Figure 3.2A 
demonstrates the co-immunoprecipitation of the CD28 receptor with the p85 adaptor 
subunit of class Ia PI3K following stimulation of Jurkat T cells.
The accumulation of 3-phosphoinositide lipids is typically exploited as a measure of 
PI3K activation following receptor ligation. In Figure 3.2B, Jurkat T cells were 
labelled with [P]-orthophosphoric acid, appropriately stimulated and then 
subsequently lysed for the extraction and analysis of cellular lipids. Consistent with 
previous findings, stimulation of the CD28 receptor by anti-CD28 monoclonal 
antibody (9.3) or the physiological ligand B7 resulted in the time-dependent 
generation of PI(3,4,5)P3.
3.3 -  LIGATION OF CD28 STIMULATES THE TYROSINE
PHOSPHORYLATION OF GAB-2
The p85 subunit of the class Ia PI3K isoforms can interact directly with the CD28 
receptor via a (p)Y173MNM motif in the cytoplasmic tail of this protein (Prasad et al., 
1994). However, ablation of binding at this site by tyrosine->phenylalanine mutation 
does not bring about a complete block in PI3K-dependent signalling events 
(Okkenhaug et al., 2001). This observation led to speculation that CD28 may employ 
additional methods for the recruitment of PI3K. Indeed, CD28 may couple to PI3K 
indirectly through docking proteins, like GAB-2, which contain the appropriate 
binding motifs. The principal aim of this study was to see whether GAB-2 complexes 
contribute to the recruitment and activation of class Ia PI3K by CD28.
A key requirement for the formation of signalling complexes by GAB-2 is its 
tyrosine phosphorylation. To examine whether this could be induced by CD28 
receptor ligation, Jurkat T cells were appropriately stimulated by co-sedimentation 
with CHO-B7 and the resultant tyrosine phosphorylated proteins analysed. In Figure 
3.3A, CD28 stimulation resulted in the rapid and transient tyrosine phosphorylation 
of a protein with the approximate molecular weight of 100 kDa, the size of GAB-2 in 
whole cell lysates. To examine whether a portion of this protein band corresponded 
to GAB-2, immunoprecipitations were prepared from CHO-B7 stimulated extracts 
using the anti-GAB-2 antibody (Figure 3.3B) and the anti-phosphotyrosine antibody, 
4G10, (Figure 3.3C). In each instance, the stimulation kinetics for GAB-2 tyrosine
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Ligation of CD28 Stimulates the Tyrosine Phosphorylation of GAB-2
Jurkat T cells were stimulated for the indicated times by co-sedimentation with CHO- 
B7.1 cells. Cell extracts were prepared and protein concentrations determined by 
Bradford assay. A, 20pg o f each sample was separated by SDS-PAGE. Immunoblotting 
with the anti-phosphotyrosine antibody 4 G 10 was used to detect tyrosine-phosphorylated 
proteins (a-PY ). B, 200pg o f cell extract were imm unoprecipitated with the anti-GAB-2 
antibody (a-G A B -2). Immunoblotting with the anti-phosphotyrosine antibody 4G10 was 
used to detect tyrosine-phosphorylated GAB-2. The immunoblot was stripped and 
reprobed with the anti-GAB-2 antibody to allow parity o f loading to be examined. C, 
200pg of cell extract were immunoprecipitated with the 4G10 antibody (a-PY ). 
Immunoblotting was perform ed using the anti-GAB-2 antibody (a-G A B -2). Results are 
representative o f at least 3 independent experiments in A, 2 experiments in B and one 
experiment in C.
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phosphorylation were similar. Phosphorylation was rapidly detected after 1 minute of 
CD28 stimulation with levels observed to decline over time. At 10 minutes post 
treatment, the levels of phosphorylated GAB-2 protein were comparable with those 
in the control.
3.4 -  LIGATION OF CD28 STIMULATES THE CO-ASSOCIATION OF GAB-2 
WITH SHP-2 AND PI3K
Once tyrosine phosphorylated, GAB-2 has the potential to recruit other important 
signal relay molecules within the cell. The association of GAB-2 with both SHP-2 
and the p85 adaptor subunit of PI3K has been documented downstream of many 
receptors, including the TCR (Frearson et al., 1998; Pratt et al., 2000; Yamasaki et 
al., 2001). It was therefore appropriate to examine whether similar protein 
interactions were stimulated by CD28.
The interactions of GAB-2 were investigated by co-immunoprecipitation. Jurkat T 
cells were stimulated by co-sedimentaion with CHO-B7 or left unstimulated as 
control. In Figure 3.4A, immunoprecipitations were prepared using the anti-CD28 
monoclonal antibody (9.3). The co-precipitation of GAB-2 with the CD28 receptor 
was detected by immunoblotting with the anti-GAB-2 antibody. Similarly, GAB-2 
was shown to co-precipitate with the protein tyrosine phosphatase SHP-2 (Figure 
3.4B) and class Ia PI3K (Figure 3.4C) upon CD28 stimulation. In the latter 
experiment, class Ia PI3K isoforms were immunoprecipitated from whole cell lysates 
using a monoclonal antibody directed against the p85a adaptor subunit of these 
enzymes.
3.5 -  LIGATION OF CD28 STIMULATES THE CO-ASSOCIATION OF SHP-2 
WITH CD28 AND PI3K
In examining the nature of GAB-2 complex formation downstream of CD28, the 
associations of SHP-2 were analysed. Again, Jurkat T cells were stimulated by co- 
sedimentaion with CHO-B7 or left unstimulated as control. In Figure 3.5A 
immunoprecipitations were prepared using the anti-CD28 monoclonal antibody (9.3).


















CD28 Stimulates the Co-precipitation of GAB-2 with SHP-2 and Class IA PI3K
Jurkat T cells were stimulated for the indicated times by co-sedimentation with CHO- 
B7 cells. Cell extracts were prepared and protein concentrations determined by 
Bradford assay. A, B and C, Cell extracts (200pg) were immunoprecipitated with the 
anti-CD28 antibody (9.3), with the anti-SHP-2 antibody (a-SH P-2) and with the p85 
antibody (a-p85), respectively. Immunoblotting was performed using the anti-GAB-2 
antibody (a-GA B -2). The immunoblots were stripped and reprobed with the 
appropriate antibody to allow parity o f loading to be examined. Results are 
representative o f at least 2 independent experiments.
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CD28 Stimulates the Co-precipitation of SHP-2 with Class IA PI3K and the CD28 
Receptor
Jurkat T cells were stimulated for the indicated times by co-sedimentation with CHO-B7 
cells. Cell extracts were prepared and protein concentrations determined by Bradford 
assay. A and B, Cell extracts (200pg) were immunoprecipitated with the anti-CD28 
antibody (9.3) and with the an ti-p ll0 8  antibody (a -  p i 108 ), respectively. 
Immunoblotting was performed using the anti-SHP-2 antibody (a-SH P-2). The 
immunoblots were stripped and reprobed with the appropriate antibody to allow parity of 
loading to be examined.
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The co-precipitation of SHP-2 with CD28 was detected by immunoblotting with the 
anti-SHP-2 antibody. In a similar experiment SHP-2 was also demonstrated to co­
precipitate with class Ia PI3K (Figure 3.5B) upon receptor stimulation. In this 
instance the leukocyte specific class Ia PI3K isoform, pi 108, was 
immunoprecipitated using an antibody against the pi 10 catalytic subunit of this 
enzyme.
3.6 -  LIGATION OF CD28 STIMULATES LIPID KINASE ACTIVITY IN  GAB-2 
IMMUNOPRECIPITA TES
The GAB-2 interaction with PI3K was further verified by determining whether any 
lipid kinase activity could be detected in the GAB-2 immunoprecipitates. In these 
experiments, GAB-2 immunoprecipitates were prepared from CHO-B7 stimulated 
Jurkat cells and incubated in the presence of [P]-y-ATP and phosphatidylinositol 
(applied exogenously as the substrate for the reaction). The resultant formation of the 
radiolabelled PI3K product, PI(3)P, is depicted by the autoradiograph in Figure 3.6A. 
Interestingly, the pattern of accumulation of PI(3)P in the GAB-2 
immunoprecipitates appeared to fluctuate ie, it was increased at 1 minute, declined, 
and then increased again at 10 minutes post stimulation. In figure 3.6B, the lipid 
kinase activity associated with the GAB-2 immunoprecipitates was inhibited in those 
samples pre-treated with the PI3K inhibitor Wortmannin (lOnM). 
Immunoprecipitates of the p85a subunit of PI3K were assayed as a positive control 
for lipid kinase activity in these experiments.
3.7 -  DEFINING THE NATURE OF THE MOLECULAR INTERACTION 
BETWEEN GAB-2 AND PI3K
In cytokine and growth factor signalling, the interaction between GAB-2 and class 
Ia PI3K occurs via both the SH2 domains of p85 and the corresponding tyrosine 
residues within GAB-2 (reviewed in section 1.20.2). To resolve the exact nature of 
the molecular interactions between GAB-2 and PI3K downstream of CD28, proteins 
from appropriately stimulated Jurkat T cells were pulled-down using GST-fusion
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Figure 3.6
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CD28 Stimulates Lipid Kinase Activity in GAB-2 Immunoprecipitates
Jurkat T cells were stimulated for the indicated tim es by co-sedimentation with CHO- 
B7. A, 200pg o f cell extract were immunoprecipitated with the anti-GAB-2 antibody (a - 
GAB-2). B, Immunoprecipitates were perform ed as in A, however some samples were 
pretreated with Wortmannin for 30 mins prior to analysis o f kinase activity. In vitro lipid 
kinase assays were performed as described in ‘m aterials and m ethods’, using PI as a 
substrate. The position o f the lipid product PI(3)P on the autoradiograph is shown. 
Results are representative o f 2 independent experiments in A and one experiment in B.
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Figure 3.7
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Defining the Nature of the M olecular Interactions Between GAB-2 and Class 1A 
PI3K
Jurkat T cells were stimulated for the indicated times by co-sedimentation with CHO- 
B7 cells. Cell extracts were prepared and protein concentrations determined by 
Bradford assay. Pull downs were performed using GST fusion proteins comprising 
either the N-terminal SH2 domain of p85 (N-SH2 p85) or the C-terminal SH2 domain 
of p85 (C-SH2 p85). Immunoblotting was performed using the anti-GAB-2 antibody 
(a-GAB-2).
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proteins comprising either the N-terminal or C-terminal SH2 domains of the p85 
subunit of PI3K. Immunoblotting with an anti-GAB-2 antibody revealed that GAB-2 
co-precipitated predominantly with the N-terminal SH2 domain of p85, following 
stimulation with CHO-B7 (Figure 3.7).
3.8 -  IS  GAB-2 A POTENTIAL SHP-2 SUBSTRATE?
The identification of GAB-2 as a hyperphosphorylated protein in cells expressing 
catalytically inactive (substrate-trapping) mutants of SHP-2 led to the suggestion that 
GAB-2 itself may be a target for dephosphorylation (Frearson et al., 1998). In order 
to investigate whether GAB-2 was a potential substrate for SHP-2 downstream of 
CD28, in vitro phosphatase assays were performed. SHP-2 immunoprecipitates from 
CHO-B7 stimulated T cells were incubated in the presence (+) or absence (-) of 
phosphatase inhibitors. The theory underlying this approach relies upon the 
assumption that in those precipitates lacking phosphatase inhibitors, SHP-2 would 
remain catalytically active and therefore free to dephosphorylate its target substrates. 
Analysis of the tyrosine phosphorylated proteins associated with the SHP-2 
immunoprecipitates in Jurkat T cells (Figure 3.8A) revealed the presence of a protein 
of approximately 100 kDa molecular weight whose tyrosine phosphorylation was 
diminished in those samples without inhibitors. An almost identical loss of protein 
tyrosine phosphorylation was also observed in the CD28-transfected murine 
hybridoma T cell line, DC27.1 (Figure 3.8B) and in human blood-derived T 
lymphoblasts (Figure 3.8C).























Is GAB-2 a Substrate for the Protein Tyrosine Phosphatase Activity of SHP-2?
Cells were stimulated for the indicated times by co-sedimentation with CHO-B7 cells. 
Cell extracts were prepared and protein concentrations determined by Bradford assay. 
200pg of cell extract were immunoprecipitated with the anti-SHP-2 antibody (a-SH P- 
2) and incubated in the presence (+) and absence (-) o f phosphatase inhibitors (sodium 
orthovanadate, sodium fluoride and sodium molybdate). Immunoblotting with the anti- 
phosphotyrosine antibody 4G10 was used to detect tyrosine-phosphorylated proteins. 
Results shown are representative o f 2 experiments in A and C and one experiment in 
B.
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SUMMARY OF FINDINGS
• Co-ligation of T cells via the TCR and CD28 is necessary for optimal cellular 
proliferation.
• CD28 co-precipitates with class Ia PI3K isoforms and stimulates PI(3,4,5)P3 
accumulation in Jurkat T cells.
• CD28 stimulates the rapid and transient tyrosine phosphorylation of GAB-2.
• GAB-2 co-precipitates with SHP-2 and PI3K following CD28 stimulation.
• CD28 ligation stimulates lipid kinase activity in GAB-2 immunoprecipitates.
• GAB-2 co-associates predominantly with the N-terminal SH2 domain of p85.
• GAB-2 is a potential substrate for SHP-2 catalytic activity.
DISCUSSION
3.9 - THE REQUIREMENT OF CD28 IN  THE CO-STIMULATION OF T CELL 
ACTIVATION AND A S A MAJOR REGULATOR OFPI3K
Despite being highly specific, engagement of the TCR/CD3 complex alone is 
insufficient to elicit functional T cell activation. In order to prevent the induction of 
anergy, the T cell needs to receive a second co-stimulatory signal (Bretscher and 
Cohn., 1970). To date, a number of receptors have been identified that can augment 
the T cell response to antigenic peptide or anti-CD3. However, CD28 remains the 
best defined of the co-stimulatory molecules. Ligation by its endogenous ligands B7 
or anti-CD28 antibodies has been shown to promote the classical markers of T cell 
activation; IL-2 production, T cell proliferation and cell survival (reviewed by Ward 
et al., 1996). Consistent with this, the present study verified that individually neither 
the TCR nor CD28 could influence cellular proliferation. The combination of CD3
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and CD28 receptor ligation was required to generate a productive T cell proliferative 
response.
CD28 has been identified as a major regulator of PI3K in T cells (Ward et al., 1993; 
Prasad et al., 1994). Furthermore, PI3K may be a critical factor in establishing CD28 
co-stimulation, since its activation is necessary for optimal cellular proliferation and 
IL-2 production. (Ward et al, 1993; Ward et al, 1995). In this study the p85 adaptor 
subunit of the Class Ia PI3K isoforms was shown to co-precipitate with the CD28 
receptor upon stimulation. Indeed, PI3K has been demonstrated to physically 
associate with the CD28 receptor via a (p)Y173MNM motif in its cytoplasmic tail 
(Prasad et al., 1994). In confirmation of previous findings, the activation of PI3K in 
CD28 stimulated Jurkat cells was also demonstrated. Engagement of CD28 by 
antibody and the more physiologically relevant ligand B7.1 elicited a time-dependent 
accumulation of the PI3K product PI(3,4,5)P3.
3.10 - THE REGULA TION OF GAB-2 SIGNALLING COMPLEXES B Y  CD28
The present study sought to examine whether GAB-2 signalling complexes were 
involved in signal transduction by the CD28 receptor. Accordingly, CD28 
stimulation was shown to induce the tyrosine phosphorylation of GAB-2 and its co- 
precipitation with both SHP-2 and the class Ia PI3Ks. Taken together, these results 
seemed consistent with the formation of a multimeric signalling complex, similar to 
that suggested by others to exist downstream of cytokine receptors (Craddock and 
Welham 1997; Gu et al., 1998) and the TCR (Frearson and Alexander., 1998; Pratt et 
al., 2000).
Figure 3.9 represents a model for these interactions, based on the present findings 
and in accordance with the published literature governing the relationship between 
GAB-2, SHP-2 and PI3K. In this model, the initial event following CD28 receptor 
ligation is the tyrosine phosphorylation of cytosolic GAB-2. Whilst the present study 
provides the first evidence that GAB-2 is a substrate for protein tyrosine kinase 
activity following CD28 ligation, the enzyme responsible for this phosphorylation 
remains to be identified.
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Figure 3.9  -  M odel fo r  GAB-2 Signalling Complexes Downstream o f  CD28; The initial event following 
receptor ligation is the tyrosine phosphorylation o f GAB-2. Appropriately phosphorylated GAB-2 then 
mediates the recruitment o f  SHP-2 and PI3K. Stabilisation o f  PI3K at the membrane (perhaps involving 
PH domain binding o f  GAB-2 to membrane phospholipids) along with occupation o f the two SH2 
domains o f  the p85 adaptor subunit could help promote the activation o f  this enzyme. Similarly, SHP-2 
may be recruited and activated within the same complex, perhaps in turn modulating GAB-2 
phosphorylation and PI3K activation.
3.10.1 - GAB-2, p85 Interaction
The appropriate phosphotyrosine binding motifs for the SH2 domains of p85 have 
been identified within the GAB-2 amino acid sequence (Y ^V PM , Y461IPM, 
Y574VPM) ( G u  et al., 1998; Nishida et a l 1999). Moreover, in vitro studies have 
established that this physical interaction is important in mediating PI3K signalling 
downstream of receptors that lack the ability to bind p85 directly (eg. the IL-3R) 
(Craddock and Welham., 1997; Gu et al., 1998). In this report GAB-2 was shown to 
co-precipitate with the p85 subunit of PI3K in response to CD28 ligation. 
Interestingly, this association appeared to be mediated by the N-terminal rather than 
the C-terminal SH2 domain of p85. In our model, the C-terminal SH2 domain of p85 
is shown bound directly to the CD28 receptor. This seems compatible with the 
former observation by Prasad and co-workers, that the C-terminal SH2 domain of
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p85 interacts with the CD28 (P)Y173MNM motif with a 10 fold higher affinity than 
the N-terminal SH2 domain (Prasad et al., 1994). Indeed, the potential for the C- 
terminal SH2 domain of p85 to be bound to the CD28 receptor could feasibly explain 
the relative lack of GAB-2 binding observed in this case.
It seems somewhat surprising that CD28 should require additional methods for the 
recruitment of PI3K, given the fact that the receptor can couple directly to this 
enzyme. One possible explanation is that the interaction of the p85 subunit with 
GAB-2 simply helps to stabilise PI3K at the plasma membrane close to its 
phospholipid substrates. In an elegant scenario, the GAB-2 PH domain might be 
involved in this process, co-ordinating the translocation of the GAB-2, PI3K 
complex to the appropriate subcellular location by anchoring itself to membrane 
phospholipids. However, the specificity of the GAB-2 PH domain is not yet known 
and the membrane recruitment of GAB-2 was not demonstrated here. It is also 
conceivable that occupation of both the SH2 domains of p85 may be required for the 
complete stimulation of catalytic activity (Carpenter et al., 1993a). Significantly, the 
detection of lipid kinase actvity in the CD28 stimulated GAB-2 immunoprecipitates 
lends support to the notion that the associated pool of PI3K is conformationally 
active.
3.10.2 - The GAB-2, SHP-2, PI3K Interaction
This research also examined the associations between the protein tyrosine 
phosphatase, SHP-2, and the class U PI3Ks, since previous reports have indicated 
that these two proteins may exist in the same complex (Craddock and Welham., 
1997; Gu et al., 1998; Frearson and Alexander., 1998). Accordingly, SHP-2 was 
shown to co-precipitate with the leukocyte specific pi 108 subunit and the p85 
subunit of PI3K. Due to the absence of any known consensus binding sites for the 
p85 subunit within SHP-2 (Freeman et al., 1992), it has been proposed that GAB-2 
may mediate an indirect coupling between p85 and SHP-2. In this study, GAB-2 was 
identified in SHP-2 immunoprecipitates upon stimulation of the CD28 receptor. 
Indeed, the interaction between GAB-2 and SHP-2 has been described in many 
cellular systems, downstream of multiple receptors (reviewed by Liu and 
Rohrschneider., 2002). It has been suggested that GAB-2 may not only be involved
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in the recruitment of SHP-2, but may also serve to promote the catalytic activity of 
this enzyme. Notably, two tyrosines located in the C-terminal end of GAB-2 fall 
within consensus binding motifs for the SH2 domains of SHP-2 upon 
phosphorylation (Y614LAL/Y643VQV) (Gu et al., 1998). Moreover, occupation of 
both the SH2 domains of SHP-2 is known to relieve the conformational inhibition 
that these motifs exert over the phosphatase domain and be optimal for stabilising the 
‘open’ active form of the enzyme (Pluskey et al., 1995; Hof et al., 1998).
3.10.3 - Is GAB-2 a Substrate for the Protein Tyrosine Phosphatase Activity of 
SHP-2?
In reviewing the literature, the complex interplay between SHP-2, GAB-2 and PI3K 
and the significance of this to downstream signalling events has been difficult to 
define. It is clear that identification of the cellular substrates of SHP-2 would greatly 
precipitate our present understanding. The observation that GAB-2 is a 
hyperphosphorylated protein in cells expressing catalytically inactive (substrate- 
trapping) mutants of SHP-2, led to the prediction that GAB-2 itself may be a target 
for de-phosphorylation (Herbst et al., 1996; Gu et al., 1997; Frearson and 
Alexander., 1998). In support of this premise, the present study found that the 
tyrosine phosphorylation of a 100 kDa protein (GAB-2?) was attenuated in SHP-2 
phosphatase assays. Naturally, such regulation of GAB-2 phosphorylation would be 
expected to impact on the binding and signalling of its other protein partners. 
However, the results of these in vitro assays must be interpreted with caution. It is 
conceivable that additional enzymes may have been precipitated that could mediate 
the observed de-phosphorylation. In this regard, GAB-2 associates with and is a 
potential substrate for the related protein tyrosine phosphatase SHP-1 in vitro 
(Wheadon et al., 2002). One alternate possibility is that the association of SHP-2 
with GAB-2 may simply serve to localise SHP-2 into the vicinity of other proteins, 
which may then be targeted by its catalytic activity. It has been suggested that SHP-2 
can positively regulate PI3K activation (Frearson et al., 1998; Yu et al., 2002). 
Indeed, this mechanism could putatively involve de-phosphorylation of an as yet 
unidentified SHP-2 substrate.
CHAPTER 3: In Vitro Co-associations o f GAB-2, SHP-2 and PI3K 106
CONCLUDING REMARKS
This in vitro study has provided insight into the potential molecular interactions 
between, GAB-2, SHP-2 and PI3K following the stimulation of Jurkat T cells with 
CD28. It is important now to characterise the role of these signalling complexes in 
the regulation of functional T cell activation by CD28.
4THE FUNCTIONAL ROLE OF GAB-2 IN 
TCR/CD28-DEPENDENT ACTIVATION OF THE
IL-2 PROMOTER
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RESULTS
The ability of T cells to generate IL-2 is one of the major influences governing their 
continued participation in the immune response, since this factor promotes cell cycle 
progression and rescues cells from their anergic fate. Accordingly, signals emanating 
from both the TCR and CD28 have been demonstrated as being both necessary and 
sufficient for optimal IL-2 production. The transcriptional regulation of IL-2 is 
ultimately controlled by the IL-2 gene enhancer, which in turn is fine-tuned by 
several transcriptional elements (reviewed in sections 1.14 -  1.17). Of particular 
importance to the co-stimulatoiy dependence of IL-2 expression is the CD28 
responsive element, which is thought to comprise an NFicB-like binding site, 
together with an adjacent AP-1 site.
It has been previously reported that GAB-2 negatively regulates TCR signalling to 
the IL-2 promoter by the recruitment of inhibitory molecules. In studies by Pratt et 
al, it was suggested that wild-type GAB-2 interfered with NFAT and NFkB 
transactivation by mediating an inhibitory pool of PI3K (Pratt et al., 2000). However, 
in similar experiments by Yamasaki and co-workers, the role of GAB-2 in the down- 
regulation of TCR-mediated NFAT activation and IL-2 production was found to be 
largely dependent on SHP-2 and not PI3K (Yamasaki et al., 2001). Having gathered 
evidence in this study for the exsistence of a not dissimilar GAB-2 complex 
downstream of CD28, the appropriate next step was to re-examine the role of GAB-2 
in both CD28 and TCR-dependent activation of the IL-2 promoter.
4.1-DEVELOPMENT OF LUCIFERASE REPORTER ASSAYS
As mentioned, two critical elements in the IL-2 gene enhancer are the binding sites 
for the transcription factors NFkB and AP-1, which together are thought to confer 
CD28 responsiveness. Therefore, to investigate the role that GAB-2 plays in the co­
stimulatory dependence of IL-2 transcription, assays were developed to examine the 
effect of overexpressing wild-type (WT) and various GAB-2 mutant proteins on the 
activation of NFkB and AP-1-directed luciferase reporters. Details of the GAB-2 
expression constructs used in this study are shown in Figure 4.1.




• GAB-2-3YF - Y-»F mutation of the three tyrosines (Tyr441, Tyr461, Tyr574) 
that fall within the binding sites for the SH2 domains of p85 (Y).
• GAB-2-APH -  N-terminal PH domain truncation mutant.
• GAB-2-YFDH - Y-»F mutation of the two tyrosines (Tyr604, Tyr633) that fall 
within the binding sites for the SFI2 domains of SHP-2 (Y).
Figure 4.1 -  The Schematic Structure o f  the HA-tagged GAB-2 Constructs; Constructs encoding the 
GAB-2 expression mutants were kindly donated by Dr. B. N. Neel (Dept.M edicine, Beth Israel- 
Deaconess Medical Centre, Boston, MA, USA). All proteins were HA-tagged at the C-terminus. PH = 
Pleckstrin homology domain, P = Proline rich regions.
The use of reporter constructs enables the attachment of multiple copies of a 
transcription factor binding sequence upstream of the gene coding for a stable 
enzyme. This provides a convenient system whereby transcription of the enzyme is 
dependent upon induction of functional transcription factor complexes. The detection 
of luciferase activity is commonly employed and in these investigations constructs 
were used comprising 4 tandem repeats of the NFkB and AP-1 binding sites of the 
CD28RE cloned into the pGL2-luciferase vector (Promega) (generated by Dr. C. 
Edmead, The University of Bath).
4.1.1 - Optimisation of Transfection Conditions for the GAB-2 Expression 
Plasmids
Optimisation of the conditions for transfection of the WT-GAB-2 and GAB-2 mutant 
constructs into Jurkat T cells was required to ensure levels of overexpression of these
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proteins that would be necessary to out compete endogenous GAB-2 in the assays of 
IL-2 promoter activity. In this study, a brief comparison of the electroporation 
(950pF, 300V) and lipofection (using the DMRIE-C compound, Invitrogen) methods 
as techniques for introducing plasmid DNA into Jurkat T cells was performed. In 
previous studies electroporation had been used as the transfection method of choice 
(Pratt et al., 2000; Yamasaki et al., 2001). However, superior performance for the 
transfection of DNA into Jurkat T cells had been reported for the DMRIE-C 
lipofection compound (Schifferli and Ciccarone., 1996).
Firstly, to determine the relative transfection efficiency of each method, cells were 
appropriately transfected with 5pg of a GFP plasmid (pGFP-Cl, Clontech). Figure
4.2 shows the result of FACS analysis on these Jurkat T cells, examining percentage 
cell viability and percentage cells expressing the GFP protein following transfection. 
Both methods resulted in similar transfection efficiencies with 63.2% cell viability 
and 25.8% cells expressing GFP for the electroporation method, compared to 61.6% 
cell viability and 29.7% cells expressing GFP for the lipofection method (Figure 4.2 
B and C, respectively).
Jurkat T cells were then transfected with the WT-GAB-2 expression plasmid to 
determine whether comparable protein expression could also be achieved using the 
different methods. Figure 4.3 depicts the expression of the WT-GAB-2 protein 
following transfection, assessed by immunoblot analysis with both the anti-GAB-2 
and anti-HA antibodies. It is clear that despite the transfection efficiencies of the two 
methods appearing similar in the experiment shown in Figure 4.2, the lipofection 
technique produced considerably better expression of the WT-GAB-2 protein than 
that achieved by the electroporation procedure. On the basis of this evidence, 
lipofection was the transfection method of choice for the final assay protocol.
In these preliminary optimisation experiments, expression of the GAB-2 mutant 
proteins was also observed to be dependent upon the amount of plasmid DNA 
introduced into the cell. In Figure 4.4A it can be seen that good overexpression of
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Figure 4.2






















2 9 . 7 %
LIPOFECTION
Optimisation of Transfection Method for the GAB-2 Expression Plasmids
Jurkat cells were left untransfected (A) or transiently transfected with 5pg GFP plasmid 
using either the electroporation (B) or lipofection method (C). The percentage viable 
cells and cells expressing GFP was determined by FACS analysis (10,000 events 
counted) at 24 hours post-transfection.
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O ptim isation  o f T ransfection  M ethod fo r  the G A B -2 E xpression Plasm ids
Jurkat c e l l s  w e r e  tra n sien tly  tra n sfe c te d  w ith  5 p g  W T -G A B -2  e x p r e s s io n  p la sm id  or  
e x p r e s s io n  v e c to r  a lo n e  u s in g  e ith er  th e  e le c tr o p o r a tio n  or  l ip o fe c t io n  m eth o d  (a s  
in d ic a te d ). C y to p la sm ic  ex tra cts  w e r e  r e s o lv e d  b y  S D S -P A G E  an d  tran sferred  to  
n itr o c e llu lo s e  m em b ra n es . M em b ra n es  w e r e  p r o b e d  w ith  th e  rab b it p o ly c lo n a l an ti-  
G A B -2  a n tib o d y  ( a - G A B —2 )  or w ith  th e  m o u s e  m o n o c lo n a l a n ti-H A  a n tib o d y  ( a -H A ) .  
A, E x p r e ss io n  o f  tr a n sfe c te d  and  e n d o g e n o u s  G A B -2  p ro te in s . B, E x p r e ss io n  o f  
tr a n sfe c te d  H A -ta g g e d  W T -G A B -2  p ro te in  at 2 4  h o u rs p o st-tr a n s fe c tio n .
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Optimisation of Transfection Conditions for the GAB-2 Expression Plasmids
Jurkat cells were transiently transfected with varying amounts o f the GAB-2 expression 
plasmids (as indicated) or expression vector alone using the lipofection method. 
Cytoplasmic extracts were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes. Membranes were probed with the rabbit polyclonal anti-GAB-2 antibody (a - 
GAB—2). A, Relative expression o f endogenous and transfected proteins (5pg), 24 hours 
post-transfection. B, Relative expression o f endogenous and transfected proteins (lOfig), 
48 hours post-transfection.
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WT-GAB-2 relative to endogenous GAB-2 protein (in cells transfected with vector 
only) was achieved when 5pg of DNA was initially transfected. Moreover, lowering 
the amount of WT-GAB-2 plasmid transfected down to 3pg and lpg of DNA was 
mirrored by a parallel reduction in the levels of expression of this protein. Notably, 
whilst the introduction of 5 fig of plasmid DNA was sufficient for the overexpression 
of WT-GAB-2, the same was not applicable for the other GAB-2 mutant proteins, 
expression of which was not detectable above that of endogenous. In subsequent 
manipulations it was revealed that lOpg of transfected DNA would yield satisfactory 
expression of all the GAB-2 constructs. Levels of protein expression were also 
examined at 24 and 48 hours post-transfection, with the latter time-point chosen as 
optimum for subsequent measurements (Figure 4.4B).
The final luciferase assay protocol outlined in Figure 4.5 reflects the findings of 
these optimisation experiments.
TRANSFECTION 1 Ogg GAB-2 plasmid / vector + 3pg REPORTER + 
(using DMRIE-C) 2.5pg (3-gal normalisation plasmid
1 48h







AMP + PPi + C 0 2 
hv (562nm)
Figure 4.5 -  Schem atic o f  Final Luciferase Reporter Assay Protocol; Jurkat T cells were transiently 
transfected using the lipofection method with lOpg o f Gab-2 expression plasmid or expression vector 
alone in combination with 3fig o f the appropriate luciferase reporter. This ratio was chosen to increase 
the probability that cells expressing the reporter would also express the transfected GAB-2 protein. At
CHAPTER 4: Functional GAB-2 114
48 hours post-transfection cells were stimulated for 6 hours with anti-CD28 antibody (9.3) and anti- 
CD3 antibody (UCHT1). Previously it has been shown that peak levels of IL-2 mRNA are detectable 
around 6 hours following T cell activation. Luciferase activity was determined with the addition of the 
Bright-Glo luciferase assay reagent (Promega) and measuring emitted light at 595nm in a 96-well Top 
Count luminometer (Packard). In these transient expression assays, cells were transfected with the 
pSV-P-galactosidase control vector (promega) as an internal control for monitoring cell viability and 
transfection efficiency. This enabled valid comparisons to be made between the luciferase data 
obtained from Jurkat cells transfected with the different GAB-2 expression constructs.
4.2 -  EFFECT OF GAB-2 EXPRESSION PLASMIDS ON CD3/CD28 
STIMULATED NF kB-LUCIFERASE ACTIVITY
Figure 4.6 summarises the assays performed in an attempt to understand the 
mechanism by which GAB-2 regulates NFicB-directed transcriptional activity of the 
IL-2 gene enhancer. The various GAB-2 expression plasmids were co-transfected 
along with an NFicB-luciferase reporter construct into Jurkat T cells. Cells were left 
unstimulated or were stimulated with anti-CD3 (UCHT1) and anti-CD28 (9.3) alone 
or in combination. As shown in Figure 4.6A, significant stimulation of NFkB 
required signals from both the TCR and CD28. Stimulation with anti-CD3 and anti- 
CD28 alone evoked little NFkB activity, whereas co-stimulation with these 
antibodies resulted in robust activation (approx. 12 fold increase above unstimulated 
controls) of NFKB-directed transcription in the vector-transfected cells. In contrast, 
co-expression of WT-GAB-2 dramatically inhibited NFKB-luciferase activity 
stimulated by anti-CD3 and anti-CD28 (Figure 4.6B).
To begin to understand how GAB-2 mediates this negative regulation, the effect of 
WT-GAB-2 was compared with that of the GAB-2 mutant proteins. It has been 
established that tyrosine phosphorylated GAB-2 binds to both SHP-2 and PI3K. 
Furthermore, the interaction of GAB-2 with each of these proteins has been 
suggested to mediate its inhibitory effect on IL-2 promoter activity (Pratt et al., 2000, 
Yamasaki et al., 2001). However, in the present study Y-»F mutation of the three 
YXXM motifs that constitute potential binding sites for p85 (GAB-2-3YF) and both 
the SHP-2 binding sites (GAB-2-YFDH) had little effect on the ability of GAB-2 to 
inhibit CD28/CD3 stimulated NFKB-luciferase activity (as shown in Figure 4.6C and
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Figure 4.6
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Effect of GAB-2 Expression on CD3/CD28 Stimulated NFKB-luciferase Activity
Luciferase assays were performed as described in ‘Materials and M ethods’. Jurkat T cells 
were transiently transfected with GAB-2 expression plasmids or expression vector alone 
(lOpg) in combination with the NFKB-luciferase plasmid (3pg) and (3-galactosidase 
normalization plasmid. A, CD3 and CD28 stimulated NFKB-luciferase activity ( 0 ) .  B,C, 
D and E, Effect o f expressing WT GAB-2 and GAB-2 m utant proteins on CD3 and CD28 
stimulated NFKB-luciferase activity (H  ). F, Expression o f  transfected and endogenous 
GAB-2 proteins was determined by anti-GAB-2 immunoblot analysis o f whole cell lysates 
from the transfected cells. Statistical analysis was perform ed on this data using a paired 
t-test and significant differences at the p<0.001 denoted by (***) and p<0.01 denoted by 
(**). Results are displayed as mean ± SEM of 3 independent experiments.
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E, respectively). Interestingly, it can be seen in Figure 4.6D that deletion of the 
GAB-2 PH domain (GAB-2-APH) completely eliminated the GAB-2-mediated 
inhibition.
4.3 -  EFFECT OF GAB-2 EXPRESSION PLASMIDS ON CD3/CD28 
STIMULATED AP-1-LUCIFERASE ACTIVITY
Induction of the Jun and Fos component proteins of AP-1 transcripition factor 
complexes cannot be stimulated through the TCR alone, but requires co-stimulatory 
signals provided by CD28. As expected, therefore, the combination of anti-CD28 and 
anti-CD3 stimulation was necessary for significant stimulation of AP-1-directed 
luciferase activity in the vector-transfected Jurkat cells (Figure 4.7A). Overall, 
similar effects of the GAB-2 expression plasmids were observed in these 
experiments on AP-1 activation as were seen for NFkB activation. Expression of 
WT-GAB-2 also blocked AP-1-directed transcription induced by anti-CD3 plus anti- 
CD28 (Figure 4.7B). Likewise, the inhibitory effect of GAB-2 was abolished by the 
PH domain truncation (Figure 4.7D). In Figure 4.7E it can be seen that mutation of 
the two consensus binding sites for the SH2 domains of SHP-2 had little effect on the 
ability of GAB-2 to inhibit CD28/CD3 stimulated AP-1-luciferase activity. The 
effect of the GAB-2-3YF mutant depicted in Figure 4.7C was inconclusive, but it is 
important to note that the level of expression of this mutant protein was consistently 
not as good as that of WT-GAB-2 in these assays, which may have accounted for 
some of the effects observed.
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Effect of GAB-2 Expression on CD3/CD28 Stimulated AP-l-luciferase Activity
Luciferase assays were performed as described in ‘M aterials and M ethods’. Jurkat T 
cells were transiently transfected with GAB-2 expression plasmids or expression 
vector alone (lOpg) in combination with the A P-l-luciferase plasm id (3pg) and (3- 
galactosidase normalization plasmid. A, CD3 and CD28 stimulated NFxB-luciferase 
activity (0 ). B,C, D and E, Effect o f expressing W T GAB-2 and GAB-2 mutant 
proteins on CD3 and CD28 stimulated A P-l-luciferase activity ( J ) .  F, Expression of 
transfected and endogenous GAB-2 proteins was determined by anti-GAB-2 
immunoblot analysis o f whole cell lysates from  the transfected cells. Statistical 
analysis was performed on this data using a paired t-test and significant differences at 
the p<0.001 level denoted by (***) and p<0.01 denoted by (**). Results are displayed 
as mean ± SEM of 4 independent experiments.
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SUMMARY OF FINDINGS
•  Conditions for the transient transfection of Jurkat T cells were successfully 
optimised and good levels of overexpression of the WT-GAB-2 and GAB-2 mutant 
proteins compared to endogenous GAB-2 protein was achieved.
•  Co-transfection of WT-GAB-2 markedly inhibited CD3 and CD28-evoked 
activation of both NFkB and AP-1-directed transcription.
•  The PH domain of GAB-2 was required for this inhibition, whereas the ability of 
GAB-2 to interact with PI3K or SHP-2 appeared not to be important.
DISCUSSION
4.4 - DEVELOPMENT OF LUCIFERASE REPORTER ASSA YS
A fundamental goal of these investigations was to develop a reliable assay for use in 
examining the role of GAB-2 in the co-stimulatory dependence of IL-2 transcription. 
Accordingly, conditions were optimised for the transient transfection of various 
GAB-2 expression plasmids, so that the effect of their overexpression could be 
measured upon CD3 and CD28 stimulation of NFkB and AP-1-directed luciferase 
reporters.
4.5 - THE ROLE OF GAB-2 IN  THE CO-STIMULATORY DEPENDENCE OF 
IL-2 TRANSCRIPTION
IL-2 is the critical factor required for the progression of a newly activated T cell from 
G1 to S phase of the cell cycle. Hence, dissection of the biochemical events that 
regulate IL-2 transcription may be key in identifying which processes eventually 
determine T cell fate ie, anergy or activation. A number of studies have highlighted 
GAB-2 as a negative regulator of TCR signalling. However, the exact mechanism by 
which this protein mediates its inhibitory effect remains a matter for contention. In 
Jurkat T cells, Pratt et al first proposed that GAB-2 mediated an inhibitory PI3K
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pathway in TCR signalling (Pratt et al., 2000). Subsequently, Yamasaki and co­
workers argued that the association of GAB-2 with SHP-2, and not PI3K, was 
important (Yamasaki et al., 2001). This investigation attempted to resolve the current 
disparity within the literature by re-examining the effect of GAB-2 on CD3/CD28 
co-stimulation of IL-2 promoter activity.
This study confirmed that overexpression of WT-GAB-2 negatively regulates 
CD3/CD28 induced activation of the IL-2 promoter, since the transcription of both 
NFkB and AP-1-directed reporters was suppressed. Surprisingly, the ability of GAB- 
2 to interact with SHP-2 or PI3K seemed not to be involved in this inhibitory 
mechanism. In direct contrast with previous reports, GAB-2 mutants defective in 
SHP-2 and PI3K binding still retained their inhibitory potency. Notably, only the 
deletion of the PH domain was able to rescue the GAB-2 mediated inhibition of 
NFkB and AP-1-directed transcription. In view of the findings contained in this 
chapter, some alternative explanations may be suggested as to how the 
overexpression of GAB-2 modulates transcription of the IL-2 gene;
1. These investigations demonstrated that the PH domain of GAB-2 was 
required for the inhibitory effect on NFkB and AP-1-dependent 
transcriptional activation. PH domains are protein moieties that mediate 
binding to specific phospholipids. The binding specificity of the GAB-2 PH 
domain has yet to be determined. However, its sequence is highly similar to 
the PH domain of GAB-1 (73% identity), which specifically binds 
PI(3,4,5)P3. (Gu et al., 1998; Maroun et al., 1999). It seems reasonable to 
suggest, therefore, that the GAB-2 PH domain might also bind this lipid. 
Considering this, the effect of overexpressing WT-GAB-2 in these 
experiments could have been to interfere with the binding to P I P 3 of other 
important PH domain-containing proteins, such as PKB. Indeed, the PI3K 
target PKB is activated upon ligation of the CD28 co-receptor (Parry et al., 
1997). Moreover, in Jurkat T cells PKB has been shown to mimic the effects 
of CD28 co-stimulation by synergizing with TCR-induced signals to increase 
transcription from a composite CD28RE/AP reporter (Kane et ah, 2001). It is 
conceivable, therefore, that down-regulation of PKB signalling pathways as a 
potential consequence of WT-GAB-2 overexpression, could account for the
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observed inhibition of CD3/CD28 induced NFkB and AP-1-directed 
transcription (as shown in Figure 4.8)
To address this possibility, a number of key experiments would need to be 
performed. Firstly, the effect of overexpressing the GAB-2 PH domain in 
isolation would be examined to see if this yielded the same result as the WT- 
GAB-2 protein. Secondly, it would be necessary to determine the 
phosphoinositide-binding property of the GAB-2 PH domain. This could be 
analysed by protein-lipid overlay assay using various GAB-2 GST-fusion 














Figure 4.8  -  Potential Effect o f  WT-GAB-2 Overexpression on CD3/CD28 Stim ulated  
N F kB/A P-1- directed transcription. The PH domain o f  GAB-2 could interact with 
phosphoinositide lipids and prevent the activation o f  positive signalling cascades downstream 
o f  CD28/CD3. It has been suggested that the PH domain o f  GAB-2 binds to PI (3,4,5)P3, 
due to its sequence similarity with the PH domain o f  GAB-1, which specifically binds this 
lipid. However, so far this has not been proven and other factors such as protein folding 
could influence the presentation o f  the GAB-2 PH domain to PI lipids. I f  the GAB-2 PH
CHAPTER 4: Functional GAB-2 121
domain were to interact with PI(4,5)P2 this would also affect PI3K effector pathways, by 
preventing the access of this kinase to its lipid substrate.
2. The ability of GAB-2 to interact with SHP-2 or PI3K was dispensable for the 
negative regulation of NFkB and AP-1-directed transcription. However, the 
possibility that another molecule interacts with GAB-2 and is responsible for 
mediating its inhibitory effects cannot be ruled out. Indeed, a number of other 
potential SH2 domain binding motifs have been identified within the GAB-2 
sequence that could alternatively coordinate the recruitment of effector 
proteins (Gu et al., 1998). In an elegant scenario, the PH domain binding of 
GAB-2 would contribute to the overall mechanism by functioning to localise 
the inhibitory GAB-2 complex to the specific subcellular compartment/ 
receptor where it exerts its negative effect.
At present, the reason for the apparent discrepancies between the findings 
contained here and those of previous studies regarding the involvement of 
PI3K and SHP-2 in the GAB-2 mediated effect is unclear. However, the 
differences might be explained due to the alternative methods of stimulation 
employed. In these experiments, anti-CD3 plus anti-CD28 was utilized to 
stimulate transcription, whereas formerly anti-CD3 alone or in combination 
with PMA had been used (Pratt et al., 2000; Yamasaki et al., 2001). It is 
important to note that the role of PI3K with regard to regulation of the IL-2 
promoter has already been the matter of some debate, due to the number of 
conflicting reports within the literature (Ueda et al., 1994; Ward et al., 1995; 
Reif et al., 1997; Kane et al., 2001). PI3K has previously been shown to 
inhibit TCR-evoked activation of an NFAT-driven reporter construct in 
Jurkat and EL4 T cells (Reif et al., 1997). In contrast, PKB (a downstream 
effector of PI3K) has been reported to positively regulate the NFKB-like 
RE/AP element, an important site of integration for TCR and co-stimulatory 
signals (Kane et al., 2001). One possible explanation is that depending upon 
cellular context (ie, in the presence or absence of co-stimulation), PI3K can 
influence IL-2 transcription either positively or negatively by selective 
modulation of transcription factor binding. The current investigations focused 
on TCR/CD28 stimulation of NFkB and AP-1-directed transcription and 
found no evidence that PI3K was involved in the GAB-2 mediated inhibition.
CHAPTER 4: Functional GAB-2 122
Future experiments would need to compare the effects of WT-GAB-2 and the 
GAB-2 mutant expression constructs on the activation of NFAT induced by 
anti-CD3 alone and in combination with anti-CD28. Under conditions of co­
stimulation, the overall role that GAB-2 plays in the transcriptional regulation 
of the full length IL-2 promoter could also be examined. An overview of the 
results presented here compared with those of Pratt et al and Yamasaki et al 
is shown in Table 4.1.
Table 4.1 -  Overview o f  GAB-2 Luciferase Assay Data
REFERENCE GAB-2 M UTANT STIM ULATION REPORTER OUTCOM E
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Although initially identified and best understood as mediators of positive 
signalling, growing evidence supports the existence of adaptor proteins with 
potential negative regulatory function. It is conceivable that GAB-2 could 
represent one of a number of such proteins involved in the maintenance of 
immunological homeostasis. In B cells, p62-Dok, a PH-domain containing 
adaptor molecule similar to GAB-2, has been shown to down-regulate 
immunoreceptor signalling by recruiting the GTPase, RasGAP (Tamir et al.,
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2000). Whereas, another member of the Dok family, Dok3, was demonstrated to 
associate with the negative regulatory signalling molecules SHIP and Csk in 
order to inhibit BCR-induced IL-2 production and NFAT activity (Lemay et al., 
2000). More recently, a novel adapter protein, termed DAPP1, was proposed to 
down-regulate B cell signalling downstream of PI3K by interfering with PH- 
domain binding of Btk to PIP3 and its subsequent association with PLCy2 
(Dowler et al., 2000; Marshall et al., 2000). Indeed, this observation lends 
support to the current speculation that the PH-domain binding of GAB-2 may 
similarly act to displace positive regulatory effector molecules in T cells.
CONCLUDING REMARKS
In contrast to its potential inhibitory role in CD3/CD28 co-stimulation of the IL-2 
promoter, GAB-2 acts as a positive signal transducer in many systems. Indeed, 
the association of GAB-2 with both SHP-2 and PI3K is vital for normal cytokine 
signalling (reviewed in section 1.20). Whilst the concept of inhibitory adaptor 
proteins is not without precedent, it seems difficult to reconcile the possibility 
that GAB-2 and its associated protein complexes should have such distinctly 
different roles in different cell types. It is clear that further studies are required to 
fully elucidate the GAB-2 inhibitory pathway in T cells and its importance in the 
immune response. Naturally, the primary objective of these experiments would 
be to rule out the possibility that, as an artefact of its overexpression, WT-GAB-2 
prevents the activation of positive signalling cascades downstream of 
CD28/CD3.
5THE ROLE OF SHP-2 IN MITOGENIC
SIGNALLING
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RESULTS
Gathered evidence suggests that the protein tyrosine phosphatase SHP-2 plays a 
positive role in mammalian cell signalling (reviewed in section 1.19). In particular, 
SHP-2 has been identified as a critical component linking many cytokine and growth 
factor receptors to the downstream activation of the MAP kinases, ERK1 and 2 
(Noguchi et al., 1994; Xiao et al., 1994; Tang et al., 1995; Shi et al., 1998; Craddock 
et al., 2001). In light of the fact that SHP-2 has been proposed to regulate TCR 
coupling to the Ras/MAPK cascade (Frearson and Alexander., 1998), and having 
identified the recruitment of SHP-2 within complexes downstream of CD28, the next 
phase of this study sought to further define the role of this enzyme in mitogenic 
signalling and also in the functional regulation of the IL-2 promoter.
A common molecular approach used to dissect the role of a given enzyme in cellular 
responses is to establish stable transfectants that overexpress dominant-negative 
forms of the enzyme. In these investigations variants of SHP-2 were stably expressed 
in Jurkat T cells, under the control of the tetracycline-inducible gene expression 
system.
5.1-DOMINANT-NEGATIVESHP-2 CONSTRUCTS
Mutant versions of SHP-2 which have little or no activity when compared with wild- 
type, can effectively out compete and thus block normal protein function when 
ectopically expressed within the cell. Such mutant forms are appropriately termed as 
dominant-negative proteins.
The expression of dominant-negative SHP-2 has already been used in a variety of 
studies to examine the role of this phosphatase in growth factor responsive cells 
(Milarski et al., 1994; Noguchi et al., 1994; Bennet et al., 1996; Frearson and 
Alexander., 1998). In these studies, SHP-2 is typically rendered inactive by the point 
mutation of a critical cysteine residue that is found conserved within the active site of 
all protein tyrosine phosphatases. Whilst the mutation of Cys459 to Serine ablates 
catalytic activity, the ability of the enzyme to bind phosphotyrosine is retained (it 
simply cannot be cleaved). Accordingly, these dominant-negative mutant proteins are 
often also referred to as substrate-trapping mutants.
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In the current work, an alternative mutant protein comprising the two-tandem N- 
terminal SH2 domains of SHP-2 was used to perturb endogenous SHP-2 signalling. 
Since this protein was lacking the C-terminal phosphatase domain, it was assumed 
that it could no longer support any enzymatic activity and that it might act as a 
dominant-negative mutant. The use of the 2SH2-SHP-2 mutant protein in studies of 
T cell activation has not previously been reported.
5.2 -  PRINCIPLES OF THE TETRACYCLINE-OFF (TET-OFF) INDUCIBLE 
EXPRESSION SYSTEM
The tetracycline-inducible expression system was developed by Gossen and co­
workers as a tool for the stringent regulation of gene expression in mammalian cells 
(Gossen and Bujard., 1992; Gossen et al., 1993). It is a two-vector system, 
comprising a regulatory plasmid (pUHD 15-1) and a response plasmid (pUHD 10-3). 
The regulatory plasmid encodes for a tetracycline-sensitive transactivator protein 
(tTA), which is a hybrid transactivator generated by combining the tetracycline 
repressor (tetR) from E.coli with the C-terminal transactivator domain of VP 16 from 
Herpes simplex virus. The response plasmid comprises a minimal CMV promoter 
fused to a heptameric repeat of the tetracycline operator sequence (tetO), lying 
upstream of the gene of interest. The transactivator tTA binds to tetO sequences and 
stimulates expression of the gene of interest. However, in the presence of low 
concentrations of tetracycline, the promoter is silenced by virtue of the fact that the 
tetracycline-controlled tTA can no longer bind and induce gene expression. A simple 
overview of this system is shown in Figure 5.1.




i i tTA-dependent promoter








Response plasmid pUHD10-3hygro Response plasmid pUHD10-3hygro
Figure 5.1 -  Schematic Representation o f  the Tetracycline-Regulated Gene Expression System; The 
regulatory plasmid pU H D 15-lneo constitutively produces a tetracycline-controlled transactivator 
(tTA). In the absence o f  tetracycline, the tTA binds to its response element on the response plasmid 
and initiates transcription o f the gene o f interest. In the presence o f  tetracycline, the tTA is prevented 
from binding to the response plasmid and gene expression is switched off.
An inducible expression system such as the one described here has several 
advantages over a constitutive expression system.
1. Gene expression can be controlled during the generation of the stable 
transfectants, with little or no expression of the proteins that could potentially 
be toxic to the host cells.
2. Inducible expression reduces the probability of selecting transfectants that 
may have developed an additional phenotype in order to compensate for the 
effect of expressing the primary mutant.
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3. The level of expression achievable using the tetracycline-inducible system 
has been reported to be greater than in a constitutive system using the same 
CMV promoter (Yin et al., 1996).
5.3 -  DEVELOPMENT OF pUHD 10-3 SHP-2 CONSTRUCTS
Mutant constructs of SHP-2 were sub-cloned into the response vector pUHD 10-3- 
hygro, which contained a hygromycin resistance gene for the direct selection of 
transfectants. The cDNA sequences encoding for the WT and 2SH2 mutant version 
of SHP-2 were kindly provided by Dr. H. Wheadon (The University of Bath). Both 
constructs were N-terminally tagged with the c-Myc decapeptide, which is 
recognised by the monoclonal antibody 9E10, thus enabling the eventual screening 
for expressing clones. The schematic structures of the myc epitope-tagged SHP-2 
proteins used in this study are shown in Figure 5.2.
WT-SHP-2
N








MYC ■■ N-SH2 C-SH2 C
C—»S-SHP-2
MYC wm N-SH2 C-SH2 PTPase
Figure 5.2  -  The Schematic Structure o f  the M yc-tagged SH P-2 Constructs; R, C and D shown on 
the W T-SHP-2 structure are three conserved residues in the catalytic site required for phosphatase 
activity. A ll the proteins were myc-tagged at the N-terminus.
In order to generate pUHD 10-3-hygro constructs containing either the 2SH2-SHP-2 
or the C->S-SHP-2 mutant, a multi-staged sub-cloning strategy was used. The C-»S- 
SHP-2 mutant was generated by PCR-based site-directed mutagenesis from the WT- 
SHP-2 insert. Primers were also designed for the generation of 2SH2-SHP-2 and 
C—»S-SHP-2 coding fragments with the addition of Xbal restriction enzyme sites at
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each end. Following PCR, the resultant DNA fragments were gel purified and then 
ligated into the TOPO vector (Invitrogen, Life technologies). These were analysed by 
sequencing in order to select those PCR products incorporating the appropriate 
mutation and Xba-1 sticky ends. The correct inserts were excised from the TOPO 
vector with Xba-1 and ligated into the pUHD 10-3-hygro response vector, also 
linearised with Xba-1. Finally, the ligation products were sequenced to determine the 
identity and correct orientation of the 2SH2-SHP-2 and C-»S-SHP-2 inserts in 
pUHD-10-3-hygro.
5.4 -  TRANSFECTION AND SELECTION OF TET-OFF DOMINANT- 
NEGATIVE SHP-2 MUTANT JURKAT CLONES
The pUHD 10-3 SHP-2 mutant constructs were linearised with PvuII and transfected 
into the Tet-OFF Jurkat cells, already stably expressing the pUHD 15-1-neo 
regulatory plasmid (as described in section 2.24). Transfectants were selected in 
tetracycline, G418 and hygromycin B, with surviving clones being further expanded 
to enable screening for the level and inducibility of SHP-2 mutant protein expression.
5.4.1 - Characterisation of the 2SH2-SHP-2 Clones
Figure 5.3 shows examples of primary screening blots looking at the expression of 
the 2SH2-SHP-2 mutant protein in the Tet-OFF Jurkat clones. Cells were washed 
and incubated both in the presence and absence of tetracycline for 24h and lysed. The 
myc epitope-tagged protein was visualized by immunoblot analysis using the 9E10 
monoclonal antibody. Several clones inducibly expressing the 2SH2-SHP-2 mutant 
were identified, two of which (clones 6 and 11) were selected for further analysis.
The expression of 2SH2-SHP-2 is dependent upon initial seeding density. Figure 
5.4A shows that optimal expression of the selected clones was achieved when the 
cells were initially seeded at 2X105 cells/ml. At cell densities above this, expression 
was observed to be markedly reduced and less controllable with tetracycline. 
Subsequent time course analyses were also carried out on the 2SH2-SHP-2 mutant 
clones. Figure 5.4B reveals that expression of the mutant protein was maintained 
from 24 to 48h, following removal of tetracycline from the incubation media.
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Figure 5.3
MW(kDa)





1 2 3 4 5
*
6
+ - + - + - + - + - + -
—  —  —
*
7 8 9 10 11 12
+ - + - + - + - +  - + -






Inducible Expression of 2SH2-SHP-2 Constructs in Jurkat T Cells
A and B. Examples o f screening blots. 2SH2-SHP-2 transfectants were selected in 
tetracycline, G418 and hygromycin and incubated in the presence (+) or absence (-) of 
2 fig/ml tetracycline for 24 hours. Cytoplasmic extracts were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes. M embranes were probed with the c-myc 
monoclonal antibody 9E10. Clones showing high levels o f expression and good 
inducibility were selected (*•).
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Figure 5.4
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Characterisation of the Tetracycline-regulated 2SH2-SHP-2 Clones
A, cells were incubated in the presence (+) or absence (-) o f 2pg/ml tetracycline at 
different cell densities. B, cells were cultured as in A, with samples taken at the indicated 
tim es after the initiation o f induction. Cytoplasmic extracts were resolved by SDS-PAGE 
and transferred to nitrocellulose membranes. M embranes were probed with the c-myc 
monoclonal antibody 9E10.
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5.4.2 - Characterisation of the C-»S—SHP-2 Clones
Figure 5.5 shows examples of primary screening blots looking at the expression of 
the C—»S-SHP-2 mutant protein in the Tet-OFF Jurkat clones. Cells were washed and 
incubated both in the presence and absence of tetracycline for 24h and lysed. In this 
instance both the C-»S-SHP-2 and endogenous SHP-2 proteins could be visualized 
on the same immunoblot using the anti-SHP-2 antibody. Due to its greater size, the 
myc-tagged mutant protein exhibited reduced motility through an SDS-PAGE gel 
compared with endogenous SHP-2 protein. Hence, the relative over-expression of the 
C-»S-SHP-2 protein could be assessed, along with its inducibility by the removal of 
tetracycline. The two clones (clones 2 and 10) with the greatest degree of expression 
were selected for the remaining analyses.
Again, the expression of the C—»S-SHP-2 protein was found to be critically 
dependent upon initial seeding density. Figure 5.6 demonstrates that good levels of 
inducible expression could be achieved at cell densities of 2X105 cells/ml and below. 
Unfortunately, whilst expression of the C-»S mutant version of SHP-2 was clearly 
achieved, at different times the level and inducibility of protein expression was found 
to be inconsistent. Therefore, all subsequent data will focus on the use of the 2SH2- 
SHP-2 mutant.
5.5 -  EFFECT OF 2SH2-SHP-2 EXPRESSION ON TCR-DEPENDENT 
PHOSPHORYLATION OF THE MAP KINASES E R K 1 AND 2
In T cells, the MAP kinases ERK 1 and 2 have been implicated in the regulation of 
those cellular processes fundamental to T cell activation, such as proliferation, 
differentiation and IL-2 production (Rayter et al., 1992; Woodrow et al., 1993; 
Yamashita et al., 1999; reviewed by Rincon., 2001). As yet, however, the distinct 
signalling pathways involved in the activation of these family enzymes are not fully 
understood. Previous experiments have suggested that SHP-2 might be a positive 
regulator in mitogenic signal transduction upstream of ERK. Notably, expression of 
a catalytically inactive (C—»S) mutant of SHP-2 attenuated TCR-induced ERK 
activation (Frearson and Alexander., 1998).
















+ + + + Tet
C—»S-SHP-2 
SHP-2
Inducible Expression of C->S-SHP-2 Constructs in Jurkat T Cells
A and B. Examples o f screening blots. C —>S-SHP-2 transfectants were selected in 
tetracycline, G 4 18 and hygromycin and incubated in the presence (+) or absence (-) o f 
2pg/ml tetracycline for 24 hours. Cytoplasmic extracts were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes. M embranes were probed with the rabbit 
polyvlonal anti-SHP-2 antibody (a-SH P-2). Clones showing high levels o f expression 
(*).
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Figure 5.6
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C haracterisation  o f the T etracycline-regulated C -> S -S H P -2  C lones
A  an d  B, c e l ls  w e r e  in cu b a ted  in th e  p re se n c e  (+ )  o r  a b se n c e  ( - )  o f  2 p g /m l te tr a c y c lin e  at 
d iffe r e n t  c e l l  d e n s it ie s . C y to p la sm ic  ex tra cts  w ere  r e s o lv e d  b y  S D S -P A G E  a n d  tran sferred  
to  n itr o c e llu lo s e  m em b ra n es . M em b ra n es w e r e  p ro b ed  w ith  th e  rabb it p o ly v lo n a l a n ti-  
S H P -2  a n tib o d y  (a -S H P -2 ) .
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Having established the inducible expression of 2SH2-SHP-2 in Jurkat T cells, the 
next stage of this study was to investigate the effect of this dominant-negative protein 
on MAP kinase activation. Figure 5.7 demonstrates the effect of 2SH2-SHP-2 protein 
expression on the phosphorylation of ERK 1 and 2 induced by anti-CD3. Cells were 
grown in the presence or absence of tetracycline for 24 hours prior to stimulation and 
inducible protein expression was confirmed by immunoblot analysis with the anti- 
myc antibody, 9E10. Activation of the serine/threonine kinase activity of ERK 1 and 
2 strongly correlates with their phosphorylation on two key residues, threonine202 and 
tyrosine 204. Accordingly, immunoblotting with a phospho-specific antibody targeted 
against these residues can be used as a crude determinant of enzyme activation.
In Figure 5.7A, anti-CD3 stimulation of clone 6 provoked a fairly persistent ERK 
activation, with high levels of phosphorylated protein still detectable at the 60 min 
time point. The initial phase of ERK activation by the TCR appeared not to be 
significantly affected by the expression of 2SH2-SHP-2. However, TCR ligation 
failed to sustain ERK phosphorylation during the later stages of the response in those 
cells expressing the dominant-negative mutant. At 30 and 60 min of stimulation, 
levels of ERK phosphorylation were severely abrogated (highlighted by red box). 
This loss of ERK activation at the later time points of anti-CD3 stimulation was also 
observed in the independently isolated clone 11. In figure 5.7B it can be seen that 
levels of ERK phosphorylation were no longer detectable at 15, 30 and 60 min of 
stimulation in those cells expressing the 2SH2-SHP-2 protein (highlighted by red 
box). In contrast to those effects observed in clone 6, the initial phase of ERK 
activation was slightly delayed in clone 11 by the expression of the dominant- 
negative mutant. As yet, the reason for this apparent inconsistency between the two 
clones is not clear. However, it could perhaps be explained due to differences in the 
levels of inducible expression of the 2SH2-SHP-2 protein between the two clones, or 
possibly clonal variation in the relative surface expression of the TCR/CD3 receptor 
complex.
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A a n d  B, T h e  2 S H 2 -S H P -2  tra n sfec ta n ts  w e r e  in c u b a te d  in th e  p r e s e n c e  ( + )  or a b se n c e  
( - )  o f  2 p g /m l te tr a c y c lin e  fo r  2 4  h ou rs p rior  to  b e in g  s t im u la te d  w ith  5 p g /m l w ith  th e  
a n ti-C D 3  a n tib o d y  (U C H T 1 )  fo r  th e  in d ic a te d  t im e  p o in ts . C e ll ly s a te s  w e r e  p rep ared  
a n d  p ro te in  c o n c e n tr a t io n s  d e term in ed  b y  p e r fo r m in g  a B r a d fo rd  a ssa y . 2 0  p g  o f  ea ch  
sa m p le  w a s  r e s o lv e d  b y  S D S -P A G E . Im m u n o b lo ttin g  w ith  th e  a n ti-p h o p sh o -E R K  
a n tib o d y  (a -P -E R K )  w a s  u se d  to  d e te c t  p h o sp h o r y la te d  E R K  p ro te in s . A r r o w s in d ica te  
b a n d s, th e  rep ro d u ctio n  o f  w h ic h  w a s  p o o r  fr o m  th e  o r ig in a l im m u n o b lo t. T h e  
im m u n o b lo t  w a s  str ip p ed  an d  rep ro b ed  w ith  a n ti-E R K  (a -E R K )  to  a l lo w  th e  p arity  o f  
lo a d in g  to  b e  e x a m in e d . Im m u n o b lo ttin g  w ith  th e  c -m y c  m o n o c lo n a l a n tib o d y  9 E 1 0  
c o n f ir m e d  th e  reg u la tio n  an d  e x p r e s s io n  o f  th e  2 S H 2 -S H P -2  p ro te in . T h e  resu lt is  
re p r e se n ta tiv e  o f  tw o  in d ep en d e n t e x p e r im e n ts  in  tw o  d iffe r e n t  c lo n e s .
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5.6 -  EFFECT OF 2SH2-SHP-2 EXPRESSION ON CD3/CD28 STIMULATED 
N F kB AND AP-1-DIRECTED LUCIFERASE REPORTERS.
The ability of T cells to synthesise and respond to IL-2 is a critical determinant of T 
cell activation. Consistent with this, both TCR-mediated and CD28 co-stimulatory 
signals are necessary for the optimal transcription of this autocrine growth factor. 
Given the functional importance of IL-2 in T cells, the current study sought to 
investigate whether SHP-2 had any impact on signalling to the IL-2 promoter.
Shown in Figure 5.8 and 5.9 are the representative results of luciferase assays 
performed on the 2SH2-SHP-2 mutant clones. Cells were transiently transfected with 
either the NFkB or AP-1-luciferase plasmids and incubated in the presence or 
absence of tetracycline prior to stimulation and assay of luciferase activity. 
Expression of 2SH2-SHP-2 failed to modulate CD3/CD28 stimulated NFkB 
luciferase activity, as shown in Figure 5.8. In contrast, a moderate reduction (approx. 
2 fold lower) in the ability of CD3/CD28 to induce AP-1 luciferase activity was 
observed in those cells expressing the mutant protein, as demonstrated in Figure 5.9. 
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Clone 6 Clone 11
Effect of 2SH2-SHP-2 Expression on CD3/CD28 Stimulated NFKB-Iuciferase 
Activity
Luciferase assays were performed as described in ‘M aterials and M ethods’. The 2SH2- 
SHP-2 transfectants were transiently transfected with the NFicB-luciferase plasmid (3fig) 
and P-galactosidase normalization plasmid and incubated in the presence ( 0 )  or absence 
(jH) of 2 |ig/m l tetracycline for 24 hours. A, Effect of 2SH2-SHP-2 expression on CD3 
and CD28 stimulated NFicB-luciferase activity. B, cell lysates from transfected cells 
were immunoblotted with the c-myc monoclonal antibody 9E10 to confirm the 
regulation and expression o f the 2SH2-SHP-2 protein . Results are representative of 2 
independent experiments in the 2 different clones. Mean values o f 4 replicates are 
plotted ±  standard deviation. Statistical analysis was performed on this data using a 
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Figure 5.9
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Clone 6 Clone 11
Effect of 2SH2-SHP-2 Expression on CD3/CD28 Stimulated AP-l-luciferase Activity
Luciferase assays were performed as described in ‘Materials and M ethods’. The 2SH2- 
SHP-2 transfectants were transiently transfected with the A P-l-luciferase plasmid (3pg) 
and (3-galactosidase normalization plasmid and incubated in the presence ( □ )  or absence 
( H ) o f 2pg/m l tetracycline for 24 hours. A, Effect o f 2SH2-SHP-2 expression on CD3 
and CD28 stimulated NFKB-luciferase activity. B, Cell lysates from transfected cell were 
immunoblotted with the c-myc monoclonal antibody 9E10 to confirm the regulation and 
expression o f the 2SH2-SHP-2 protein. Results are representative of 2 independent 
experiments in 2 different clones. Mean values o f 4 replicates are plotted ± standard 
deviation. Statistical analysis was performed on this data using a paired t-test and 
significant differences at the p<0.05 level denoted by (*).
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SUMMARY OF FINDINGS
• Stable transfectants were successfully generated with the inducible expression of 
2SH2-SHP-2 in Jurkat T cells.
• The inducible expression of the C—>S-SHP-2 dominant-negative mutant was found 
to be inconsistent.
• In cells expressing 2SH2-SHP-2 phosphorylation of ERK 1 and 2 was not sustained 
at later time points following TCR stimulation.
• Expression of 2SH2-SHP-2 had no observable effect on the ability of CD3/CD28 to 
induce NFicB-directed reporter activity.
• Expression of 2SH2-SHP-2 moderately reduced AP-1- directed reporter activity 
following CD3/CD28 stimulation.
DISCUSSION
5.7 - THE GENERATION OF STABLE TRANSFECTANTS THAT EXPRESS 
DOMINANT-NEGATIVE FORMS OF SHP-2
The principal aim of this study was to generate stable transfectants that express 
dominant-negative versions of SHP-2 as a probe for dissecting the role of this 
enzyme in T cell signalling. Accordingly, Jurkat T cell clones were established that 
expressed 2SH2-SHP-2 and C-»S SHP-2 under the control of a tetracycline-OFF 
inducible system. The expression of the 2SH2-SHP-2 protein was found to be robust 
and strongly inducible. Moreover, good levels of the mutant protein were maintained 
for at least 48 hours following induction by the removal of tetracycline. The 
generation of stable transfectants expressing detectable levels of the C->S-SHP-2 
was accomplished. However, subsequent experiments revealed that the inducible 
expression of this protein was inconsistent. In addition, overexpression of the C—»S- 
SHP-2 mutant relative to endogenous SHP-2 protein was not always achieved. It was
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evident that the culture conditions of these mutant clones needed more rigorous 
examination before they could be used reproducibly in investigations.
It is particularly important that dominant-negative proteins are ectopically expressed 
within the cell so that they can out-compete and block normal protein function. 
Interestingly, in Frearson’s experiments an inhibition of ERK-2 activation was 
reported, despite the maximum expression of C-*S-SHP-2 achieved being only 50% 
of total SHP-2 in Jurkat T cells (Frearson and Alexander., 1998).
5.8 - THE ROLE OF SHP-2 IN  THE REGULATION OF THE MAP KINASE 
FAMILY ENZYMES, ERK 1 AND 2, DURING T CELL ACTIVATION
The Ras-regulated ERK/MAP kinase cascade is one of the major pathways involved 
in the transduction of mitogenic signals during T cell activation. However, the exact 
mechanisms that ultimately govern the magnitude and duration of ERK activation 
have not been completely resolved. Multiple studies have implicated SHP-2 as 
positive regulator of MAP kinase activation in response to various mitogenic stimuli 
(Noguchi et al., 1994; Bennet et al., 1996; Shi et al., 1998). Of particular relevance 
to the current investigation, was the finding that a catalytically inactive, dominant- 
negative mutant of SHP-2 significantly inhibited TCR-induced activation of ERK 
(Frearson and Alexander., 1998). In light of these observations and the potential 
physiological importance of sustained ERK activation during the co-stimulation of T 
cells, the role of SHP-2 in the regulation of this pathway was examined.
Consistent with previous reports, the present study found that SHP-2 function was 
indeed required for the phosphorylation of ERK 1 and 2 following TCR stimulation. 
Naturally, the precise mechanism of action of SHP-2 in TCR-mediated ERK 
activation could not be defined based solely upon the observed effect of the 2SH2- 
SHP-2 mutant presented here. Nevertheless, a few ideas may be discussed;
1. The catalytic activity of SHP-2 is clearly necessary for signalling to the ERK MAP 
kinases, suggesting the importance of substrates of SHP-2 in the transduction 
mechanism. One plausible explanation is that SHP-2 acts to dephosphorylate and 
activate signalling molecules, which in turn propagate positive signals towards the 
activation of ERK 1 and 2. It is possible that the mutual association of SHP-2 and
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PI3K with the scaffolding protein GAB-2 may be significant. Given the potential of 
PI3K to stimulate the Ras-MAP kinase cascade, the activity of this enzyme would 
represent a good target for modulation by SHP-2 (Duckworth and Cantley., 1997; 
Grammer and Blenis., 1997). Interestingly, based on findings with a C-»S-SHP-2 
mutant downstream of the TCR, Frearson postulated that the regulation of the GAB- 
2 tyrosine phosphorylation, by SHP-2, could perhaps facilitate the release and/or 
activation of PI3K at its appropriate site of action (Frearson and Alexander., 1998).
2. Promotion of ERK activity downstream of the TCR could be alternatively 
explained if SHP-2 were to interfere with a negative regulator of this pathway. In this 
regard, recent studies in SHP-2 deficient mice have suggested that SHP-2 may in fact 
function to prevent down regulation of the Src family kinases. The mechanism by 
which SHP-2 has been proposed to mediate this positive effect involves the putative 
dephosphorylation of the transmembrane adaptor protein PAG (phosphoprotein 
associated with glycosphingolipid-enriched microdomains), a major Csk binding 
protein in cells (Brdicka et al., 2000; Kawabuchi et al., 2000). Significantly, PAG 
was shown to be hyperphosphorylated in T cells derived from SHP-2'7' mice, which 
also exhibited a marked reduction in Src PTK activity (Ben Neel, conference 
communication; EMBO/FEBS Euro Phosphatase metting, Barcelona, 29th June-3rd 
July 2003). Indeed, the cytoplasmic tail of PAG contains a number of potential 
tyrosine-based signalling motifs amongst which at least one (Y317 in human PAG) 
mediates an association with the negative effector, Csk (Brdicka et al., 2000; 
Lindquist et al., 2003). The interaction between raft-associated PAG and Csk is 
critical, since it not only serves to co-localise this enzyme with its substrates, the Src 
family kinases, but also mediates the stimulation of catalytic activity (Takeuchi et al., 
2000). As a consequence, Csk is perfectly primed to phosphorylate an inhibitory 
tyrosine residue in the C-terminal of the Src kinases and thereby down-regulate the 
activity of these enzymes (Brdicka et al., 2000).
It is conceivable, therefore, that during TCR stimulation SHP-2 targets for 
dephosphoiylation the very tyrosines involved in the recruitment of Csk to PAG, so 
preventing the premature termination of mitogenic signals. The likelihood that this 
mechanism hinges on the initial stimulation of SHP-2 phosphatase activity could also 
explain why the effects of the 2SH2-SHP-2 mutant were not observed until the later
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time points of TCR ligation. Finally, it is tempting to speculate that the association of 
SHP-2 with GAB-2 might be involved in the activation of enzyme activity and in the 
targeting of SHP-2 to the subcellular compartment where PAG resides.
3. It is important to note that the two carboxy-terminal tyrosine residues of SHP-2, 
which are the potential binding sites for SH2 domain-containing proteins, such as 
Grb-2, are no longer present in the 2SH2-SHP-2 mutant protein. However, it is 
unlikely that the loss of such interactions has any relevance in this investigation, 
since it has been previously demonstrated that SHP-2 is not tyrosine phosphorylated 









Figure 5.10 -  Possible Mechanisms o f  Action f o r  SH P-2 in the Promotion o f  the Ras-M APK  
Cascade Downstream o f  the TCR; 1. The transmembrane adaptor PAG functions to down-regulate 
TCR signalling events via its association with Csk, which phosphorylates and inhibits the Src family 
kinases (eg Lck). 2. Catalytically active SHP-2 putatively dephosphorylates PAG, thereby preventing 
the recruitment o f  Csk and the premature termination o f  TCR-induced MAPK activation. One 
possibility is that GAB-2 coordinates both the activation o f  SHP-2 and its translocation into the 
vicinity o f PAG (perhaps involving PH domain binding o f  GAB-2 to components o f  the lipid rafts). 
The mutual association o f  SHP-2 and PI3K with GAB-2 could also be important, since modulation o f 
PI3K activity by SHP-2 might also promote MAPK phosphorylation.
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Having identified SHP-2 within signalling complexes downstream of the CD28 
receptor, it would be interesting to see in future experiments whether co-ligation of 
the TCR and CD28 modulated the requirement for SHP-2 in sustained MAP kinase 
activation. It is important to note that individually CD28 does not have the capacity 
to couple to the Ras/MAP kinase pathway following ligation by its physiological 
ligand B7.1 (by contrast, some anti-CD28 mAbs are able to induce activation of ERK 
1 and 2) (Nunes et al., 1994). However, since CD28 is able to recruit SHP-2 upon 
stimulation it remains possible that co-stimulation could modify the involvement of 
this enzyme in the regulation of signalling pathways downstream of the TCR. 
Notably, the expression of 2SH2-SHP-2 was shown to reduce anti-CD3 plus anti- 
CD28 stimulation of AP-1-directed transcription. Thus, under conditions of co­
stimulation it seems highly likely that SHP-2 has a positive role in the functional 
regulation of T cell activation via the overall promotion of the MAP kinase signalling 
pathway.
CONCLUDING REMARKS
Taken as a whole, use of the 2SH2-SHP-2 dominant-negative mutant in these 
experiments has highlighted a positive role for SHP-2 downstream of the TCR and 
CD28. However, based solely upon this evidence no ultimate conclusions can be 
drawn regarding the role that SHP-2 plays in controlling the overall magnitude and 
duration of the MAP kinase phosphorylation during T cell activation. It is clear that 
future experiments would need to fully address the effect of the 2SH2-SHP-2 mutant 
upon co-ligation of the TCR and CD28. The priority of these would be to establish 
which tyrosine phosphoiylated proteins interact with the SH2 domains of the SHP-2 
mutant. In addition, the considered analysis of stable transfectants that inducibly 
express WT-SHP-2 and C—»S-SHP-2 proteins may also prove useful in helping to 
shed further light on the potential mechanism of action of SHP-2.
6THE ROLE OF GAB-2, SHP-2 AND PI3K IN SDF-1 
SIGNAL TRANSDUCTION AND T CELL
CHEMOTAXIS
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RESULTS
6.1 -SDF-1 STIMULATES THE LIPID KINASE ACTIVITY OF CLASS IA PI3K
Multiple biological roles have been identified for SDF-1 and its cognate receptor 
CXCR4. However, characterisation of the biochemical pathways that constitute 
signal transduction by this chemokine/receptor pair has been an altogether slower 
process. Recent attention has focused on the regulation of PI3K isoforms by SDF-1 
and their relative contribution to chemokine-stimulated cell migration. In this 
respect, activation of both class Ia and class Ib PI3K isoforms has been reported to 
support optimal chemotactic responses to SDF-1 (Cumock et al., 2003b).
The present study sought to confirm the activation of the class Ia PI3Ks by SDF-1. 
Jurkat T cells were appropriately stimulated with human recombinant SDF-1 a  or left 
unstimulated as control. The class Ia PI3K enzymes were immunoprecipitated from 
cell extracts using antibodies against the p85 adaptor subunit and the pi 10 catalytic 
subunit of pi 108 (a leukocyte specific isoform of PI3K). In order to assay for lipid 
kinase activity, precipitates were incubated with [P]-y-ATP and 
phosphatidylinositol as the substrate. The accumulation of the PI3K product, PI(3)P, 
is depicted by the autoradiograph in Figure 6.1. Treatment with SDF-1 a  resulted in a 
stimulation of lipid kinase activity associated with the class 1 a isoforms. In the pi 108 
immunoprecipitates the accumulation of PI(3)P was sustained over the first 10 
minutes post-stimulation. At 15 minutes, levels of this lipid were comparable to the 
unstimulated control.
6.2 -  SDF-1 STIMULATES THE TYROSINE PHOSPHORYLATION OF GAB-2 
AND ITS CO-ASSOCIATION WITH SHP-2 AND CLASS IA PI3K.
In common with all chemokine receptors, CXCR4 is G-protein coupled. Hence, the 
mechanism of activation of the GPy-sensitive class Ib PI3K isoform (pllOy) is 
readily explained. As demonstrated, stimulation of the class Ia PI3Ks also occurs 
downstream of SDF-1. However, the mechanism of recruitment and activation of 
these PI3K isoforms has not yet been defined. This led to the current speculation that
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Figure 6.1
pi 105 IP p85 IP
SDF-1: C I ’ 5’ 10’ 15’ 30’ C 5’
PI(3)P
SDF-1 S tim ulates the Lipid K inase Activity of C lass 1A PI3K
Cells were stimulated for the indicated periods o f time with human recombinant SDF-1 a . 
Cell extracts (200pg protein) were subjected to immunoprecipitation with an ti-p ll0 8  
antibody or anti-p85 antibody. In vitro lipid kinase assays were perform ed as described in 
‘Materials and M ethods’, using PI as a substrate. The position of the lipid product PI(3)P on 
the autoradiograph is shown. The experiment shown was the only one performed o f this 
type.
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SDF-1 S tim ulates the T yrosine P hosphory lation  of GAB-2 and  its C o-precip ita tion  
w ith SHP-2 and  Class 1A PI3K
Jurkat T cells were stimulated for the indicated tim es with human recombinant SDF-1 a . 
Cell extracts were prepared and protein concentrations determined by Bradford assay. A, 
Cell extracts (200pg protein) were immunoprecipitated with the anti-GAB-2 antibody 
(a-GA B -2). Immunoblotting with the anti-phosphotyrosine antibody 4 G 10 was used to 
detect tyrosine-phosphorylated GAB-2. B and C, Cell extracts (200pg protein) were 
immunoprecipitated with the anti-pl 105 antibody (a -  p i 105 ) and with the anti-SHP-2 
antibody (a-SH P-2), respectively. Immunoblotting was performed using the anti-GAB-2 
antibody (a-G A B -2). The immunoblots were stripped and reprobed with the appropriate 
antibody to allow parity o f loading to be examined. In each case results shown are 
representative of two independent experiments.
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chemokine receptors, like cytokine receptors, may utilise proteins such as GAB-2 in 
order to couple to the class Ia PI3Ks.
Figure 6.2A shows the sustained tyrosine phosphorylation of GAB-2 following SDF- 
la  treatment of Jurkat T cells. Immunoprecipitations were prepared from stimulated 
extracts using the anti-GAB-2 antibody and protein tyrosine phosphorylation was 
determined by immunoblotting with the anti-phosphotyrosine antibody, 4G10. Co­
precipitation of GAB-2 with class Ia PI3K and SHP-2 was also examined, as shown 
in Figure 6.2B and 6.2C respectively. The appearance of GAB-2 in precipitates of 
both pi 108 and SHP-2 seemed to closely mirror the stimulation kinetics for GAB-2 
tyrosine phosphorylation. At 30 minutes post-treatment the co-associations were still 
maintained.
6.3 -  SDF-1 STIMULATES THE CO-ASSOCIATION OF GAB-2 WITH CLASS 
IA PI3K IN  MOUSE THYMOCYTES AND SPLENOCYTES
Mice individually lacking both SDF-1 and CXCR4 exhibit almost identical defects in 
haematopoiesis (Nagasawa et al., 1996; Zou et al., 1998). In the mutant embryos, a 
reduction in the number of lymphoid progenitors and bone marrow myeloid 
precursors is observed. In light of this evidence, it has been suggested that SDF-1 
may act to direct haematopoietic progenitor cells into the correct microenvironment 
so as to receive those signals necessary for proliferation and differentiation. In 
humans, T cells mature within the thymus from where they migrate to occupy the 
secondary lymphoid organs. In fact, the spleen is the largest lymphoid organ within 
the body and as such is a rich source of immunocompetent T cells. During times of 
severe haematological stress eg. haemolytic anaemia, thalassaemia, the spleen may 
also contribute to the generation of new blood cells.
Given the suspected role of SDF-1 chemotaxis in lymphopoiesis, the GAB-2/PI3K 
interaction was investigated in mouse splenocytes and thymocytes. In the 
experiments shown in Figure 6.3, four mice were sacrificed and cells subsequently 
isolated from the collected thymus and spleens. After equilibration at 37°C for 1 
hour, cells were stimulated with SDF-1 a  or left unstimulated as control. The class Ia 
PI3K isoform, pi 108, was immunoprecipitated using an antibody directed against the
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SDF-1 Stimulates the Co-precipitation of GAB-2 with Class 1A PI3K in Mouse 
Thymocytes and Splenocytes
Mouse splenocytes and thymocytes were isolated as described in ‘Materials and 
M ethods’. Cells were stimulated for the indicated times with human recombinant SDF- 
la .  Cell extracts were prepared and protein concentrations determined by Bradford 
assay. A (thymocyte) and B (splenocyte), cell extracts were imm unoprecipitated with the 
anti-pl 108 antibody (a -  p i 108 ). Immunoblotting was perform ed using the anti-GAB-2 
antibody (a-G A B -2). Results shown are representative o f two independent experiments.
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catalytic subunit of this enzyme. Co-precipitation of GAB-2 was determined by 
immunoblot analysis with the anti-GAB-2 antibody. The appearance of GAB-2 in the 
pi 108 immunoprecipitates was comparable between the thymocytes (Figure 6.3A) 
and the splenocytes (Figure 6.3B). A gradual increase in the co-precipitation of these 
proteins was observed, which was still maintained at 30 minutes post SDF-la 
stimulation. Moreover, the kinetics of association in these cell populations were 
reminiscent of those observed in Jurkat T cells.
6.4 -  THE INVOLVEMENT OF SHP-2 IN  SDF-1-MEDIATED CHEMOTAXIS 
OF JURKAT T CELLS
A number of studies have implicated SHP-2 in the regulation of cell motility in 
response to different integrins and chemotactic factors (Yu et al., 1998; Manes et al., 
1999). Thus, the aim of the present work was to use the inducible expression of 
2SH2-SHP-2 in Jurkat T cells (characterised in section 5.4) to investigate the role of 
SHP-2 in SDF-1-induced chemotaxis.
Shown in Figure 6.4 is a representative result of chemotaxis assays performed on the 
2SH2-SHP-2 mutant clones. Cells were grown in the presence or absence of 
tetracycline for 24 hours prior to the assay and inducible protein expression was 
confirmed by immunoblot analysis with the anti-myc antibody, 9E10. SDF-la 
stimulated the chemotaxis of Jurkat T cells in a bell-shaped, concentration-dependent 
manner, as has been previously described (Sotsios et al., 1999). A dramatic reduction 
in the chemotactic response to SDF-la was observed due to the expression of the 
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Figure 6.4
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The Effect of 2SH2-SHP-2 Expression on SDF-l-mediated Chemotaxis of Jurkat T 
cells
A and B,Chemotaxis assays were performed as described in ‘M aterials and M ethods’. The 
2SH2-SHP-2 transfectants were incubated in the presence (Q )  or absence (E3) o f 2pg/m l 
tetracycline for 24 hours prior to the measurement o f chemotaxis. M igration towards 
varying concentrations of human recombinant S D F -la  was analysed, as indicated. Results 
are expressed as a mean chemotactic index (± stdev), which is the ratio o f migration o f 
stimulated cells against control samples incubated with medium alone. Statistical analysis 
was perform ed on this data using a paired t-test and significant differences at the p<0.001 
level denoted by (***), p<0.01(**) and p<0.05(*). The data is representative o f 2 
independent experiments in clone 6 and 3 experiments in clone 11..
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SUMMARY OF FINDINGS
• SDF-1 stimulates the lipid kinase activity of class Ia PI3K.
• SDF-1 stimulates the relatively sustained tyrosine phosphorylation of GAB-2.
• GAB-2 co-precipitates with SHP-2 and class Ia PI3K following SDF-1 stimulation.
• SHP-2 participates in SDF-1-mediated chemotaxis of Jurkat T cells. 
DISCUSSION
6.5 - THE REGULATION OF GAB-2, SHP-2 AND CLASS IA PI3K 
SIGNALLING COMPLEXES B Y  SDF-1.
6.5.1 - The Involvement of GAB-2 in the Recruitment of Class Ia PI3K
The association of SDF-1 with CXCR4 activates multiple signalling pathways that 
influence cellular migration. In particular, the activation of both class Ia and class Ib 
PI3K isoforms has been shown to be essential for SDF-1-mediated chemotaxis of T- 
lymphocytes (Cumock et al., 2003b). However, until now, the mechanism for 
recruitment of the class Ia PI3Ks to CXCR4 has remained obscure. The findings 
presented in this chapter provide the first evidence that GAB-2 may be involved in 
this process.
Based on the current data, Figure 6.5 represents an overall model for the regulation 
of GAB-2, SHP-2 and PI3K by SDF-1. Here, the initial event shown following SDF- 
1 stimulation is the activation of the class Ib PI3K isoform, pllOy. This is in direct 
accordance with previous reports that the wave of lipid kinase activity associated 
with anti-pllOy immunoprecipitates is both rapid and transient; in Jurkat T cells, 
elevated levels of the 3-phosphoinositides were detectable within 30s of receptor 
ligation, with a return towards near basal levels at 5 min (Sotsios et al., 1999). In this 
study, GAB-2 was shown to be tyrosine phosphorylated following SDF-1
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stimulation, by an as yet un-defined mechanism. It does seem likely, however, that 
the membrane localisation of GAB-2 could help facilitate this process by perhaps 
bringing it into the close proximity of an activated PTK. Furthermore, it is 
conceivable that the first peak of PI(3,4,5)P3 production may play a role in co­
ordinating the membrane translocation of GAB-2, via the potential binding of its PH 
domain. Indeed, due to the sequence similarity between the GAB-2 PH domain and 
the PH domain of GAB-1, which specifically binds PI(3,4,5)P3, it has been proposed 
that GAB-2 might also bind this lipid (Maroun et ol., 1999).
Demonstrated here, for the first time, was the co-precipitation of GAB-2 with class 
Ia  PI3K following SDF-1 ligation. Fittingly, the slow time course kinetics for the 
interaction between GAB-2 and pi 108 seemed to closely correlate with the relatively 
late stimulation of lipid kinase activity associated with this isoform. Taken together, 
this data suggests that GAB-2 may not only be involved in the recruitment of the 
Class Ia PI3K enzymes, but also in the regulation of their activation by SDF-1. 
Indeed, the sustained accumulation of the 3-phosphoinositide lipids, brought about 
by the activation of multiple PI3Ks, could be a critical factor in maintaining the 
chemotactic response. The proposed model for the involvement of GAB-2 and class 
Ia  PI3K in SDF-1 chemotaxis, as outlined above, is further reinforced by the 
observations of Yu and co-workers. In these experiments, the PH domain of GAB-2 
along with its ability to bind PI3K appeared to be important for fibronectin-related 
haematopoietic adhesion and migration (Yu et al., 2002).
6.5.2 - The Importance of SHP-2 in SDF-1 Chemotaxis
In addition to the class Ia PI3K isoforms, another key binding partner of GAB-2 is 
the protein tyrosine phosphatase SHP-2. As had been predicted, SHP-2 was also 
observed to co-precipitate with GAB-2 following SDF-1 stimulation. In light of this 
new finding, and the fact that SHP-2 has formerly been implicated in the regulation 
of cell motility, the present study sought to next examine the role of this phosphatase 
in SDF-1-induced chemotaxis. Accordingly, expression of a dominant negative 
version of SHP-2 severely limited the migratory capacity of Jurkat T cells towards 
SDF-1. Indeed, this result is highly suggestive of a positive role for SHP-2 in cell
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migration and could have a number of possible explanations when interpreted in the 
context of previous observations.
1. Firstly, SHP-2 exists within the same complex as class Ia PI3K and could 
perhaps modulate the activity of this family of enzymes. In support of this 
notion is the observation by Yu et ah, that the dissociation of SHP-2 from the 
GAB-2 complex significantly reduced PI3K activation in response to integrin 
cross-linking (Yu et al., 2002).
2. The regulation of cell migration by SHP-2 has also been correlated with its 
activity to control the phosphorylation of focal adhesion kinase (FAK); an 
important enzyme which, in turn, promotes the dynamic turnover of focal 
adhesions (Yu et ah, 1998; Manes et ah, 1999; Oh et ah, 1999). SDF-1 is 
known to induce the tyrosine phosphoiylation of a number of focal adhesion 
complex components (Ganju et ah, 1998) and the potential regulation of these 
by SHP-2 could alternatively explain its positive effect on chemotaxis.
3. Finally, it is tempting to speculate that SHP-2 might work at multiple levels 
in order to preserve the chemotactic response, perhaps acting to regulate the 
activity of both FAK and PI3K in concert.
CONCLUDING REMARKS
This investigation has demonstrated that SDF-1 stimulates the tyrosine 
phosphorylation of GAB-2, which in turn, appears to mediate the recruitment of both 
SHP-2 and class Ia PI3K. Whilst the class Ia PI3K isoforms already have an 
established role in SDF-1 chemotaxis, the present study provided the first evidence 
for the involvement of SHP-2 in this functional effect.
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Figure 6 .5 -M o d e lf o r  GAB-2, SH P-2 and Class 1A PI3K in SDF-1 Chemotaxis; 1. The initial event following SDF-1 ligation is the activation 
o f the class 1B PI3K isoform (p i 10y), thus triggering the first wave of PIP3 production. 2. This could be involved in the translocation o f GAB-2 to 
the membrane, bringing it into juxtaposition with a PTK perhaps activated by the a , subunit o f CXCR4. 3. Once tyrosine phosphorylated GAB-2 


















7GENERAL DISCUSSION AND FUTURE
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GENERAL DISCUSSION
7.1 - THE ROLE OF GAB-2, SHP-2 AND PI3K SIGNALLING COMPLEXES IN T 
CELL ACTIVATION
The T lymphocyte through its ability to specifically recognize and appropriately 
respond to foreign antigen, is a fundamental cell within the adaptive immune system. 
Accordingly, the biochemical pathways that fine-tune the T cell functional response 
represent attractive targets for modulation in the therapy of autoimmune disease, 
malignancy and host versus graft rejection.
Not surprisingly, the activation of a T cell following an encounter with antigenic 
peptide is a complex process, the intricacies of which are not fully understood. The 
co-ordination and integration of signalling pathways downstream of both the TCR 
and CD28 receptors is known to be a critical feature of T cell activation, underscored 
by the fact that only co-stimulation may promote cell survival and clonal expansion. 
On the whole, signal transduction by the TCR has been fairly well characterised, 
with the Ras-regulated MAPK cascade and calcium/PKC signaling pathways being 
particularly important for relaying signals to those nuclear factors involved in the 
transcriptional promotion of genes such as IL-2 (outlined in section 1.6). However, 
defining the nature of CD28 signalling pathways and how these may ultimately 
encourage T cell activation has been an altogether slower process. Consequently, 
these investigations were aimed to further uncover the biochemical signalling 
pathways downstream of the CD28 receptor.
Complexes involving GAB-2, SHP-2 and PI3K have been variously implicated in 
the control of MAP kinase activation and in the transcriptional regulation of the IL-2 
gene downstream of the TCR (as discussed in sections 1.19.2 and 1.20.3). The 
present study provided the first evidence that similar signaling scaffolds were formed 
downstream of CD28. Using a biochemical approach, CD28 stimulation was shown 
to induce the tyrosine phosphorylation of GAB-2 and its co-precipitation with both 
SHP-2 and class Ia PI3K. Given that CD28 can couple directly to PI3K via a 
pYI73MNM motif in its cytoplasmic tail (Ward et al., 1994; Prasad et al., 1994; Ward 
et al., 1995), it was speculated that the interaction of GAB-2 with the p85 subunit
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may perhaps help to amplify PI3K signaling downstream of CD28, by stimulating 
the catalytic activity of this enzyme and/or stabilizing it at the membrane close to its 
phospholipid substrates. It has similarly been proposed that GAB-2 may not only be 
involved in the recruitment of the protein tyrosine phosphatase SHP-2, but also in the 
stimulation of its enzymatic activity. Furthermore, it has been suggested that GAB-2 
may represent a potential target for de-phosphorylation by this enzyme (reviewed in 
section 1.20.1). Importantly, the findings of this study supported the argument that 
GAB-2 is at least an in vitro substrate for SHP-2 downstream of CD28. Taken as a 
whole, the evidence gathered in the initial phase of this project inferred that GAB-2 
might act as a key modulator of both SHP-2 and PI3K during T cell activation.
The appropriate next stage of this study was therefore to examine the impact of these 
signalling complexes on functional aspects of T cell activation, such as regulation of 
the IL-2 promoter. In these experiments GAB-2 was implicated in the negative 
regulation of IL-2 gene transcription during the co-stimulation of Jurkat T cells. 
Overexpression of a WT-GAB-2 expression construct significantly inhibited NFkB 
and AP-1-directed reporters, the transcription of which was dependent upon signals 
from both the TCR and CD28. As yet, the exact mechanism by which GAB-2 
orchestrates this negative effect has not been resolved. Interestingly, only the 
deletion of the PH domain was able to rescue the GAB-2 mediated inhibition of 
NFkB and AP-1 transcription, prompting speculation that the inhibitory effects 
observed might be caused by the forced overexpression of this lipid binding moiety 
in the WT-GAB-2 transfection assays. Moreover, in contrast with previous 
observations (Pratt et al., 2000; Yamasaki et al., 2001) the ability of GAB-2 to 
interact with either SHP-2 or PI3K was proven dispensable, since GAB-2 mutants 
defective in the binding of these enzymes still retained their inhibitory potency.
The present study used a novel approach to investigate the role of SHP-2 in T cell 
function. Whilst a number of investigators have examined the effects of expressing a 
catalytically inactive C-»S mutant version of SHP-2 (Gu et al., 1997; Milarski et al., 
1994; Frearson and Alexander., 1998), the use of a 2SH2-SHP-2 mutant has not been 
previously described. Examination of stable transfectants that inducibly expressed 
the 2SH2-SHP-2 protein revealed that that this mutant also acts in a dominant- 
negative fashion and confirmed the role of SHP-2 as a facilitator of MAP kinase
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signalling during TCR stimulation. Unfortunately, due to constraints of time, the 
function of SHP-2 downstream of the CD28 receptor was not investigated. 
Nonetheless, the development of these 2SH2-SHP-2 expressing clones has yielded a 
powerful tool for the future study of this enzyme in T cell signalling.
7.2 - THE INVOLVEMENT OF GAB-2, SHP-2 AND CLASS IA PI3K IN  
SIGNAL TRANSDUCTION B Y  THE CXC CHEMOKINE SDF-1.
The chemokine SDF-1 has been implicated in a range of functional settings, 
including haematopoiesis, the trafficking of T lymphocytes and in the 
pathophysiology of HIV infection (reviewed in section 1.22). Conveniently, SDF-1 
binds exclusively to the chemokine receptor CXCR4 hence any signalling responses 
may be attributed to selective ligand-receptor interactions. By contrast, other 
chemokines exhibit promiscuous receptor binding, which naturally complicates 
analysis of signalling events induced by these ligands. The study of SDF-1 signalling 
in T cells is also facilitated by virtue of the fact that CXCR4 is constitutively 
expressed on the leukaemic T cell line, Jurkat, as well as on normal peripheral blood- 
derived T cells and most T cell subsets (Sotsios et al., 1999).
Over recent years, a range of biochemical, pharmacological and genetic evidence 
has emerged that strongly implicates PI3K family enzymes in the chemotaxis of 
leukocytes (reviewed by Cumock et al., 2002). Notably, both the class Ia and Class 
I b  PI3K isoforms have been demonstrated to support the optimal migratory response 
of Jurkat T cells to SDF-1 stimulation (Cumock and Ward., 2003). Whilst the 
mechanism for the activation of the Gpy-sensitive class Ib PI3K isoform, pllOy, has 
been largely defined, the way in which CXCR4 couples to the class Ia PI3Ks has 
remained obscure. Here, for the first time, SDF-1 was shown to induce the tyrosine 
phosphorylation of GAB-2 and its co-association with class Ia PI3K, highlighting 
one potential mechanism for the recmitment and activation of these isoforms by G- 
protein coupled receptors.
In this study, the co-precipitation of GAB-2 with SHP-2 was also observed upon 
SDF-1 stimulation. Given the fact that SHP-2 had formerly been implicated in the 
regulation of cell motility, the specific role of this phosphatase in SDF-1-mediated
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chemotaxis was an obvious choice for further investigation (Yu et al., 1998; Manes 
et al., 1999; Oh et al., 1999; Chemock et al., 2001). Accordingly, analysis of the 
2SH2-SHP-2 expressing clones in Jurkat T cell chemotaxis assays revealed that 
SHP-2 positively influences migration towards SDF-1.
Taken together, the findings of this project have highlighted that GAB-2, SHP-2 and 
PI3K complexes are not simply restricted to signal transduction by cytokine and 
growth factor receptors. A broader role for these protein complexes has now been 
identified downstream of the TCR and CD28 during T cell activation, and in the 
signalling events that govern SDF-1-induced T cell chemotaxis.
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FUTURE DIRECTIONS
A number of avenues for further investigation have become apparent during the 
course of this study. These could potentially provide fresh insight into the role of 
GAB-2, SHP-2 and PI3K complexes in T cell signalling.
• Further investigation is required in order to determine the PTK that is responsible 
for the tyrosine phosphorylation of GAB-2 downstream of CD28 and SDF-1. This 
could be achieved using Jurkat T cell lines deficient in kinases such as Lck and ZAP- 
70.
• It is alleged that the PH domain of GAB-2 may play an important role in co­
ordinating the appropriate subcellular localisation of PI3K and SHP-2. To examine 
this further, subcellular fractionation experiments could be performed to initially 
compare the distribution of GAB-2 signalling complexes in the cytosol and 
membrane fractions following TCR and CD28 stimulation. The localization of GAB- 
2 could then be more accurately determined by transiently transfecting GFP-tagged 
GAB-2 expression constructs into Jurkat T cells and visualizing these under the 
confocal microscope, before and after stimulation. In addition, it would be interesting 
to determine the exact phosphoinositide binding specificity of the GAB-2 PH 
domain, since this has not yet been defined. This could be analysed by protein-lipid 
overlay assay as described by Dowler et al (Dowler et al., 1999; Dowler et al., 
2000).
• In examining the nature of GAB-2 signalling to the IL-2 promoter, it was suspected 
that the inhibition of NFkB and AP-1 directed transcription mediated by WT-GAB-2 
could be an artefact of overexpressing its PH domain in these experiments. A simple 
way of addressing this possibility would be to compare the effect of overexpressing 
the GAB-2 PH domain in isolation with that of the WT-GAB-2 protein.
• In this study only a preliminary examination of the role of SHP-2 in T cell 
signalling was performed. However, these initial experiments using Jurkat T cell 
clones that inducibly expressed a dominant-negative 2SH2-SHP-2 mutant
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highlighted the enormous scope for future investigation. Firstly, it would be 
interesting to identify the tyrosine phosphorylated proteins associating with the 
2SH2-SHP-2 mutant. This could be achieved by immunoprecipitating this myc- 
tagged protein and blotting for phosphotyrosine. Naturally, one candidate protein for 
examination in these precipitates would be PAG. In expanding this work, it would 
also be necessary to continue the development of Jurkat T cell clones that inducibly 
express C->S-SHP-2 and WT-SHP-2 constructs. A comparison of the effects of 
these proteins with those of the 2SH2-SHP-2 mutant would help to consolidate the 
role that SHP-2 plays downstream of the TCR and CD28.
• Complexes involving GAB-2, SHP-2 and class Ia PI3K were implicated in 
signalling downstream of SDF-1 and in the ultimate regulation of T cell migration 
towards this chemokine. In future experiments it would be interesting to look at the 
tyrosine phosphorylated proteins interacting with the 2SH2-SHP-2 mutant following 
SDF-1 stimulation. In particular, the proposed role that SHP-2 plays in regulating the 
tyrosine phosphorylation status of FAK could be examined. Ongoing work would 
also need to analyse the effect of various GAB-2 expression mutants on SDF-1 
chemotaxis, to see if this scaffolding protein is indeed a key co-ordinator of PI3K 
and SHP-2 in this functional response. In addition, it would be interesting to define 
whether coupling to GAB-2, SHP-2 and PI3K signalling complexes is shared by all 
chemokine receptors and not just CXCR4.
• In this study, Jurkat T cells were used as a convenient model for the study of T cell 
signalling events. However, it is recognized that these leukaemic cells might 
physiologically be quite far removed from a normal, primary T cell. To address the 
role of GAB-2, SHP-2 and PI3K in primary T cells, RNA interference (RNAi) 
technology could be used. This newly developed technology allows the expression of 
cellular proteins to be effectively ‘silenced’ by the introduction of small interfering 
RNAs (siRNAs) that selectively target and cleave the homologous mRNA transcript. 
Techniques are also now being developed which will allow the high-throughput 
analysis of the interactions, post-translational modification and levels of every 
protein in a cell. These techniques, grouped under the umbrella term of ‘Proteomics’, 
promise to revolutionise cell biology research and could conceivably be used in the
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future to examine the relationship between GAB-2, SHP-2 and PI3K within real 
cells.
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